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Background: Sciatica is a common condition reported to affect > 3% of the UK population at any time
and is most often caused by a prolapsed intervertebral disc. Currently, there is no uniformly adopted
treatment strategy. Invasive treatments, such as surgery (i.e. microdiscectomy) and transforaminal
epidural steroid injection, are often reserved for failed conservative treatment.
Objective: To compare the clinical effectiveness and cost-effectiveness of microdiscectomy with
transforaminal epidural steroid injection for the management of radicular pain secondary to lumbar
prolapsed intervertebral disc for non-emergency presentation of sciatica of < 12 months’ duration.
Interventions: Patients were randomised to either (1) microdiscectomy or (2) transforaminal epidural
steroid injection.
Design: A pragmatic, multicentre, randomised prospective trial comparing microdiscectomy with
transforaminal epidural steroid injection for sciatica due to prolapsed intervertebral disc with < 1 year
symptom duration.
Setting: NHS services providing secondary spinal surgical care within the UK.
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Participants: A total of 163 participants (aged 16–65 years) were recruited from 11 UK NHS
outpatient clinics.
Main outcome measures: The primary outcome was participant-completed Oswestry Disability
Questionnaire score at 18 weeks post randomisation. Secondary outcomes were visual analogue
scores for leg pain and back pain; modified Roland–Morris score (for sciatica), Core Outcome Measures
Index score and participant satisfaction at 12-weekly intervals. Cost-effectiveness and quality of life
were assessed using the EuroQol-5 Dimensions, five-level version; Hospital Episode Statistics data;
medication usage; and self-reported cost data at 12-weekly intervals. Adverse event data were
collected. The economic outcome was incremental cost per quality-adjusted life-year gained from
the perspective of the NHS in England.
Results: Eighty-three participants were allocated to transforaminal epidural steroid injection and
80 participants were allocated to microdiscectomy, using an online randomisation system. At week 18,
Oswestry Disability Questionnaire scores had decreased, relative to baseline, by 26.7 points in the
microdiscectomy group and by 24.5 points in the transforaminal epidural steroid injection. The difference
between the treatments was not statistically significant (estimated treatment effect –4.25 points, 95%
confidence interval –11.09 to 2.59 points). Nor were there significant differences between treatments
in any of the secondary outcomes: Oswestry Disability Questionnaire scores, visual analogue scores for
leg pain and back pain, modified Roland–Morris score and Core Outcome Measures Index score up to
54 weeks. There were four (3.8%) serious adverse events in the microdiscectomy group, including one
nerve palsy (foot drop), and none in the transforaminal epidural steroid injection group. Compared with
transforaminal epidural steroid injection, microdiscectomy had an incremental cost-effectiveness ratio
of £38,737 per quality-adjusted life-year gained and a probability of 0.17 of being cost-effective at a
willingness to pay threshold of £20,000 per quality-adjusted life-year.
Limitations: Primary outcome data was invalid or incomplete for 24% of participants. Sensitivity analyses
demonstrated robustness to assumptions made regarding missing data. Eighteen per cent of participants
in the transforaminal epidural steroid injection group subsequently received microdiscectomy prior to
their primary outcome assessment.
Conclusions: To the best of our knowledge, the NErve Root Block VErsus Surgery trial is the first
trial to evaluate the comparative clinical effectiveness and cost-effectiveness of microdiscectomy and
transforaminal epidural steroid injection. No statistically significant difference was found between the
two treatments for the primary outcome. It is unlikely that microdiscectomy is cost-effective compared
with transforaminal epidural steroid injection at a threshold of £20,000 per quality-adjusted life-year
for sciatica secondary to prolapsed intervertebral disc.
Future work: These results will lead to further studies in the streamlining and earlier management of
discogenic sciatica.
Trial registration: Current Controlled Trials ISRCTN04820368 and EudraCT 2014-002751-25.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 24. See the NIHR Journals Library website for further project information.
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Plain English summary
What is the problem?
Sciatica or pain related to nerve irritation travelling down the leg is common in young working adults
and most likely to be caused by a ‘slipped’ (prolapsed) disc. Although the majority of cases get better
on their own and within 4–6 weeks, a significant group of patients struggle with disabling symptoms
sometimes beyond 1 year. Consequently, patients struggle to maintain their home and working lives.
Many treatments are available for sciatica, but simpler treatments (e.g. pain tablets, physiotherapy and
changing one’s lifestyle) are often not very effective and patients have often tried all of them by the
time they are seen in hospital to have tests, such as scans, done.
Surgery to remove part of the disc is recommended in cases where the pain is accompanied by severe
weakness in one or both legs, or where doctors think that nerves may be damaged because patients
have bladder, bowel and sexual functioning difficulties (i.e. red flag symptoms). Surgery works well
in alleviation of referred leg pain and also to relieve pressure on a physically compressed nerve that
may be showing clinical sign of injury/weakness. An alternative to surgery is to inject a mixture of
anaesthetic and steroid close to the site of the disc injury and nerve, but at the moment we do not
know whether or not these injections work in the long term. They are cheaper and less invasive,
with fewer risks than surgery, such as from anaesthetic or infection.
What did our study investigate?
This study compared the usefulness of surgery with injections for patients who have had sciatica for
< 1 year and who have tried simple remedies but are still in pain. Patients were allocated to have
either surgery or the injection. Symptoms (e.g. pain) were assessed after 18 weeks.
What did we find?
We found that there was no significant difference between surgery and injection at the primary end
point. Surgery was not significantly different from injection in terms of clinical outcome and was not
cost-effective compared with injection.
Our conclusion and recommendation
Given the cost of surgery and the risks to patients, we suggest that further studies should be carried
out to explore whether or not all patients with sciatica due to a slipped disc should be considered
suitable for an injection, unless there is a good reason not to.
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Scientific summary
Background
Sciatica is defined as leg pain in the distribution of a lumbosacral nerve root. Estimates of caseload
vary substantially within the literature because of difficulties in definition and poor data capture.
Sciatica has a lifetime prevalence of up to 43%, an annual incidence of 5% and a point prevalence of
up to 13%. Over 90% of sciatica is due to a prolapsed intervertebral disc, and in the majority of cases
those affected are young, working adults, with the average age of sciatica patients being the early 40s.
It may be helpful to consider two groups of patients: (1) patients who have acute sciatica that lasts
< 6 weeks and may be self-limiting with little or no impact on the patient’s work, and (2) patients who
have persistent sciatica that lasts > 6 weeks and has a tremendous impact on the patient’s working
ability. Although studies have shown that most cases of sciatica resolve spontaneously within a year,
30% of patients still experience persistent troublesome symptoms after this, and 20% of patients
leave work as a result. For patients with severe sciatica, work days lost can be as high as 15 days per
calendar month. Current National Institute for Health and Care Excellence guidance recommends
investigating sciatica persisting > 6 weeks using specialised radiological investigations, such as magnetic
resonance imaging. Surgical removal of the disc prolapse in the form of microdiscectomy is widely
accepted as the gold-standard treatment option worldwide, but this is an expensive treatment with
risks and with long delays for patients in accessing surgical treatment. Previous studies of epidural
steroid injections for sciatica have been disappointing, suggesting little or no benefit beyond 2–3 weeks
post injection. By administering the epidural steroid injection closer to the site of the problem, injection
by the transforaminal route (i.e. transforaminal epidural steroid injection) may be a far more effective
treatment than either caudal or interlaminar epidural steroid injection. Although care pathways exist
for the treatment of sciatica, there is tremendous variation in practice across the UK, depending on
treatment availability and clinician preference. This largely arises from the lack of ‘level 1’ evidence
available in the literature to formulate these guidelines, and has led to variability in commissioning of
epidural steroid injection within the UK and variations in clinician preference of surgery over epidural
steroid injection. Moreover, Danish Health Authority guidelines recommend against the use of
injections owing to low-level evidence of their effectiveness for sciatica within 12 weeks of onset. To
address this controversial issue we compared two invasive treatments for sciatica, both of which are
recommended by expert pathway/guidelines:
1. surgical lumbar microdiscectomy
2. transforaminal epidural steroid injection.
Objectives
Primary objective
l To compare the clinical effectiveness of surgical microdiscectomy with transforaminal epidural
steroid injection for sciatica of < 12 months’ duration secondary to prolapsed intervertebral disc,
at 18 weeks post randomisation.
Secondary objectives
l To compare the cost-effectiveness of microdiscectomy with transforaminal epidural steroid injection
for the treatment of sciatica secondary to prolapsed intervertebral disc.
l To compare health-related quality-of-life outcomes for both treatments.
DOI: 10.3310/hta25240 Health Technology Assessment 2021 Vol. 25 No. 24
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Wilby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xxiii
Methods
Trial design
The NErve Root Block VErsus Surgery trial is a pragmatic, multicentre, Phase III randomised trial, with
an internal pilot phase, comparing microdiscectomy with transforaminal epidural steroid injection for
sciatica of < 1 year symptom duration.
Participants
Participants were recruited from 11 specialist multidisciplinary clinics receiving patients from pooled
tertiary referrals from general practitioners, allied health professionals and non-spinal consultants.
Patients were eligible for inclusion in the trial if they met the following criteria:
l They had been diagnosed with lower extremity radiculopathy (sciatica).
l They had sciatica secondary to prolapsed intervertebral disc (proven by magnetic
resonance imaging).
l The duration of their symptoms was between 6 weeks and 12 months. [Note that, if symptoms
were episodic, then ‘duration of symptoms’ refers to the initial incidence of severe symptoms
(i.e. the disc prolapse). It does not refer only to the most recent episode.]
l They had leg pain non-responsive to conservative, non-invasive management.
l They were aged 16–65 years.
l They had previously undergone at least one form of conservative (non-operative) treatment
(including but not limited to medication, physiotherapy and modification of daily activities) but this
had not provided adequate relief of pain/symptoms.
l They provided written, informed consent.
Patients were excluded from the trial if they met any of the following criteria:
l They had a serious neurological deficit (e.g. foot drop/possible cauda equina compression).
l They had previously undergone spinal surgery at the level of the prolapsed intervertebral disc.
l Their current episode of sciatica had lasted longer than 12 months.
l They were aged < 16 years or > 65 years.
l They had not previously undergone any form of conservative treatment.
l Patients with a contraindication for surgery and/or injection.
l They were known to be pregnant.
Contraindications to both groups of treatment were assessed on an individual case-by-case basis by
the local health-care team as per routine NHS practice using the current drug Summaries of Product
Characteristics and according to local policy.
Trial procedures
Informed, written consent was obtained from participants. Participants were randomised between
groups in a 1 : 1 ratio, with variable block randomisation stratified by centre. Blinding was not possible
because of the nature of the intervention.
A screening log was maintained at each trial centre, which recorded all individuals screened for the
trial and the eventual outcome. Reasons for non-recruitment were documented (e.g. not eligible,
declined consent) and the information was used for monitoring purposes. Patients were asked if
they would like to provide a reason for non-consent, although they were not obliged to provide one.
Reasons for non-participation that relate to patient preference were recorded with the undesired
treatment listed when possible.
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Data collected at the baseline visit included:
l medical and spinal surgical history
l a participant-completed questionnaire booklet [incorporating the Oswestry Disability Questionnaire;
the modified Roland–Morris (for sciatica); the Core Outcome Measures Index; visual analogue
scores for leg and back pain; the EuroQol-5 Dimensions, five-level version; and a Resource
Use Questionnaire].
Treatment started within 6 weeks of randomisation when possible and no later than 12 weeks after
randomisation. Data collected at the treatment visit included:
l treatment details
l a participant-completed Resource Use Questionnaire booklet.
Normal clinical practice usually includes a 3-month post-treatment follow-up. Therefore, participants
were followed up at approximately 18 weeks post randomisation to align with routine clinical practice,
and then at 30, 42 and 54 weeks. Participants could have also been seen at other times as clinically
indicated. Additional visits outside the trial protocol were recorded.
The 18- and 54-week follow-ups were face-to-face clinic visits when possible, and the 30- and 42-week
follow-ups were postal questionnaires sent to participants for completion and return.
Data collected at the follow-up visits included:
l work status, concomitant medications, related adverse events and additional treatments
l a participant-completed questionnaire booklet.
Outcome measures
Primary outcome
The primary outcome was the participant-completed Oswestry Disability Questionnaire score
(a condition-specific outcome measure with > 30 years of scientific validation) at 18 weeks post
randomisation.
Secondary outcomes
Secondary outcomes were Oswestry Disability Questionnaire score at 30, 42 and 54 weeks and visual
analogue scale scores for leg and back pain, modified Roland–Morris score, Core Outcome Measures
Index score and a Likert scale assessing participant satisfaction at 54 weeks. Health-related quality
of life was assessed using the EuroQol-5 Dimensions, five-level version, which was also used for
estimating quality-adjusted life-years for the cost-effectiveness analysis.
Sample size
A total of 172 participants were required to detect a clinically important difference of 10 points
between the two groups on the Oswestry Disability Questionnaire at a 5% significance level and
with 90% power. This assumed a standard deviation of 20 points based on a similar population in
previous published trials. The initial target sample size for the trial was 200 patients, which would
allow for a 10% rate of missing outcome data. As this initial sample size calculation did not account for
the analysis being adjusted for baseline values of the Oswestry Disability Questionnaire, the sample
size was recalculated after outcome data were received for 47 participants. A blinded analysis of the
correlation between baseline and follow-up Oswestry Disability Questionnaire scores was carried out
to adjust the sample size calculation. Based on the observed correlation of 0.49, the revised sample
size to achieve 90% power was 66 participants per group. Allowing for 10% loss to follow-up gave a
revised target of 74 participants per group (148 participants in total).
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Statistical methods
The primary outcome (i.e. Oswestry Disability Questionnaire score at 18 ± 6 weeks post randomisation) was
compared between groups using a linear regression model, adjusted for the randomisation stratification
variable centre and baseline Oswestry Disability Questionnaire score. Oswestry Disability Questionnaire
score at all follow-up visits, visual analogue scale scores for back and leg pain, modified Roland–Morris score
and Core Outcome Measures Index score were analysed using a repeated-measures mixed-effects model,
adjusting for baseline outcome measure, treatment arm, time (fitted as a continuous variable) and a
time–treatment arm interaction (if significant). Site was fitted as a random effect. The Likert scale for
satisfaction with care was analysed using the Mann–Whitney U-test. Employment status was analysed using
a chi-squared test. The intention-to-treat principle was applied as far as was practically possible (i.e. where
data were available). The analysis set for the primary outcome included all participants with a valid
Oswestry Disability Questionnaire score (at least 8 out of 10 items) at baseline and at 18± 6 weeks
post randomisation.
A sensitivity analysis was carried out using multiple imputation to assess the robustness of the analysis
to missing primary outcome data. Safety data on adverse events and serious adverse events are
presented descriptively, with no inferential statistics.
A post hoc analysis was carried out using joint modelling of the longitudinal outcomes (i.e. Oswestry
Disability Questionnaire scores, visual analogue scale scores for back and leg pain, modified Roland–Morris
score and Core Outcome Measures Index score) and the time to study dropout for each outcome to
address the possibility of informative dropout.
Economic evaluation
The economic analysis adopted the perspective of the NHS in England. Resource use was estimated
from routine NHS data, trial case report forms and patient-completed questionnaires, comprising
Hospital Episode Statistics data, medication usage and self-report cost data at 12-weekly intervals.
Utilities were estimated from responses to the EuroQol-5 Dimensions, five-level version, multiattribute
utility instrument. Costs were valued in Great British pounds and based on 2017/18 prices. Inflation
indices were applied as necessary. No discounting was applied as the time horizon of analysis was
approximately 12 months. When possible, missing utility data were estimated through interpolation;
otherwise missing cost and utility data were multiply imputed. Regression analyses were used to estimate
mean total costs and quality-adjusted life-years. The primary outcome of the economic evaluation was the
incremental cost per quality-adjusted life-year of microdiscectomy compared with transforaminal epidural
steroid injection. Uncertainties in costs, quality-adjusted life-years, the incremental results and resulting
cost-effectiveness metrics were evaluated using a non-parametric bootstrap of the patient-level data.
Scenario analyses were conducted to test the impact on the incremental cost-effectiveness ratio, including
out-of-pocket costs and productivity losses arising from time off work that approximated a societal
perspective, alternative quality-adjusted life-year valuation methods, the impact of varying the doses of
‘when-needed’ medications and including only sciatica-related costs.
Results
Clinical results
There was no statistically significant difference between the groups for the primary end point.
The adjusted estimate of the effect of microdiscectomy compared with transforaminal epidural
steroid injection at 18 weeks on Oswestry Disability Questionnaire score was –4.25 (95% confidence
interval –11.09 to 2.59) points. At 18 weeks, the Oswestry Disability Questionnaire scores was
improved in 87% of participants in the microdiscectomy group compared with 90% of participants
in the transforaminal epidural steroid injection group. Among these participants, Oswestry Disability
Questionnaire scores improved by > 10 points in approximately 74% of those in the surgical group and
68% of those in the transforaminal epidural steroid injection group. The mean reduction in Oswestry
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Disability Questionnaire score at 18 weeks was slightly greater in the surgical group (i.e. 26.74 points),
but was similar to the improvement seen following transforaminal epidural steroid injection (i.e.
24.52 points). There was no significant difference in the two treatments at any time point up to 1 year
and on any outcome domain (i.e. Oswestry Disability Questionnaire score, visual analogue scale scores
for back and leg pain, modified Roland–Morris score and Core Outcome Measures Index score were
not significant). There was a slight preference in terms of participant satisfaction for microdiscectomy,
with a median score of 1 (i.e. ‘completely satisfied’) for microdiscectomy compared with a median
score of 1.5 (i.e. between ‘completely satisfied’ and ‘somewhat satisfied’) for transforaminal epidural
steroid injection.
Additional treatment
Prior to primary outcome evaluation, 14 participants (17.5%) who received transforaminal epidural
steroid injection subsequently received microdiscectomy. Overall, 28 participants (35%) received
microdiscectomy in addition to transforaminal epidural steroid injection.
Post hoc
There was no statistically significant difference between groups for the joint models of the longitudinal
outcomes (i.e. Oswestry Disability Questionnaire score, visual analogue scale scores for back and leg
pain, and modified Roland–Morris score) and the time to study dropout. The joint model for Core
Outcome Measures Index suggests a significant treatment effect of –0.78 (95% confidence interval
–1.54 to –0.02) once adjusted for informative dropout, but this is less than the minimum clinically
important difference of 2.2.
Safety
Four out of 105 participants who received microdiscectomy experienced a related serious adverse event
(i.e. 3.8%). No serious adverse events were associated with transforaminal epidural steroid injection.
Economic analysis
The mean total cost associated with microdiscectomy over the 54-week trial was £6919 (95% confidence
interval £5503 to £8046). The mean total cost associated with transforaminal epidural steroid
injection over the 54-week trial was £4706 (95% confidence interval £3821 to £5516). The mean
total quality-adjusted life-years gained was 0.616 (95% confidence interval 0.570 to 0.671) and
0.559 (95% confidence interval 0.503 to 0.620) in the microdiscectomy and transforaminal epidural
steroid injection groups, respectively. The mean incremental costs and quality-adjusted life-years were
£2212 (95% confidence interval £629 to £3677) and 0.057 (95% confidence interval –0.009 to 0.124),
respectively. This results in an incremental cost-effectiveness ratio of £38,737 per quality-adjusted
life-year gained and, at a threshold of £20,000 per quality-adjusted life-year, an incremental net health
benefit loss of 0.054 quality-adjusted life-years. The probability of microdiscectomy being cost-effective
at £20,000 per quality-adjusted life-year is 0.17, and the probability of microdiscectomy being
cost-effective at a higher threshold of £30,000 per quality-adjusted life-year is 0.37.
Conclusions
Both microdiscectomy and transforaminal epidural steroid injection are effective in producing
clinically significant improvements in pain and disability associated with sciatica secondary to a
prolapsed intervertebral disc, if treated within 12 months of symptom onset. There is no evidence
that microdiscectomy is associated with better improvements in pain and disability than transforaminal
epidural steroid injection. Microdiscectomy is unlikely to be cost-effective at a threshold of £20,000 per
quality-adjusted life-year.
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Recommendations for future research
l A longer-term outcome assessment of trial patients beyond 12 months to determine rate of
long-term relapse is required.
l A thorough health economic/safety evaluation of a proposed clinical pathway, whereby
transforaminal epidural steroid injection precedes microdiscectomy (except for individual
circumstances) for persistent sciatica, is needed.
Trial registration
This trial is registered as ISRCTN04820368 and EudraCT 2014-002751-25.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 24.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Sciatica can be described as a symptom rather than a diagnosis. It is broadly defined as leg pain inthe distribution of a lumbosacral nerve root and has already been subject to National Institute
for Health and Care Excellence (NICE) review of treatment guidance.1 Estimates of caseload vary
substantially within the literature because of difficulties in definition and poor data capture. A UK
epidemiological study suggests a lifetime prevalence of up to 43%, an annual incidence of 5% and a
point prevalence of up to 13%.2 Over 90% of sciatica is due to a prolapsed intervertebral disc (PID),
with the average age of patients being early 40s.3 As patients affected are typically young, working
adults, it may be helpful to consider two categories of sciatica: (1) acute sciatica that lasts < 6 weeks
and may be self-limiting with little or no impact on the patient’s work, and (2) persistent sciatica that
persists > 6 weeks and has a tremendous impact on the patient’s working ability.
Although the duration of pain may vary considerably, and the natural history of sciatica is favourable
within 1 or 2 years, many patients have pain that persists beyond 6 weeks that could have a considerable
impact on their employment and lives. It is generally accepted that pain persisting beyond 6 weeks is
unlikely to get better imminently and requires further patient investigation and treatment. Treatment
options include drugs, injections of drug combinations into the spine and surgical techniques to remove
the prolapsed disc. UK guidelines recommend non-routine magnetic resonance imaging (MRI) scanning
after lifestyle modifications and simple treatments.1
Spinal injection involves the administration of a mixture of local anaesthetic and steroid into the spine
via one of three main routes: (1) through the base of the spine (i.e. a caudal epidural), (2) through
the back of the spine (i.e. a interlaminar injection) or (3) through the nerve tunnel (foramen) directly
adjacent to the prolapsed disc [i.e. a transforaminal epidural steroid injection (TFESI)]. The last mode
(i.e. TFESI) is reported to be the most successful.4 This specific use of a steroid (for spine injection) is
outside the marketing authorisation (off-label). However, it is a commonly used and a widely accepted
treatment for sciatica, although the success rate reported is highly variable because of inconsistent
patient population and route, type and dose of steroid administration. Although TFESI is recommended
by a number of expert review groups, including the UK NICE guideline1 (low back and radicular pain),
a recent review from Danish experts on behalf of the Danish Health Authority recommends against its
use for sciatica > 12 weeks’ duration.5,6 Of the surgical techniques, microdiscectomy to remove the
prolapsed disc is considered highly successful, with reported success rates of 90%.7 However, as
sciatica has a favourable natural history, there is potential that the treatment administered in the form
of injection may render surgery excessive.
There is currently no care pathway in the NHS that recommends any one particular treatment over
another, and no direct comparison exists between microdiscectomy to treat sciatica secondary to
PID and nerve root blocks, such as TFESI. In addition, no international consensus agrees the use of
TFESI for sciatica within 12 weeks’ duration. This trial aims to address that by comparing surgical
microdiscectomy with steroid and local anaesthetic administered accurately to the source of leg pain
against various objective outcomes.
Scientific background
Sciatica is a common condition. In the UK, in 2010/11, > 25,000 therapeutic epidural steroid injections
(ESIs) were administered and > 9000 surgical procedures to remove herniated lumbar disc prolapses were
performed for sciatica [Hospital Episode Statistics (HES) data].8 In the USA, > 200,000 microdiscectomies
are performed per year.9 In the UK, the cost to the NHS is estimated to be £700 per TFESI and
approximately £4500 for surgical microdiscectomy (which requires patients to be hospitalised for
2 nights, on average).
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Previous studies of surgical microdiscectomy for sciatica
Surgical removal of the PID is believed to be the treatment of choice for symptomatic PID, with > 90%
success rates, return to work within 1 month in the majority of cases and complications of around 2%.10
Several trials have attempted to compare surgical microdiscectomy with non-operative treatments, but
with notable methodological flaws. Population studies have suggested that surgery is more effective than
non-surgical treatments, but these studies were affected by selection bias and lacked clear definitions of
the non-operative treatment arm.3,11–13 The two most notable studies are large, prospective case series
studies, the Maine Lumbar Spine Study12 and the Spine Patient Outcomes Research Trial,11 and are worthy
of specific mention.
Recruiting > 500 patients treated by spinal specialist teams across Maine, almost an equal number
of surgical patients were compared with non-surgical patients with sciatica.12 Surgery was deemed
effective in 71% of patients compared with 43% of non-surgical patients. The non-surgical group was,
however, quite heterogeneous, with only 18% of non-surgical patients receiving ESI. In addition, the
study was observational and, therefore, suffered from selection bias.
The Spine Patient Outcomes Research Trial11 had two main arms: an observational reporting group
in which patients selected their treatment (surgical or not) and a randomised arm. Owing to a large
degree of treatment crossover in the randomised section, intention-to-treat (ITT) analyses showed no
significant difference in outcomes. However, the as-treated analysis favoured surgery. Once again,
however, the non-surgical treatments being compared with surgery were heterogeneous.
To our knowledge, only one previous study14 (n= 100) has directly compared surgery with ESI (interlaminar
route) and this study reported that ESI could prevent surgery in approximately 50% of cases. This study
was a single practitioner cohort, but randomisation was employed in design of the study.
Previous studies of epidural steroid injections for sciatica
Epidural steroid injections are known to improve patients’ sciatica, but their efficacy varies widely
throughout the literature.15 A wide variation in practice exists across the UK in the methods of
administration of the ESI.
Epidural steroid injections involve the administration of a mixture of local anaesthetic and steroid into
the epidural space via one of three main routes: (1) through the base of the spine (i.e. a caudal epidural),
(2) through the back of the spine (i.e. a interlaminar injection) or (3) through the nerve tunnel directly
adjacent to the prolapsed disc (i.e. transforaminal injection). In the past, the most widely used injection
therapy route was ESI, by either the interlaminar route or the caudal route. However, placing the needle
through the bony tunnel through which the lumbar nerve root exits the spine can accurately place the
drug closer to the target site (i.e. TFESI). Currently, ESI is not commissioned by all local commissioning
groups within the NHS in the UK for sciatica, whereas TFESI is. This technique routinely requires X-ray
guidance or computerised tomography (CT) scanning guidance and most pain clinics in the UK are able
to offer this treatment.
Although randomised controlled trials (RCTs) have tested ESI for acute sciatica, these trials have not
included comparisons between TFESI and interlaminar ESI. However, prospective and case–control
studies have compared the two techniques and demonstrated a superior efficacy of TFESI.13,16,17
A comprehensive review of the literature has recently been published by the Health Technology
Assessment (HTA) programme.15 Only one small RCT14 (n = 100) directly compared interlaminar ESI
with surgery for sciatica secondary with PID and suggested that ESI could prevent 50% of surgical
interventions. One previous UK RCT, the Wessex Epidural Steroid Trial (WEST)18 (n = 228), funded by
the HTA programme, compared interlaminar injection of steroid with placebo (i.e. injection of saline
between the spinous processes) in patients with sciatica ranging in duration from 4 weeks to 18 months
and found no benefit of steroid injections beyond 3 weeks of follow-up. However, in this study, MRI
was not undertaken as part of the trial to confirm pathology, with this relying on clinical findings alone.
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These possibly could be some of the factors contributing to less than promising results for ESI. Various
other studies have shown that ESIs have only a small short-term effect on leg pain and disability
compared with placebo, and no effect in the long term.19 These poor medium- to long-term results
have given ESIs poor perceived efficacy and hence they are not commissioned or recommended in the
treatment and clinical pathway of sciatica secondary to PID management.
A prospective randomised study20,21 reported that transforaminal administration of the drug mixture
into the epidural space (i.e. TFESI) under fluoroscopic guidance is the most successful route (more so
than injection of saline or local anaesthetic into the epidural space, or intramuscular steroid or saline
injection), and this route was used in this study. Relief of pain was corroborated by significant
improvements in function and disability, and reductions in use of other health care.
Transforaminal epidural steroid injection is believed to be superior in efficacy to interlaminar administration
of ESI, as the drug is delivered more accurately and closer to the site of the pathology/disc prolapse.
A prospective study17 of TFESI (n = 48) for acute sciatica suggests long-term pain reduction in > 80% of
patients. One RCT published in 201120 (n = 150) compared the outcomes of selective nerve root injection
and local anaesthetic, local anaesthetic alone, normal saline and intramuscular injection of steroid or
normal saline. The only radiological feature associated with successful outcome was the grade of nerve
root compression. Of patients with low-grade root compression (n = 71), 75% responded favourably to
selective nerve root injection and avoided surgery by 54 weeks’ follow-up.
Although there are few data directly comparing TFESI with interlaminar steroid injections for sciatica,
during the recruitment stage of this trial a number of ongoing studies throughout the world were
specifically looking at this. However, these studies were experiencing recruitment difficulties because
of the lack of a surgical treatment arm.22,23 One recent study24 (n = 238) reported that 65% of injections
were effective at follow-up of > 6 months (based on patient-reported measures).
Adverse events (AEs) associated with TFESI procedures are rare, typically < 1%, but can be severe and
include paraplegia, infection, haematoma, intravascular injection of medication, direct nerve trauma,
subdural injection of medication, air embolism, disc entry, urinary retention, radiation exposure and
hypersensitivity reactions.
The advantages of spinal injections include:
l The injections are a relatively cheap and low-risk procedure compared with surgery.
l Success rates have been estimated to be as high as 75%.
l Injections are delivered as a day-case procedure and, therefore, require no hospital admission and
can be easily repeated.
l There is a range of treatment providers, including radiologists, surgeons and pain physicians.
The disadvantages of spinal injections include:
l The true success rate of injections is largely unknown. The injections may work well in the short
term, but pain may return some weeks later.
l Injections are not able to prevent physical nerve root compression and are inappropriate for
massive disc prolapses that cause motor weakness or numbness in the leg.
Economic background
Although there are a number of published economic evaluations of interest in the treatment of sciatica,
they are of limited applicability, as none has directly compared microdiscectomy with TFESI. A recent
systematic review25 of economic evaluations in sciatica included 16 decision-analytic models that
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compared a selection of management strategies. The review25 found that analyses were generally
associated with poor modelling techniques, analytical methods and data quality, specifically in terms
of health state representation, time horizons and utility values. Uncertainty associated with the clinical
evidence populating the models was an identified contributor to these limitations.
A number of the US studies identified by Hall et al.25 compared surgical techniques with epidural
injection techniques in the treatment of sciatica. Parker et al.,26 taking a payer perspective, including
the cost of patient care (i.e. index procedures and any follow-up care or repeat procedures), reported
a cost per quality-adjusted life-year (QALY) of US$16,300 (2014 US$) when comparing interspinous
spacer surgery with conservative care (which could include steroid injection). Skidmore et al.27
compared spacer surgery with conservative care (including ESI) and, in taking a broader cost
perspective (i.e. patient, physician or payer, but excluding productivity losses), reported a cost per QALY
of US$17,894 (2009 US$). Udeh et al.28 estimated the cost-effectiveness of minimally invasive lumbar
decompression as US$37,758 per QALY gained (2013 US$) compared with ESIs from a Medicare
payer’s perspective. An evaluation29 including societal costs associated with lumbar disc herniation
surgery and non-surgical treatments (including ESI) for privately insured, working patients identified
that after fully accounting for the effects of disc herniation surgery on worker productivity (based
on changes in earnings and missed work days) the cost per QALY gained of surgery reduced from
US$52,416 to US$35,146 (2009 US$), based on a 4-year time horizon.
Economic evidence from the UK is limited. Lewis et al.15,30 estimated the cost-effectiveness of
alternative management strategies for sciatica using a deterministic model informed by an evidence
synthesis based on a review of > 100 potential treatment scenarios. A 12-month time horizon was
selected on the basis that patients would be managed through one of three treatment pathways:
(1) primary care, (2) stepped approach or (3) immediate referral to more invasive treatments (i.e.
epidural and disc surgery). Utilities derived from the EuroQol-5 Dimensions (EQ-5D) were sourced
from a Dutch study31 comparing prolonged conservative care with early surgery, and costs were based
on clinical opinion and derived from published UK cost sources (2008/9 prices). The results indicated
that stepped-care approaches to patient management based on initial treatment with non-opioids were
likely to represent the most cost-effective approach relative to strategies that involved direct referral
for disc surgery.
Vertuani et al.32 assessed the cost-effectiveness of minimally invasive surgery compared with open
surgery for lumbar spinal fusion in the treatment of degenerative lumbar spinal conditions. Using
published data derived from a number of sources and UK costs (subsequently converted to euros),
the results indicated that minimally invasive surgery was the dominant strategy, yielding both cost
savings and improved health outcomes. A cost saving of €1666 (2013 costs) per procedure was
estimated, based on shorter length of hospital stay, reduced blood loss and fewer complications,
and with a corresponding improvement of 0.04 QALYs over 2 years.
Price et al.18 conducted an economic evaluation of ESI compared with placebo within a 12-month double-
blind placebo-controlled randomised clinical trial in four UK hospitals. A bottom-up costing approach
was applied, with resource use estimated from data on drugs, equipment, pathology and radiology
services collected within the trial and supplemented by a survey of non-RCT patients for clinical staff
time-based activities. QALYs were derived from Short Form questionnaire-6 Dimensions preference-
based utilities from the Short Form questionnaire-36 items questionnaire over the initial 12-week
period. Taking a provider perspective, an incremental cost per QALY of £44,701 was estimated for up
to three injections over a 12-week period, reducing to £25,745 per QALY gained if only one injection
was administered, on the basis that there are no significant health benefits beyond the first injection
(2002/3 prices). An alternative perspective, reflecting the charge levied on the purchaser as opposed
to the actual resource cost, yielded incremental cost-effectiveness ratios (ICERs) of £354,171 and
£167,145 per QALY gained for up to three injections and only one injection, respectively.
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However, by the nature of their setting, perspectives, interventions and comparators, these studies are
unlikely to be directly generalisable or informative to the present decision problem concerning the
cost-effectiveness of microdiscectomy compared with TFESI in the setting of the NHS in England.
The aim of the economic evaluation conducted as part of the NErve Root Block VErsus Surgery
(NERVES) trial was to establish which intervention, microdiscectomy or TFESI, for the treatment of
sciatica secondary to PID herniation offered greater value for money from the perspective of the NHS
in England.
Rationale for research
To the best of our knowledge, there is no evidence comparing steroid injections given via the nerve
foramen with any other form of treatment (i.e. surgical microdiscectomy). Neither has a robust
economic analysis been performed for this condition and these treatment paradigms.
Intervention
The technologies compared are standard surgical lumbar microdiscectomy (i.e. microdiscectomy) and
fluoroscopically guided TFESI of a standard combination of local anaesthetic and steroid drug.
Objectives
The NERVES trial is a pragmatic, multicentre, Phase III randomised trial comparing microdiscectomy
with TFESI for persistent sciatica caused by a PID of < 12 months’ duration. An internal pilot was
completed with two trial centres as part of an initial feasibility study.
Primary objective
l To compare the clinical effectiveness of microdiscectomy with TFESI at 18 weeks
post randomisation.
Secondary objectives
l To compare the clinical effectiveness of microdiscectomy with TFESI up to 1 year post treatment.
l To compare the cost-effectiveness of microdiscectomy with TFESI.
l To compare quality-of-life (QoL) outcomes for both treatments.
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Chapter 2 Trial design and methods
Trial design
Figure 1 shows the NERVES trial design.
Trial registration and ethics
This trial falls within the remit of the European Union Directive 2001/20/EC, transposed into UK law as
the UK Statutory Instrument 2004 number 1031: Medicines for Human Use (Clinical Trials) Regulations
2004 as amended. This trial has been registered with the Medicines and Healthcare products Regulatory
Agency (MHRA) and has been granted a Clinical Trial Authorisation. The Clinical Trial Authorisation
reference is 21322/004/001 and the EudraCT number is 2014-002751-25.
Baseline
Patients screened using
inclusion/exclusion criteria
1−9a
Randomisation (1 : 1)
Eligible participants
randomised using online
randomisation system
Treatment
TFESI
6, 8a
Treatment
Microdiscectomy
6, 8a
18-week follow-up
1−12a
30-week follow-up
1–6 and 11a
42-week follow-up
1−6 and 11a
54-week follow-up
1−12a
Additional treatments/
treatment failure
FIGURE 1 The NERVES trial design. a, Trial-specific outcome assessments undertaken at each time point: (1) Oswestry
Disability Questionnaire (primary outcome at the 18-week follow-up); (2) modified Roland–Morris outcome score for
sciatica; (3) Core Outcome Measures Index score; (4) visual analogue scale scores for leg and back pain; (5) EuroQol-5
Dimensions, five-level version; (6) Resource Use Questionnaire; (7) physical examination; (8) pregnancy; (9) concomitant
medications; (10) return to work; (11) treatment satisfaction (Likert scale); and (12) AEs. Orange indicates the possibility
or option of additional treatment if primary treatment deemed unsuccessful.
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Ethics considerations
The trial abided by the principles of the World Medical Association Declaration of Helsinki.33
Both of the treatments offered as part of the trial are standard NHS practice. As such, there were no
major ethics concerns. When treatment has been considered to be unsuccessful, participants had full
access to additional treatment needed as per routine care. Participation in the trial did not prevent
access to additional treatments needed.
The specific issues pertaining to this trial are:
l requirement for an additional visit
l patients were randomised and, therefore, were unable to choose their own treatment.
Funding was in place to allow reimbursement of financial costs incurred by the trial participant to
attend an additional appointment (i.e. a 54-week follow-up appointment post randomisation).
Patients provided informed consent to participate, with information provided about the randomisation
process, data collection and other trial processes.
Ethics approval
The trial protocol received the favourable opinion of a Research Ethics Committee prior to initiation
at the Liverpool Clinical Trials Centre (LCTC) and underwent independent review at the research
and development (R&D) offices of participating centres. Local R&D offices were sent the appropriate
centre-specific information form to complete with the necessary authorisation signatures, plus any
other documentation requested for review. A copy of local R&D approval was forwarded to the LCTC
before the centre was initiated and patients recruited.
Consent from patients was obtained prior to participation in the trial and after a full explanation had been
given of the treatment options, including the conventional and generally accepted methods of treatment.
Patients were asked to read and review a patient information sheet and consent form (PISC) containing
key information about the trial, and then complete, sign and date the consent form if they consented to
take part in the trial. The right of the patient to refuse consent to participate in the trial without giving
reasons was respected. After the patient entered the trial, the clinician remained free to give alternative
treatment to that specified in the protocol, at any stage, if he/she felt it to be in the best interest of the
participant. However, the reason for doing so was recorded and the participant remained within the trial
for the purpose of follow-up and data analysis, according to the treatment option to which they have been
allocated. Similarly, participants remained free to withdraw at any time from the protocol treatment and
trial follow-up without giving reasons and without prejudicing further treatment.
Selection of centres/clinicians
The trial was run in NHS outpatient neurosurgical, pain and orthopaedic clinics and community-based
services. Patients were recruited from units receiving patients from pooled tertiary referrals from
general practitioners (GPs), allied health professionals and non-spinal consultants.
Participating centres were initiated once all regulatory approvals and trial-specific conditions
(e.g. training requirements) had been met, and all necessary documents had been returned to
the LCTC.
TRIAL DESIGN AND METHODS
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Centre/clinician inclusion criteria
(a) TFESI performed according to protocol requirements (i.e. specified pharmaceutical agents available
from pharmacy via local routine prescription routes).
(b) Able to provide both treatments within 12 weeks of randomisation.
(c) Principal investigator can be a representative of either neurosurgery or pain management
(note that both specialties should be represented within the local research team).
(d) Clinical equipoise.
(e) Local R&D approval.
(f) Completion and return of a ‘delegation of authority and signature log’ to the LCTC.
(g) Completion and return of centre suitability assessment to the LCTC.
(h) Signed contract between centre and sponsor.
(i) Receipt of evidence of adherence to points (a) to (g) by the LCTC.
(j) Complete progression through the green light checklist.
Centre/clinician exclusion criteria
l Not meeting the inclusion criteria listed above.
Participant inclusion and exclusion criteria
Inclusion criteria
Patients were eligible for inclusion in the trial if they met the following criteria:
l They had been diagnosed with lower extremity radiculopathy (sciatica).
l They had sciatica secondary to prolapsed intervertebral disc (proven by magnetic
resonance imaging).
l The duration of their symptoms was between 6 weeks and 12 months. [Note that, if symptoms
were episodic, then ‘duration of symptoms’ refers to the initial incidence of severe symptoms
(i.e. the disc prolapse). It does not refer only to the most recent episode.]
l They had leg pain non-responsive to conservative, non-invasive management.
l They were aged 16–65 years.
l They had previously undergone at least one form of conservative (non-operative) treatment
(including but not limited to medication, physiotherapy and modification of daily activities) but this
had not provided adequate relief of pain/symptoms.
l They provided written, informed consent.
Exclusion criteria
Patients were excluded from the trial if they met any of the following criteria:
l They had a serious neurological deficit (e.g. foot drop/possible cauda equina compression).
l They had previously undergone spinal surgery at the level of the prolapsed intervertebral disc.
l Their current episode of sciatica had lasted longer than 12 months.
l They were aged < 16 years or > 65 years.
l They had not previously undergone any form of conservative treatment.
l Patients with a contraindication for surgery and/or injection.
l They were known to be pregnant.
Contraindications for both groups of treatment were assessed on a case-by-case basis by the
health-care team, as per routine NHS practice and according to local policy.
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Changes to the eligibility criteria
During the course of the trial the following changes were made to the eligibility criteria.
Protocol v3.0, 15 December 2014, wording amended for clarity
l Inclusion criterion: ‘Newly diagnosed sciatica secondary to PID (proven on MRI)’ changed to
‘Newly diagnosed lower extremity radiculopathy (sciatica)’.
l Inclusion criterion: ‘Diagnosed with lower extremity radiculopathy (sciatica) secondary to a
lumber disc herniation’ changed to ‘Sciatica secondary to prolapsed intervertebral disc (PID)
(proven on MRI)’.
l Exclusion criterion: ‘Pregnancy’ changed to ‘Patient known to be pregnant’.
l Exclusion criterion: ‘Not attempted conservative non-operative treatment for a minimum of
6 weeks’ changed to ‘Patient has not attempted any form of conservative treatment’.
Protocol v4.0, 5 May 2015, wording amended for clarity
l Inclusion criterion: ‘Newly diagnosed lower extremity radiculopathy (sciatica)’ changed to
‘Diagnosed lower extremity radiculopathy (sciatica)’.
l Inclusion criterion: ‘Severe leg pain non-responsive to conservative, non-invasive management’
changed to ‘Leg pain non-responsive to conservative, non-invasive management’.
l Exclusion criterion ‘Neurological deficit (foot drop/possible cauda equina compression)’ changed to
‘Serious neurological deficit (e.g. foot drop/possible cauda equina compression)’.
Protocol v6.0, 21 March 2016, wording amended to improve recruitment
l At trial inception, 6 months was believed to be an appropriate cut-off point because the main issue
governing the selection of symptom duration was in terms of getting patients back to work faster,
and for this reason the shorter time point of 6 months was selected. During the course of the trial,
screening logs showed that the most common reason for subject ineligibility was pain duration
of > 6 months. On review, the Trial Management Group (TMG) believed that there was clinical
equipoise up to 12 months of symptom duration, after which time the disc prolapse itself was
unlikely to change significantly radiologically and there may not be equipoise. It was therefore
agreed that it was appropriate to extend the duration of symptoms to 12 months.
l Inclusion criterion: ‘Duration of symptoms between 6 weeks and 6 months’ changed to ‘Duration of
symptoms between 6 weeks and 12 months’.
l Exclusion criterion: ‘Sciatica presentation for longer than 6 months’ changed to ‘Sciatica
presentation for longer than 12 months’.
Protocol v7.0, 25 October 2017, wording amended for clarity
l Inclusion criterion: ‘Patient willing and able to give consent’ changed to ‘Patient has provided
written, informed consent’.
Recruitment
Screening
All patients who attended a participating trial centre following referral for sciatica secondary to PID
(previously proven by MRI scanning) were prospectively screened for trial eligibility. Trial information
was provided to patients at, or prior to, the clinic appointment. Potentially eligible patients (i.e. those
who met the eligibility criteria listed in Participant inclusion and exclusion criteria) were invited to
participate in the trial. At the clinic appointment, the patient was allowed time to discuss the trial,
ask questions and decide whether or not to consent to take part in the trial. Owing to the pragmatic
TRIAL DESIGN AND METHODS
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nature of the trial, patients provided written, informed consent at the initial visit without requiring
further time to consider participation. Patients requiring additional time to consider consent were
managed on a case-by-case basis at a centre level and an additional visit occurred if required.
A screening log was maintained at each trial centre to record all individuals screened for the trial and
the eventual outcome. Reasons for non-recruitment were documented (e.g. not eligible, declined
consent) and the information was used for monitoring purposes. Patients were asked if they would
like to provide a reason for non-consent, although they were not obliged to do so. Reasons for
non-participation that relate to patient preference were recorded with the undesired treatment listed
when possible.
Baseline and eligibility
After obtaining written, informed consent, the baseline case report form (CRF) was completed to
assess and confirm eligibility. The baseline CRF included a medical and neurosurgical history based on
source data in the participant’s notes and eligibility was confirmed by an appropriately qualified doctor.
The details of recruitment into the NERVES trial were recorded appropriately in the participant’s notes
[i.e. details of eligibility confirmation (when and by whom), consent and entry into the trial].
Participants were also asked to complete a questionnaire booklet [incorporating the Oswestry
Disability Questionnaire (ODQ); modified Roland–Morris (MRM); Core Outcome Measures Index
(COMI); visual analogue scale (VAS) for leg and back pain; the EuroQol-5 Dimensions, five-level version
(EQ-5D-5L); and a Resource Use Questionnaire (RUQ)], with support from a health-care professional
if needed. The participant-completed questionnaires were completed prior to randomisation, but after
provision of consent. The ODQ collected primary outcome data for the trial and so it was important
that it was completed accurately. Therefore, it was checked by centres and assistance was provided in
completing it if required.
Informed consent
Informed consent is a process initiated prior to an individual agreeing to participate in a trial and
continues throughout the individual’s participation. Informed consent is required for all patients
participating in LCTC co-ordinated trials. In obtaining and documenting informed consent, the
investigators were required to comply with applicable regulatory requirements and adhere to good
clinical practice and to the ethics principles that have their origin in the Declaration of Helsinki.
There was discussion about the objectives, risks and inconveniences of the trial, and the conditions
under which the trial would be conducted were provided to patients by staff with experience
in obtaining informed consent. Patients were provided with a PISC describing in detail the trial
interventions/products, trial procedures and risks (which was approved by an Independent Ethics
Committee), and were asked to read and review it.
After the patient had read the document, the investigator explained the research trial, emphasising
that participation in the trial was voluntary and that the participant could withdraw from the trial
at any time and for any reason. All patients were given the opportunity to ask any questions and to
discuss the trial and were given time to consider the information prior to agreeing to participate.
A contact point where further information about the trial could be obtained was included in the PISC.
Patients who agreed to participate then signed and dated the informed consent document. Both the
person taking consent and the patient personally signed and dated the form. A copy of the informed
consent document was given to the patient for their records. The original copy was filed in the
patient’s notes and a further copy of the signed consent form retained in the investigator centre file.
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One final copy of the consent form was sent to the co-ordinating centre (i.e. the LCTC). Centres were
instructed to send the consent form within 7 days of informed consent being provided.
Patients were invited to participate in the trial at their clinical visit. Consent was sought at this initial
visit, as there are no immediate routine follow-up visits. When patients requested longer to consider
their decision about whether or not to participate, the local research team managed this. Potential
participants could be invited to return to the clinic to provide consent at a later date, but the cost of
attending the visit was not reimbursed as part of the trial. This is a reflection of current NHS practice,
in which a patient would be given their treatment options and, in consultation with their health-care
provider at that same appointment, would make a decision about how they wished to proceed.
The participant could, without being subject to any resulting detriment, withdraw from the trial at
any time by revoking the informed consent. The rights and welfare of the patients were protected by
emphasising to them that the quality of medical care would not be adversely affected if they declined
to participate in this trial.
Randomisation
Patients were not randomised until:
l fully informed written consent had been obtained from the patient
l the baseline CRF had been accurately completed
l full eligibility had been confirmed by a doctor.
Participants were randomised between groups in a 1 : 1 ratio, with variable block randomisation
stratified by centre. Randomisation lists were created by a statistician who was not part of the main
trial team.
Participants were randomised using an online web randomisation system. Designated members of the
trial team at site, as detailed on the delegation of authority and signature log, were given training to
use the online system and then provided with unique log-in details. Data captured on the baseline CRF
were entered into the online system to confirm eligibility of the participant and provide information
needed for treatment allocation. Randomisation occurred at the initial clinic appointment, if possible.
The online system allocated a unique randomisation number to the participant together with their
treatment allocation. The LCTC received an e-mail notification that randomisation had taken place.
Blinding
Owing to the nature of the interventions, blinding was not possible.
Trial treatments
Ionising radiation
In accordance with the Ionising Radiation (Medical Exposure) Regulations 2000,34 participants in the
trial received a small exposure to ionising radiation in both groups of the trial. This was required to
provide imaging for verification of the treatment level for both microdiscectomy and TFESI. The
ionising radiation exposure required was part of the normal care pathway and the same exposure
would be necessary outside this clinical trial context. There was no additional ionising radiation
exposure to participants as a result of trial participation.
TRIAL DESIGN AND METHODS
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Group A: transforaminal epidural steroid injection
Standard nerve root blockade was completed, as per local policy/technique, using the lateral, foraminal
portal of entry. All fluoroscopically guided techniques (e.g. CT or X-ray screening) were permitted to
specify the correct level. Treating specialists included pain specialists, radiologists, anaesthetists,
surgeons and other appropriately qualified medical professionals, as long as radiological level
confirmation was incorporated into the procedure.
The NERVES trial is a pragmatic trial and, as such, the agents used were obtained and prescribed via
normal NHS routes. The following injection regimen was followed when possible to minimise variability
across the participating centres:
l Injectate:
¢ steroid [20–60 mg of triamcinolone acetonide (KENALOG™; Bristol-Myers Squibb
Pharmaceuticals, Uxbridge, UK)]
¢ local anaesthetic [0.25% levobupivacaine hydrochloride (2 ml) (Chirocaine®; AbbVie Inc.,
North Chicago, IL, USA)].
As the NERVES trial is a Clinical Trial of an Investigational Medicinal Product, information regarding
the pharmaceutical products used was provided to the MHRA. The following active ingredients were
notified to the MHRA and, therefore, are also accepted for use if appropriate:
l Steroid:
¢ dexamethasone
¢ methylprednisolone acetate (Depo-Medrone®, Pfizer Inc., New York, NY, USA).
l Local anaesthetic:
¢ bupivacaine hydrochloride
¢ lidocaine hydrochloride.
For the purpose of participant safety, centres were instructed to ensure that maximum doses were not
exceeded (Table 1).
Note that, if the maximum dose was exceeded, then a data query form was produced at the LCTC and
sent to the centre with a request for justification.
All participants randomised to group A received at least one therapeutic injection. As per local policy,
participants could receive another injection if there was a favourable but partial response that could be
boosted by further injections. Information about any further injections was collected.
TABLE 1 Maximum dose
Injectate Maximum dose (mg)
Triamcinolone acetonide (e.g. KENALOG) 80
Levobupivacaine hydrochloride (e.g. Chirocaine) 10
Dexamethasone 20
Methylprednisolone acetate (Depo-Medrone) 80
Bupivacaine hydrochloride 10
Lidocaine hydrochloride 40
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The steroid/anaesthetic combination used in the TFESI was distributed from pharmacy via routine
processes and so specific trial labelling was not required as per MHRA Exemption Regulation 46 of
the Medicines for Human Use (Clinical Trial) Regulations 2004.35 It is an off-label use of steroid,
but is commonly accepted practice within the NHS and in the further medical field.
Group B: microdiscectomy
Standard microdiscectomy was performed as per local treatment protocols.
Treatment specialists at centres identified the correct side (left or right) and level prior to treatment,
with level localisation advised as per local treatment protocols. Information on site and level was
collected.
Treatment specialists were an orthopaedic or neurosurgical consultant or consultant equivalent
(i.e. associate specialist), or a specialist trainee directly supervised by a consultant.
For both groups, treatment was given within 6 weeks of randomisation when possible and centres
were instructed that treatment should occur within 12 weeks of randomisation to ensure valid
collection of primary outcome data at the 18-week follow-up visit.
Additional treatments
The NERVES trial protocol allocated only initial treatment for sciatica, either microdiscectomy or
TFESI. During the course of follow-up, some participants required further intervention for sciatica,
as per routine NHS practice. Further clinical intervention was permitted for trial participants without
the participant having to withdraw from the trial.
If a participant received additional treatment, information on the type of intervention (i.e. microdiscectomy
or TFESI), the details of the treatment received and the reason were collected, and they remained in
the trial.
Trial participants were able to cross over prior to receiving their initial treatment allocation without
withdrawing from the trial (e.g. if they became unsuitable for the treatment they were initially
randomised to). This was recorded on the treatment CRF with the reason for crossover indicated.
Schedule for follow-up
All follow-up visits were scheduled from the date of randomisation.
Each participant was followed up for 54 weeks following randomisation. During this time, participants
attended scheduled follow-up visits. Table 2 shows the follow-up schedule. Any additional procedures
provided to the participant and completed at the trial centre during this period were documented.
Normal clinical practice would typically include a 3-month post-treatment follow-up. Therefore,
participants were followed up at approximately 18 weeks post randomisation to align with routine
clinical practice, and then again at 30, 42 and 54 weeks. To maintain feasibility, the 18-, 30- and
42-week visits could take place within a 2-week visit window on either side. The 54-week visit had an
acceptable window of 54–62 weeks post randomisation. Participants could be seen at other times,
as clinically indicated. Additional visits outside the trial protocol were recorded.
After randomisation, scheduled treatment and follow-up stages were as follows.
Treatment visit
Treatment details were recorded and the participant was presented with a RUQ booklet and asked
to fill it in prior to their treatment. The centres co-ordinated provision of the RUQ booklet to the
participants in preoperative assessment. Contraindications to treatment (such as pregnancy) were
TRIAL DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
assessed by centres as per NHS policy and, therefore, no additional trial-specific assessments were
conducted at this visit.
When a participant chose to not proceed with their allocated treatment prior to treatment being
given, the participant was still expected to continue with trial follow-up and attend the follow-up visits.
If a participant did not wish to continue in the trial then the date and reason for trial withdrawal
were recorded.
TABLE 2 The NERVES trial design
Procedure
Screening/
baseline
(T= 0)
Follow-up schedule
Unscheduled
visitsc
Intervention
T= 6 weeksa
T= 18
weeks
T= 30
weeksb
T= 42
weeksb
T= 54
weeks
Signed consent form ✓d
Assessment and
confirmation of eligibility
criteria
✓d
Review of medical history ✓d
Review of concomitant
medications
✓d ✓ ✓ ✓
ODQ ✓d ✓ ✓b ✓b ✓
RUQ ✓d ✓ ✓ ✓b ✓b ✓
EQ-5D-5L ✓d ✓ ✓b ✓b ✓
VAS scores for leg and
back pain
✓d ✓ ✓b ✓b ✓
MRM outcome score
for sciatica
✓d ✓ ✓b ✓b ✓
COMI score ✓d ✓ ✓b ✓b ✓
Trial intervention ✓
Pregnancy assessment ✓ ✓ ✓ ✓ ✓
Physical examination ✓d ✓ ✓
Treatment satisfaction
(Likert scale)
✓ ✓ ✓ ✓
Return to work ✓ ✓
Assessment of related AEs ✓ ✓ ✓ ✓
Assessment of additional
interventions given to the
participant during the trial
period
✓ ✓ ✓c
Telephone follow-up of
non-responders
(✓)e (✓)e
(✓), as indicated/appropriate; T, time point.
a Treatment is expected to occur within 6 weeks of randomisation and no later than 12 weeks.
b Participants were not required to attend clinic at 30 and 42 weeks. Questionnaires were posted to the participant
by the trial site and returned by post to the LCTC by the patient.
c Telephone follow-up will typically follow 1 week after initial issue of questionnaire.
d Completed prior to randomisation.
e Additional visits for further treatment (e.g. microdiscectomy or TFESI) may occur as part of routine practice.
Note
Shaded areas indicate that the procedure is not applicable at that time point.
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The 18- and 54-week visits
l A face-to-face follow-up visit (postoperative for the week 18 visit).
l Centres were responsible for organising the follow-up within the visit window (specified in the
e-mail when the participant was randomised).
l Visits were ideally arranged to occur within the first 2 weeks of the visit window, when possible,
giving the centre time within the visit window to take action if the participant did not attend
their appointment.
l Participants underwent a physical examination and data were collected, including concomitant
medications, related AEs, additional treatments and work status.
l Participants completed a questionnaire booklet (incorporating the ODQ, the MRM outcome score
for sciatica, the COMI, a Likert scale for treatment satisfaction, VAS scores for leg and back pain,
the EQ-5D-5L for QoL and the RUQ for costs).
l Pregnancy was assessed when applicable.
Participants not attending visits (weeks 18 and 54)
The primary outcome data for the trial were collected at the week 18 visit and so centres were
reminded of the importance of participants attending the week 18 visit throughout the recruitment
period. Participants were contacted as per trust policy to urge them to attend.
When these attempts failed, centres were instructed to e-mail the LCTC to seek approval to post out
the questionnaire booklet, explaining the circumstances.
Centres were instructed that visits should be arranged initially for the first 2 weeks of the visit window
to give time for the questionnaire booklet to be sent out by post and completed by participants within
the visit window in cases of non-attendance and then returned in a pre-paid envelope to the LCTC.
When visits did not take place, centres were instructed to telephone the participant to try and retrieve
as much information as possible over the telephone.
For the week 18 visit, centres could use a telephone call to collect primary outcome data (i.e. the ODQ
section within the questionnaire booklet) in exceptional circumstances, with agreement from the LCTC.
Weeks 30 and 42 (postal)
l Centres posted the questionnaire booklet to participants at the start of the weeks 30 and 42
window, with a pre-paid envelope for the participant to return the completed booklet to the LCTC.
l The date that the questionnaire booklet was posted was recorded by centres.
l When a response had not been received (notified by the LCTC), the centre research nurse telephoned
the participant to prompt completion and return of the questionnaire booklet and offer any help
required to ensure that the questionnaire booklet was completed accurately.
Data collection and management
Data collection tools
Procedures for assessing efficacy
Efficacy of trial treatment was measured through the period of the trial using a number of outcome measures:
l ODQ at 18 weeks after randomisation (approximately 3 months post treatment).
l ODQ at 30, 42 and 54 weeks after randomisation.
l VAS for leg pain at baseline and at 18, 30, 42 and 54 weeks after randomisation.
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l VAS for back pain at baseline and at 18, 30, 42 and 54 weeks after randomisation.
l Likert scale to assess patient treatment satisfaction at 18, 30, 42 and 54 weeks after randomisation.
l MRM score for sciatica at baseline and at 18, 30, 42 and 54 weeks after randomisation.
l COMI score at baseline and at 18, 30, 42 and 54 weeks after randomisation.
l work status (i.e. return to work and work days lost) at baseline and at 18, 30, 42 and 54 weeks
after randomisation.
The cost-effectiveness of trial treatment, expressed as the incremental cost per QALY, was based on
the following measures:
l EQ-5D-5L questionnaire
l RUQ
l HES
l concomitant medications.
Procedures for assessing safety
An assessment of AEs was undertaken at each trial clinic visit post treatment. These reviews were
carried out by the principal investigator or delegated research staff.
Participant-reported outcomes
Participants were asked to complete the following participant-reported outcome measures at baseline,
18, 30, 42 and 54 weeks post randomisation:
l ODQ
l MRM outcome score for sciatica
l COMI score
l Likert scale for treatment satisfaction
l EQ-5D-5L
l VAS scores for leg and back pain
l health-care resource use and participant costs (including time off work).
The questionnaire booklet was provided to the participant at the scheduled clinic visits (at baseline and
at the 18- and 54-week follow-ups) and completed in clinic. The RUQ booklet was completed at the
treatment visit before treatment and was provided to the participant in preoperative assessment.
Completion of these questionnaires was an important part of the trial. Particular emphasis was given
to part 1 of the questionnaire booklet (i.e. the ODQ) because it was used to collect primary outcome
data for the trial. It was therefore crucial that research staff at centres offered any necessary support
to participants to ensure the questionnaires were completed correctly and returned to the LCTC either
by centres or by the participant in accordance with the schedule for follow-up. The questionnaires took
approximately 15 minutes to complete and participants were advised of the extended visit time prior
to their appointment.
All questionnaires completed at baseline were completed after consent had been provided and prior
to randomisation.
Sample size
The primary outcome measure of ODQ has > 30 years of validation and is supported by Outcome
Measures in Rheumatology, an independent initiative of international health professionals and patient
research partners interested in outcome measures and measurement methodology, especially in
rheumatology. Deyo et al.36 has recommended the use of ODQ as part of the core outcome measures
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for low back research, along with the use of EQ-5D. The scale ranges from 100 (extreme disability) to 0
(extreme ability). A change of 10 points has been widely regarded in the literature as the minimal clinically
important difference (MCID). One study,37 specifically addressing this issue, has suggested a range of
10.5–15 points as clinically important. ODQ has > 30 years of validated, published data pertaining to low
back pathology and radicular symptoms. It has formed the basis for previous HTA trials exploring sciatica
and will allow useful comparisons to be made with previous data. A recent study by Chiarotto et al.38 has
sought to specify a core outcome set for low back pain (not specifically sciatica) and the authors have
recommended the use of four items: (1) physical functioning (either ODQ or MRM scores), (2) numerical
pain rating score for pain intensity, (3) health-related QoL assessment (although no consensus reached,
the Short Form questionnaire-12 items or Patient-Reported Outcomes Measurement Information System
were recommended) and (4) mortality. Although published after our trial conception, we have collected all
of these outcomes apart from EQ-5D-5L for the health-related QoL and VAS for the pain intensity score.
Original trial sample size calculation
A total of 172 participants was required to detect a difference of 10 points between the two groups
on the ODQ at a 5% significance level with 90% power. This assumed a standard deviation (SD) of
20 points based on similar populations in previous published trials.18,36,37,39,40 The previous large and
well-carried out WEST, based in the UK, suggested a baseline ODQ SD of between 16 and 18 points.18
Baseline ODQ data were collected on 11 potentially eligible patients from the fast-track sciatica clinic
at the Walton Centre, Liverpool, and this generated a SD of 14.4 points, well under the assumed value.
The initial target sample size for the trial was 200 patients, which would allow for a 10% rate of missing
outcome data. Of the originally planned seven centres involved, allowing for one to have difficulties
opening, this would require recruitment of 30 patients in total from each participating centre and
50 patients from the lead centre.
Revised sample size calculation for the primary outcome
The original sample size calculation did not assume any correlation between baseline and follow-up
ODQ scores, as no data were available to estimate this. The sample size calculation was revisited
during the trial with the agreement of the trial oversight committees. Based on a blinded analysis of
the correlation between baseline and follow-up ODQ scores in the first 47 trial participants to have
outcome data available, the correlation was estimated as 0.49.
Using this estimate, our revised sample size to achieve 90% power was 66 participants per
group. Allowing for 10% loss to follow-up gives a revised target of 74 participants per group
(i.e. 148 participants total).
Internal pilot study
An internal pilot study was included in the trial design. The study targeted two centres to open first
to collect 6 months of recruitment data before progressing to a full trial. These centres, the Walton
Centre, Liverpool, and Salford Royal, Manchester, were identified to cover recruitment of participants
within specialty and mixed care settings.
The aim of the internal pilot study was to assess the feasibility of recruitment and the rates of
potential crossover due to patient preference or treatment failure. The criteria for progression to a full
trial were:
l at least 30 patients recruited
l a consent rate of ≥ 40% or more
l < 10% of patients unhappy with allocation and receive the alternative treatment
l < 50% of patients in the injection group proceed to surgery.
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Changes to the protocol
The protocol has been previously published.41 The study opened on protocol version 3.0 and the final
approved version was 8.0, which contains a detailed list of the protocol changes [see www.fundingawards.
nihr.ac.uk/award/12/201/10 (accessed 16 July 2020)]. Table 3 lists the key protocol changes.
TABLE 3 Key protocol amendments
Protocol version (date) Key amendment
3.0 (15 December 2014) Minor amendment
Eligibility criteria changes: inclusion criteria
l ‘Newly diagnosed sciatica secondary to PID (proven on MRI)’ changed to ‘Newly
diagnosed lower extremity radiculopathy (sciatica)’
l ‘Diagnosed with lower extremity radiculopathy (sciatica) secondary to a lumber disc
herniation’ changed to ‘Sciatica secondary to prolapsed intervertebral disc (PID)
(proven on MRI)’
l Criteria addressing conservative treatments (i.e. medication, modification of daily
activities and physiotherapy) have been combined to ‘Patient has attempted at least
one form of conservative (non-operative) treatmenta but this has not provided
adequate relief of patient’s pain/symptoms’
Eligibility criteria changes: exclusion criteria
l ‘Pregnancy’ changed to ‘Patient known to be pregnant’
l ‘Not attempted conservative non-operative treatment for a minimum of 6 weeks’
changed to ‘Patient has not attempted any form of conservative treatment’
Additional expected AEs associated with microdiscectomy and TFESI added
Removal of requirement for investigators to assess expectedness when recording AEs
‘Do not include’ list for SAEs reporting updated
Minor amendments for clarity and minor corrections
4.0 (5 May 2015) Minor amendment
Eligibility criteria changes: inclusion criteria
l ‘Newly diagnosed lower extremity radiculopathy (sciatica)’ changed to ‘Diagnosed
lower extremity radiculopathy (sciatica)’
l ‘Severe leg pain non-responsive to conservative, non-invasive management’ changed
to ‘Leg pain non-responsive to conservative, non-invasive management’
Eligibility criteria changes: exclusion criteria
l ‘Neurological deficit (e.g. foot drop/possible cauda equina compression)’ changed to
‘Serious neurological deficit (e.g. foot drop/possible cauda equina compression)’
Centre inclusion criteria added
l ‘TFESI performed according to protocol requirements (i.e. specified pharmaceutical
agents available from pharmacy via local routine prescription routes)’
l ‘Able to provide both treatments within 12 weeks of randomisation’
l ‘Principal investigator can be either a representative of neurosurgery or pain
management; both specialties should be represented within the local research team’
continued
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TABLE 3 Key protocol amendments (continued )
Protocol version (date) Key amendment
Clarification of treatment timelines added
l ‘Treatment must occur within 12 weeks of randomisation to ensure valid collection
of primary outcome data at the 18 week follow-up’
Addition of an expected TFESI regimen specifically:
l ‘Injectate:
¢ steroid 20–60 mg triamcinolone (e.g. KENALOG)
l Local anaesthetic:
¢ 0.25% levobupivacaine (2 ml) (e.g. Chirocaine)’
Addition of text clarifying AE reporting requirements specifically defining ‘reactions’
(related to IMP) vs. ‘events’ (related to procedures)
Minor amendments for clarity and minor corrections
5.0 (19 August 2015) Substantial amendment
Addition of statistician sign-off and addition of IRMER
6.0 (21 March 2016) Substantial amendment
Eligibility criteria changes: inclusion criteria
l ‘Duration of symptoms between 6 weeks and 6 months’ changed to ‘Duration of
symptoms between 6 weeks and 12 months’
Eligibility criteria changes: exclusion criteria
l ‘Sciatica presentation for longer than 6 months’ changed to ‘Sciatica presentation for
longer than 12 months’
Addition of CT scanning for guidance of the TFESI injection
Addition of text outlining the procedures for follow-ups at weeks 18, 30, 42 and
54 weeks and clarification of the process for dealing with non-attendance at
weeks 18 and 54
Addition of text clarifying SAE assessment of expectedness process, specifically that the
chief investigator will undertake the assessment
Addition of ‘Recurring prolapse of the disc’ to expected list of events for
microdiscectomy table
Process of reporting AEs has been reduced to one flow chart to clarify the procedure.
The flow chart includes requirements to report pregnancies and any deaths
Minor amendments for clarity and minor corrections
7.0 (25 October 2017) Substantial amendment
Target population changed from 200 to 148 participants
Eligibility criteria changes: inclusion criteria
l ‘Patient willing and able to give consent’ changed to ‘Patient has provided written,
informed consent’
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TABLE 3 Key protocol amendments (continued )
Protocol version (date) Key amendment
Study duration changed from ‘54 weeks’ to ‘54–60 weeks’
List of accepted active ingredients for use in the TFESI group added
Table of expected maximum doses for each active ingredient used in the TFESI
group added
Section added providing guidance on what should be done when participants do not
attend the 18- and 54-week visits
Option for collection of week 18 primary outcome data to be collected by telephone as
‘last resort’ added
‘Pregnancy’ section added allowing assessment of pregnancy throughout trial
Statement added clarifying patients should not be withdrawn unless specifically
requested
‘Revised Sample Size’ section added
Pharmacovigilance section modified throughout for clarification:
l ‘Adverse reaction’ defined for the NERVES trial
l ‘Unexpected adverse reaction’ defined for the NERVES trial
l Unrelated AEs clarified as not reportable
l TFESI causality reporting requirements clarified
Definitions and responsibilities defined for assessment of expectedness: chief
investigator’s responsibility (not the principal investigator) based on relevant safety
information available at the time
Expected AE tables reworked for clarity
Addition of expected AEs ‘anaphylaxis’ and ‘low-pressure headache’ added to expected
AE tables
‘Overdose of any medication without signs or symptoms’ added to non-reportable list
Safety reporting period defined as ‘from intervention up to and including the week 54
follow-up visit’
Process for completing SAE forms amended as per the LCTC processes
Addition of ‘urgent safety measures’ and ‘protocol deviations and serious breaches’
sections
Minor amendments for clarity and minor corrections
8.0 (10 April 2019) Substantial amendment
Change in lead sponsor contact/signatory
Minor amendments for clarity and minor corrections
IMP, Investigational Medicinal Product; IRMER, Ionising Radiation (Medical Exposure) Regulations; SAE, serious
adverse event.
a Including but not limited to medication, physiotherapy and modification of daily activities.
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Patient and public involvement
The trial team collaborated with patient contributors throughout the trial, all of whom had personal
experience of the condition and/or interventions being examined.
l Prior to funding application submission, a patient representative reviewed the trial design to
confirm agreement with the principle of the trial.
l Patient representatives reviewed the full funding application prior to submission.
l Members of the public were involved in the development of the PISC by providing feedback.
l Patient representatives were recruited to the TMG and Trial Steering Committee (TSC), both of
which were actively involved at the start of the trial.
l Once the centres had been opened and recruitment was under way we entered a phase of the
trial in which the TMG discussions focused on issues relating to governance and internal trial
management. During this period, it was more difficult to engage our patient representatives and to
ensure that the discussions were relevant and interesting to them. The TMG patient representative
stopped attending meetings during this period and the TSC patient representative resigned in
March 2017.
l In December 2018, two patient representatives were recruited to join the TMG [via the INVOLVE
website (URL: www.invo.org.uk)] with the purpose of helping us to design our end-of-trial information
and ensure that the results from the trial are understandable and accessible, particularly to those
who have suffered from sciatica.
l The new TMG patient representatives have reviewed this report and we intend to involve them in
producing our end-of-trial information. We hope to encourage patient representative co-authorship
and co-presenting of our findings to patient and clinical audiences to ensure that the impact of
the findings are maximised.
Compliance with Intervention
The LCTC monitored compliance with the randomised trial intervention through completion of CRFs
at centres recording the intervention given and the allocation provided by the online randomisation
system. Any deviations from the randomised intervention were explored with centres. As the NERVES
trial was a pragmatic trial and the interventions were expected to reflect local NHS policy, the rates of
compliance with the interventions were expected to vary between NHS sites.
Trial oversight and role of funders
Trial Management Group
The TMG was a multidisciplinary team that comprised the chief investigators, several co-investigators,
patient and public involvement (PPI) representatives, a sponsor representative, health economists and
members of the LCTC. The TMG was responsible for the day-to-day clinical and practical aspects of
the trial.
Independent Data and Safety Monitoring Committee
The Independent Data and Safety Monitoring Committee (IDSMC) comprised an independent
chairperson, an expert in the field of pain and two independent members (one was an expert in the
field of neurosurgery and one was an expert in medical statistics). The main responsibilities of the
IDSMC was to safeguard the interests of the NERVES trial participants, assess the safety and efficacy
of the interventions during the course of the trial, and monitor the overall progress and conduct of the
trial. The IDSMC met at least annually during the course of the trial and provided recommendations to
the TSC. Reports to the IDSMC were produced by the statistical team at the LCTC.
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Trial Steering Committee
The membership of the TSC included an independent chairperson, an independent expert in the field
of pain, an independent expert in the field of neurosurgery and an independent statistician, as well
as representatives from the TMG. Observers from the sponsor and the funder were also invited to
meetings. The TSC met at least annually, shortly after the IDSMC met and their main role was to
provide overall oversight of the trial.
Trial funder
The membership of the oversight committees was suggested by members of the TMG to the trial
funders and appointed by the funders with their constitution following funder requirements.
Statistical methods
The main features of the analyses were specified in the protocol and a separate detailed statistical
analysis plan (see Report Supplementary Material 1) was developed prior to randomisation codes
being released.
All efficacy outcomes were analysed using the intention-to-treat principle as far as practically possible.
Safety outcomes were reported based on actual treatment received. All applicable statistical tests
were two-sided and used a 5% significance level. No adjustments for multiplicity were made for the
secondary outcomes.
Baseline data for continuous variables are presented as both means and SDs, and medians and
interquartile ranges (IQRs). Categorical variables are presented using frequencies and percentages.
The primary outcome variable (i.e. ODQ at 18 weeks) was compared between groups using a linear
regression model, adjusting for the stratification variable centre and baseline ODQ. The potential
impact of missing data on the primary outcome results was explored using multiple imputation analysis.
An extended model was also fitted, adjusting for age, sex, duration of symptoms, body mass index
(BMI) and estimated volume of canal occupied by disc prolapse as shown on MRI scan. An additional
post hoc model added an adjustment for level of disc prolapse.
The secondary outcomes measured at multiple time points were analysed using repeated measures
random-effects models, adjusting for baseline outcome score, time (as a continuous variable) and a
time–treatment interaction. The time–treatment interaction term was dropped in models when it was
found to be non-significant (p > 0.05). A post hoc analysis using joint modelling of the same longitudinal
outcome data and the time to study dropout was undertaken. The aim was to assess sensitivity of the
results for potentially informative dropout from the study.
The secondary outcome of participant satisfaction was compared between groups using a Mann–Whitney
U-test. The satisfaction with care outcome was measured using a two-item questionnaire with a 1- to 5-point
Likert scale. The average of the two items was taken, with possible values ranging from 1 to 5 and
lower values indicating higher levels of satisfaction. The return-to-work status was compared using a
chi-squared test.
Safety data on AEs and serious adverse events (SAEs) are presented descriptively, with no
inferential statistics.
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Chapter 3 Clinical effectiveness results
Screening and recruitment
The trial opened to recruitment on 4 March 2015 and closed on 9 July 2018 after the final follow-up
of all participants had been completed. A total of 1055 participants were screened for eligibility
from 12 centres and a total of 163 participants were randomised from 11 of the 12 centres. Of the
participants screened for eligibility, 723 (69%) were found to be ineligible. Of those eligible and
approached for consent, 163 (49%) consented and were randomised into the trial.
Figure 2 shows the participant flow from screening to consent and randomisation.
Internal pilot
The internal pilot phase of the trial was reviewed by the IDSMC in September 2015 after 25 participants
were recruited from two centres. The committee assessed the recruitment, consent rates, treatment
switches and crossover rates, and recommended that the trial continue with the remaining centres
being opened.
Baseline comparability
Tables 4–6 summarise baseline participant characteristics, details of management and impact of
sciatica, and relevant clinical characteristics, by randomised group. The randomised groups were
generally similar in their baseline characteristics.
Adherence to treatment, additional treatments and retention
Withdrawals
There were a total of six withdrawals from the trial (three from the microdiscectomy group and three
from the TFESI group).
The reasons given for withdrawal in the TFESI group were:
l patient unwilling to have microdiscectomy or TFESI
l site exhausted all means of communication with participant
l chest infection and investigation for possible bowel cancer.
Reasons given for withdrawal from the microdiscectomy group were withdrawal of consent for follow-up,
participant not happy with the process (one withdrawal) and withdrawal of consent for follow-up, no
additional reason (two withdrawals).
Treatment compliance
A further 14 participants did not initially receive any treatment (seven randomised to microdiscectomy
and seven to TFESI). Table 7 shows all combinations of treatments received by participants.
Eight participants did not receive their randomised treatment, but were given the alternative
treatment instead (five randomised to microdiscectomy and three randomised to TFESI). Of the five
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participants randomised to microdiscectomy, three changed because of participant preference, one
because of safety concerns from the anaesthetist and one because their symptoms had improved
and microdiscectomy was thought to be unnecessary. Of the three participants randomised to TFESI,
two changed to microdiscectomy because of participant preference and the other was reported as a
surgeon decision.
Enrolment
Assessed for eligibility
(n = 1055)
Randomised
(n = 163)
Excluded
(n = 892)
• Not meeting inclusion criteria, n = 723
• Not approached for consent, n = 24
• Declined to participate, n = 143
• Approached/consent data missing, n = 1
• Eligible y/n missing, n = 1
Allocated to surgery
(n = 83)
• Received allocated intervention, n = 71
• Received other intervention, n = 5
• Received no intervention, n = 7
Allocation
Follow-up 4
Analysed
Allocated to injection
(n = 80)
• Received allocated intervention, n = 70
• Received other intervention, n = 3
• Received no intervention, n = 7
Week 18
(n = 72)
• Lost to follow-up, n = 5, + Withdrawal, n = 3
Week 18
(n = 76)
• Lost to follow-up, n = 4, + withdrawal, n = 3
Week 30 (postal)
(n = 72)
• Lost to follow-up, n = 4
Week 42 (postal)
(n = 69)
• Lost to follow-up, n = 3
Week 42 (postal)
(n = 66)
• Lost to follow-up, n = 3
Week 54
(n = 64)
• Lost to follow-up, n = 5
Week 54
(n = 59)
• Lost to follow-up, n = 7
Week 30 (postal)
(n = 69)
• Lost to follow-up, n = 3
PO analysis
(n = 61)
• Excluded from analysis, n = 22
• Out of window, n = 7
• Invalid or missing, n = 15
PO analysis
(n = 63)
• Excluded from analysis, n = 17
• Out of window, n = 3
• Missing, n = 14
Follow-up 1
Follow-up 2
Follow-up 3
FIGURE 2 Consolidated Standards of Reporting Trials (CONSORT) flow diagram for all trial participants. PO, primary
outcome; y/n, yes/no.
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TABLE 4 Baseline participant characteristics
Characteristic Summary Microdiscectomy TFESI Overall
Number of participants
randomised
83 80 163
Sex n (missing) 83 (0) 80 (0) 163 (0)
Female, n (%) 46 (55.4) 40 (50.0) 86 (52.8)
Male, n (%) 37 (44.6) 40 (50.0) 77 (47.2)
Age (years) n (missing) 83 (0) 80 (0) 163 (0)
Mean (SD) 43.5 (9.9) 41.2 (8.6) 42.4 (9.3)
Median (IQR) 42.8 (34.9–50.5) 41.4 (35.2–47.0) 42.2 (35.2–48.9)
Range 23.2–65.6 23.3–59.8 23.2–65.6
Of reproductive potential
(female only)
n (missing) 46 (0) 40 (0) 86 (0)
No, n (%) 11 (23.9) 5 (12.5) 16 (18.6)
Yes, n (%) 35 (76.1) 35 (87.5) 70 (81.4)
Weight (kg) n (missing) 75 (8) 71 (9) 146 (17)
Mean (SD) 83.7 (16.8) 81.4 (20.7) 82.6 (18.8)
Median (IQR) 82.0 (72.0–95.1) 77.1 (67.0–94.0) 79.3 (69.8–94.0)
Range 54.0–134.0 51.7–154.0 51.7–154.0
Height (cm) n (missing) 76 (7) 71 (9) 147 (16)
Mean (SD) 171.7 (10.7) 172.6 (9.5) 172.2 (10.1)
Median (IQR) 170.1 (164.0–180.7) 173.0 (167.0–180.0) 171.5 (165.0–180.0)
Range 147.0–197.0 150.0–192.0 147.0–197.0
BMI (kg/m2) n (missing) 74 (9) 68 (12) 142 (21)
Mean (SD) 28.2 (5.3) 27.2 (6.4) 27.7 (5.9)
Median (IQR) 26.9 (24.5–31.3) 25.6 (22.9–29.4) 26.4 (24.1–30.7)
Range 18.9–44.3 17.1–47.1 17.1–47.1
TABLE 5 Baseline details of treatment and effect of sciatica
Treatment Summary Microdiscectomy TFESI Overall
Number of participants
randomised
83 80 163
Taking anticoagulant medication n (missing) 83 (0) 80 (0) 163 (0)
No, n (%) 82 (98.8) 79 (98.8) 161 (98.8)
Yes, n (%) 1 (1.2) 1 (1.3) 2 (1.2)
Number of weeks with
symptoms
n (missing) 83 (0) 80 (0) 163 (0)
Mean (SD) 21.5 (10.7) 21.1 (11.2) 21.3 (10.9)
Median (IQR) 17.0 (14.0–28.0) 18.0 (13.0–27.0) 18.0 (14.0–28.0)
Previous surgery at disc level n (missing) 83 (0) 80 (0) 163 (0)
No, n (%) 82 (98.8) 80 (100.0) 162 (99.4)
Yes, n (%) 1a (1.2) 0 (0.0) 1 (0.6)
continued
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TABLE 5 Baseline details of treatment and effect of sciatica (continued )
Treatment Summary Microdiscectomy TFESI Overall
Taken medication for pain and
symptoms
n (missing) 83 (0) 80 (0) 163 (0)
Yes, n (%) 83 (100.0) 80 (100.0) 163 (100.0)
Modified activity n (missing) 83 (0) 80 (0) 163 (0)
No, n (%) 0 (0.0) 1 (1.3) 1 (0.6)
Yes, n (%) 83 (100.0) 79 (98.8) 162 (99.4)
Attended physiotherapy n (missing) 83 (0) 80 (0) 163 (0)
No, n (%) 15 (18.1) 16 (20.0) 31 (19.0)
Yes, n (%) 68 (81.9) 64 (80.0) 132 (81.0)
Other conservative treatment n (missing) 83 (0) 80 (0) 163 (0)
No, n (%) 49 (59.0) 43 (53.8) 92 (56.4)
Yes, n (%) 34 (41.0) 37 (46.3) 71 (43.6)
Currently employed n (missing) 83 (0) 79 (1) 162 (1)
No, n (%) 21 (25.3) 13 (16.3) 34 (20.9)
Yes, n (%) 62 (74.7) 66 (82.5) 128 (78.5)
Currently unable to work
because of sciatica (of those
employed)
n (missing) 62 (0) 66 (0) 128
No, n (%) 41 (66.1) 34 (51.5) 75 (58.6)
Yes, n (%) 21 (33.9) 32 (48.5) 53 (41.4)
Currently taking analgesics/
steroids/anticoagulant
medication
n (missing) 83 (0) 80 (0) 163
No, n (%) 7 (8.4) 7 (8.8) 14 (8.6)
Yes, n (%) 76 (91.6) 73 (91.3) 149 (91.4)
a This patient was not excluded from the primary analysis as the ITT principle was followed. This was recorded as a
major protocol deviation.
TABLE 6 Baseline clinical characteristics
Clinical characteristic Summary Microdiscectomy TFESI Overall
Number of participants
randomised
83 80 163
Estimated volume of
canal occupied by
disc prolapse
n (missing) 83 (0) 80 (0) 163
< 25%, n (%) 43 (51.8) 44 (55.0) 87 (53.4)
25–49%, n (%) 36 (43.4) 34 (42.5) 70 (42.9)
≥ 50%, n (%) 4 (4.8) 2 (2.5) 6 (3.7)
Level of disc prolapsea n (missing) 75 (8) 73 (7) 148 (15)
L2/3, n (%) 1 (1.2) 0 (0.0) 1 (0.6)
L3/4, n (%) 1 (1.2) 2 (2.5) 3 (1.8)
L4/5, n (%) 27 (32.5) 25 (31.3) 52 (31.9)
L5/S1, n (%) 46 (55.4) 46 (57.5) 92 (56.4)
L2, second lumbar; L3, third lumbar; L4, fourth lumbar; L5, fifth lumbar; S1, first sacral.
a Level of disc prolapse was recorded only at treatment visit and is therefore is not available for participants who did
not receive an intervention. Further baseline clinical characteristics can be found in Table 36.
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Additional treatment
The rows in italics in Table 7 indicate participants who have received the alternative trial treatment
after their initial treatment. The largest group (28 participants) includes those who received the
TFESI initially and subsequently went on to receive microdiscectomy as an additional treatment.
The first row in italics denotes those who received their allocated treatment first and then the
alternative treatment. The second row in italics denotes those who initially received a treatment
to which they were not allocated, but then subsequently additionally received the original planned
allocation. Table 8 summarises the timing of treatments for those patients who received both TFESI
and microdiscectomy.
TABLE 7 Summary of treatments received
Detail
Microdiscectomy (N= 83),
n (%)
TFESI (N= 80),
n (%)
Received randomised treatment initially
Single randomised treatment 65 (78.31) 40 (50)
Repeated randomised treatment 3a (3.61) 2 (2.5)
Randomised treatment then the alternative treatment at least once 3 (3.61) 28 (35)
Received alternative treatment initially
Single alternative treatment 3 (3.61) 3 (3.75)
Repeated alternative treatment 1 (1.2) 0
Alternative treatment then the randomised treatment 1 (1.2) 0
Lateb/no treatment
No treatment recorded during trial 4 (4.82) 4 (5)
Late randomised treatment 0 1 (1.25)
Late alternative treatment(s) 3 (3.61) 2 (2.5)
a Repeated randomised treatments in microdiscectomy group were revision surgeries.
b Late was defined as a treatment visit that did not occur during the planned treatment window and occurred after
primary outcome assessment.
Note
The rows in italics indicate participants who have received the alternative trial treatment after their initial treatment.
TABLE 8 Patients receiving both trial treatments in relation to primary outcome completion
Timing
Microdiscectomy (N= 83),
n (%)
TFESI (N= 80),
n (%)
Received other treatment after primary outcome 2 (2.41) 13 (16.25)
Received other treatment before primary outcome 2 (2.41) 13 (16.25)
Received both treatments, but no primary outcome available 0 2 (2.50)
Total 4 (4.82) 28 (35.00)
Note
The table includes only patients who completed a valid primary outcome questionnaire.
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Protocol deviations
Prespecified protocol deviations are summarised in Table 37. The most common major protocol
deviations were missing primary outcome data (n = 28) and treatment compliance (i.e. receiving
randomised treatment) (n = 22).
Analysis sets
Table 9 gives the number of participants in the analysis sets. The ITT data set included all randomised
participants. The safety data set included every participant who received one of the trial interventions.
Note that safety outcomes are analysed based on actual treatment received, rather than randomised groups.
Primary outcome: Oswestry Disability Questionnaire at 18 weeks
The primary outcome was the ODQ measure at 18 weeks after randomisation. Questionnaires
completed within a window of 6 weeks either side of 18 weeks (i.e. 12–24 weeks) were included in
this analysis. The ODQ is a 10-item questionnaire; item 8 (‘sex life’) may not be applicable. If the
number of items answered is fewer than eight items then this questionnaire was excluded from the
analysis and considered invalid (as specified in the statistical analysis plan, see Report Supplementary
Material 1). Table 10 shows descriptive statistics of the ODQ at baseline and at week 18, including the
difference between baseline and week 18 values. The differences are also categorised into those who
improved by ≥ 10 points (considered clinically significant), those who improved < 10 points but at least
0 and those for whom the symptoms got worse.
Table 10 shows the improvements in ODQ compared with baseline for both microdiscectomy and
TFESI groups. Both groups showed similar improvements in ODQ (27 points following microdiscectomy
and 25 points following TFESI). Comparable numbers of patients in each group achieved a MCID
(defined as an improvement of > 10 points: 74% following microdiscectomy and 69% following TFESI).
In both groups, the majority of participants’ symptoms improved from baseline to 18 weeks, with only
13% in the microdiscectomy group and 10% in the TFESI group showing a deterioration in symptoms.
Figure 3 shows the distributions of the differences between baseline and 18-week scores by group.
The primary outcome was compared between groups using a linear regression model, adjusting for
centre and baseline ODQ score. There was no statistically significant difference in ODQ between the
randomised groups, with the model estimate of the effect of microdiscectomy compared with TFESI
being –4.25 points, with a 95% confidence interval (CI) of –11.09 to 2.59 points (p = 0.221). From this
model, we estimate that microdiscectomy will result in an improvement in ODQ of 4.25 points more
than TFESI, which is less than the MCID of 10 points (although the 95% CI narrowly includes values
> 10 points, which suggests that a significant clinical difference is just plausible).
TABLE 9 Summary of data sets analysed
Population Microdiscectomy, n TFESI, n Total, n
Randomised 83 80 163
ITT 83 80 163
Safetya 105 82 155
a The safety analysis set is defined by what participants actually received. As some participants had received
treatments in both treatment groups, they are included in the safety set for both treatment groups. Total for safety
group is the number of participants who received either treatment.
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TABLE 10 Summary of ODQ scores (points) at baseline and week 18
Time point Summary Microdiscectomy TFESI Overall
Baseline n 83 79 162
n missing 0 1 1
Mean (SD) 49.39 (17.81) 53.74 (19.35) 51.51 (18.64)
Median (IQR) 46.67 (36.00–62.22) 54.00 (40.00–71.11) 50.00 (38.00–66.00)
Week 18 n 61 63 124
n missing/invalid 22 17 39
Mean (SD) 22.30 (19.83) 30.02 (24.38) 26.22 (22.51)
Median (IQR) 18.00 (6.00–36.00) 22.22 (10.00–50.00) 20.00 (9.00–37.89)
Difference n 61 63 124
n missing/invalid 22 17 39
Mean (SD) –26.74 (21.35) –24.52 (18.89) –25.61 (20.09)
Median (IQR) –26 (–40 to –8.89) –26 (–38 to –6) –26 (–39 to –8)
95% CI –32.21 to –21.27 –29.28 to –19.76 –29.18 to –22.04
Difference category n 61 63 124
Improvement of
≥ 10 points, n (%)
45 (73.8) 43 (68.3) 88 (71.0)
Improvement of
< 10 points, n (%)
8 (13.1) 14 (22.2) 22 (17.7)
Deterioration in
symptoms, n (%)
8 (13.1) 6 (9.5) 14 (11.3)
CI, confidence interval.
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FIGURE 3 Distribution of differences between baseline and 18-week ODQ scores.
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Adjustment for additional covariates
An additional model was fitted, adjusting for other prespecified variables, age, sex, duration of
symptoms, BMI and estimated volume of canal. This adjusted model gave an estimate of the effect
of microdiscectomy compared with TFESI of –5.03 with a 95% CI of –12.76 to 2.70. An additional
variable, level of disc prolapse, was included in a post hoc analysis. This model resulted in an estimate
of –4.94 (95% CI –12.81 to 2.93). Table 11 shows the full parameter estimates for both models.
A further post hoc analysis was conducted to assess if there was an interaction between duration of
symptoms at baseline and randomised treatment. The interaction term was not statistically signficant
and the estimated difference in least squares means between treatment groups for microdiscectomy
compared with TFESI (when an interaction with duration of symptoms was adjusted for) was –4.18
(95% CI –11.06 to 2.70; p = 0.231). Therefore, there is no statistically significant difference between
treatment groups when an interaction with the duration of symptoms at baseline is considered.
This supports the conclusion of the primary outcome analysis.
Sensitivity analysis
As > 10% of data on the primary outcome were missing, a sensitivity analysis was conducted using
multiple imputation. This analysis used treatment group, centre and all available measurements of
ODQ at various time points to impute data to create 50 complete data sets, which were then analysed
and combined to give the imputed estimate.
The estimate of the effect of microdiscectomy compared with TFESI from the imputation analysis was
–3.08 (95% CI –10.16 to 3.99).
TABLE 11 Parameter estimates for extended primary outcome models
Variable Level
Model 1a Model 2b
Estimate (95% CI) p-value Estimate (95% CI) p-value
Intercept 3.40 (–29.36 to 36.17) 5.95 (–28.76 to 40.66)
Baseline ODQ
score
0.62 (0.42 to 0.82) 0.63 (0.43 to 0.83)
Age (years) –0.16 (–0.56 to 0.23) –0.20 (–0.61 to 0.21)
Sex Female vs. male 7.7 (0.05 to 15.34) 5.78 (–2.06 to 13.63)
Duration of
symptoms (weeks)
0.167 (–0.26 to 0.59) 0.22 (–0.21 to 0.65)
BMI (kg/m2) –0.26 (–0.90 to 0.39) –0.22 (–0.88 to 0.45)
Location L2/3 vs. L5/S1 –17.07 (–56.93 to 22.79)
L3/4 vs. L5/S1 13.81 (–25.93 to 53.55)
L4/5 vs. L5/S1 –5.6 (–13.48 to 2.29)
Volume Between 25% and
50% vs. < 25%
–0.19 (–7.85 to 7.48) –0.82 (–8.68 to 7.04)
> 50% vs. < 25% –10.76 (–31.03 to 9.52) –11.84 (–32.05 to 8.36)
Allocation Microdiscectomy
vs. TFESI
–5.03 (–12.76 to 2.70) 0.1991 –4.94 (–12.81 to 2.93) 0.215
L2, second lumbar; L3, third lumbar; L4, fourth lumbar; L5, fifth lumbar; S1, first sacral.
a Model 1 covariates: age, sex, duration of symptoms, BMI and estimated volume of canal.
b Model 2 covariates: age, sex, duration of symptoms, BMI, estimated volume of canal and level of disc prolapse.
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A post hoc sensitivity analysis was conducted to using multiple imputation, as above, but using only
baseline ODQ to impute a week 18 score. The estimate of the effect of microdiscectomy compared
with TFESI from the post hoc imputation analysis was –3.26 points (95% CI –9.91 to 3.39 points).
Table 12 summarises the estimates from the primary outcome analyses. All estimates lead to the
same conclusion, that is there is no statistically significant difference between the treatments, with all
estimates showing slightly better outcomes in the microdiscectomy group, although smaller than the
prespecified clinically important difference.
Secondary outcomes
Longitudinal outcomes
For the longitudinal outcomes (i.e. ODQ, VAS leg pain, VAS back pain, MRM and COMI) the
questionnaires were collected at four key time points (i.e. 18, 30, 42 and 54 weeks post
randomisation). The 18- and 54-week follow-up visits were conducted face to face, whereas the
30- and 42-week follow-up time points were postal questionnaires. As a result, the rates of completion
are lower at these time points.
For the change from baseline summaries in the following sections the prespecified windows from the
protocol for a questionnaire to be included were ± 2 weeks for the 18-, 30- and 42-week follow-ups
and between 54 and 62 weeks for the 54-week follow-up. However, in the longitudinal mixed-effects
models the time (in weeks) was treated as continuous and all valid and completed questionnaires were
included in the analyses.
Secondary outcome 1: Oswestry Disability Questionnaire at 18, 30, 42 and 54 weeks
The ODQ data are analysed using longitudinal models and include the primary outcome time point of
18 weeks.
Table 13 shows the mean and SDs of the change from baseline for the observations at each time point.
Table 13 includes observations in the prespecified time windows from the protocol. The longitudinal
TABLE 13 Change from baseline summaries for ODQ score (points)
Time point (week)
Microdiscectomy TFESI Overall
n Mean change (SD) n Mean change (SD) n Mean change (SD)
18 46 –27.18 (22.31) 51 –24.29 (18.28) 97 –25.66 (20.24)
30 40 –26.62 (19.12) 30 –23.25 (17.45) 70 –25.17 (18.37)
42 40 –31.40 (17.22) 34 –25.51 (23.74) 74 –28.69 (20.54)
54 48 –30.38 (17.77) 42 –31.10 (24.35) 90 –30.71 (20.97)
TABLE 12 Summary of estimates from primary outcome analyses
Analysis Estimate 95% CI p-value
Primary analysis –4.27 –11.09 to 2.59 0.221
Extended model –5.03 –12.76 to 2.70 0.199
Post hoc extended model –4.94 –12.81 to 2.93 0.215
Multiple imputation –3.08 –10.16 to 3.99 0.393
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analysis includes all ODQ measurements taken at any point during the trial. Table 13 shows that most
improvement in both groups happens between baseline and week 18, with any further improvements
being relatively small.
The longitudinal mixed-model analysis adjusted for baseline ODQ initially included a time–treatment
interaction term, but as this was non-significant it was removed from the final model, as prespecified
in the statistical analysis plan. The adjusted estimate for the effect of microdiscectomy compared with
TFESI was –4.67 points (95% CI –10.61 to 1.28 points; p = 0.123). This estimate is consistent with that
shown in the primary outcome analysis of ODQ at 18 weeks.
For the joint modelling post hoc analysis of ODQ scores, the adjusted estimate for the effect of
microdiscectomy compared with TFESI was –4.62 points (95% CI –9.84 to 1.27 points; p = 0.108). The
estimate is similar to the longitudinal mixed model and the conclusions remained unchanged once adjusted
for informative dropout. Figure 4 shows profile plots of mean ODQ score at each scheduled time point.
Secondary outcome 2: visual analogue scale score for leg pain at 18, 30, 42 and 54 weeks
Table 14 shows change from baseline at each time point for VAS leg pain rating, where valid
measurements were available within the prespecified time window. After an initial large reduction
between baseline and week 18, average VAS leg pain ratings were similar over the further follow-up
visits. Figure 5 shows profile plots of mean VAS leg pain rating at each scheduled time point.
TABLE 14 Change from baseline summaries for VAS leg pain rating
Time point (week)
Microdiscectomy TFESI Overall
n Mean change (SD) n Mean change (SD) n Mean change (SD)
18 45 –58.31 (34.51) 49 –43.55 (32.52) 94 –50.62 (34.12)
30 38 –54.37 (27.05) 30 –42.70 (35.27) 68 –49.22 (31.25)
42 37 –55.81 (31.66) 33 –47.12 (42.28) 70 –51.71 (37.03)
54 43 –55.44 (33.57) 39 –47.08 (33.06) 82 –51.46 (33.39)
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FIGURE 4 Mean profile plot of ODQ scores with standard error bars.
CLINICAL EFFECTIVENESS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
The longitudinal mixed-model analysis adjusted for baseline VAS leg pain initially included a
time–treatment interaction term, but as this was non-significant it was removed from the final model,
as prespecified in the statistical analysis plan. The adjusted estimate for the effect of microdiscectomy
compared with TFESI was –7.04 (95% CI –15.81 to 1.73; p = 0.115).
For the joint modelling post hoc analysis of VAS leg pain scores the adjusted estimate for the effect of
microdiscectomy compared with TFESI was –7.06 (95% CI –15.82 to 0.86; p = 0.098). The estimate is
similar to the longitudinal mixed model and the conclusions remained unchanged once adjusted for
informative dropout.
Secondary outcome 3: visual analogue scale score for back pain at 18, 30, 42 and 54 weeks
Table 15 shows change from baseline at each time point for VAS back pain rating, where valid
measurements were available within the prespecified time window. The largest reduction was between
baseline and week 18, with average VAS back pain ratings similar over the further follow-up visits. VAS
back pain score reductions were smaller than VAS leg pain score reductions. Figure 6 shows profile
plots of the mean VAS back pain rating at each scheduled time point.
The longitudinal mixed-model analysis adjusted for baseline VAS back pain initially included a
time–treatment interaction term, but as this was non-significant it was removed from the final model,
as prespecified in the statistical analysis plan. The adjusted estimate for the effect of microdiscectomy
compared with TFESI was –3.01 (95% CI –11.29 to 5.26; p = 0.473).
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FIGURE 5 Mean profile plot of VAS leg pain scores with standard error bars.
TABLE 15 Change from baseline summaries for VAS back pain rating
Time point (week)
Microdiscectomy TFESI Overall
n Mean change (SD) n Mean change (SD) n Mean change (SD)
18 45 –26.02 (32.83) 49 –23.41 (27.69) 94 –24.66 (30.12)
30 38 –25.00 (32.04) 30 –24.33 (31.95) 68 –24.71 (31.77)
42 37 –20.81 (37.43) 33 –23.00 (37.29) 70 –21.84 (37.11)
54 42 –23.07 (34.54) 39 –22.90 (29.11) 82 –22.99 (31.84)
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For the joint modelling post hoc analysis of VAS back pain scores, the adjusted estimate for the effect
of microdiscectomy compared with TFESI was –2.87 (95% CI –10.58 to 3.16; p = 0.457). The estimate
is similar to the longitudinal mixed model and the conclusions remained unchanged once adjusted for
informative dropout.
Secondary outcome 4: satisfaction with care
The two questions on the satisfaction with care questionnaire were (1) ‘Over the course of treatment
for your low back pain or leg pain (sciatica), how satisfied are you with your overall medical care?’ and
(2) ‘How satisfied are you with the treatment outcome of your leg pain (sciatica)?’. A score of 1 on either
question would be ‘very satisfied’ with care, a score of 2 ‘somewhat satisfied’, a score of 3 ‘neither
satisfied nor dissatisfied’, a score of 4 ‘somewhat dissatisfied’ and a score of 5 ‘very dissatisfied’ with
care. Therefore, an average score of 1 would imply being ‘very satisfied’ for both aspects of care and
an average score of 5 would imply being ‘very dissatisfied’ with both aspects of care. Groups were
compared using a Mann–Whitney U-test. The median score at 54 weeks in the microdiscectomy group
was 1 (IQR 1–2) and in the TFESI group was 1.5 (IQR 1–3). Figure 7 shows the profile plot of median
satisfaction with care scores at each scheduled time point.
The difference between the groups was statistically significant (p = 0.021, Mann–Whitney U-test), with
participants in the microdiscectomy group being more satisfied with their care than participants in the
TFESI group.
Secondary outcome 5: modified Roland–Morris score at 18, 30, 42 and 54 weeks
Table 16 shows change from baseline at each time point for the MRM score, where valid
measurements were available within the prespecified time window. After an initial large reduction
between baseline and week 18, average MRM scores were similar over the further follow-up visits.
Figure 8 shows the profile plots of mean MRM score at each scheduled time point.
The longitudinal mixed-model analysis, adjusted for MRM initially included a time–treatment
interaction term, but as this was non-significant it was removed from the final model, as prespecified in
the statistical analysis plan. The adjusted estimate for the effect of microdiscectomy compared with
TFESI was –1.82 (95% CI –3.67 to 0.03; p = 0.054).
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FIGURE 6 Mean profile plot of VAS back pain scores with standard error bars.
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TABLE 16 Change from baseline summaries for MRM score
Time point (week)
Microdiscectomy TFESI Overall
n Mean change (SD) n Mean change (SD) n Mean change (SD)
18 47 –9.09 (6.27) 51 –7.73 (5.91) 98 –8.38 (6.09)
30 40 –9.58 (5.60) 31 –7.48 (6.68) 71 –8.66 (6.14)
42 39 –9.56 (5.86) 34 –8.35 (8.56) 73 –9.00 (7.21)
54 47 –9.74 (6.65) 42 –9.24 (6.68) 89 –9.51 (6.63)
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FIGURE 8 Mean profile plot of MRM scores with standard error bars.
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For the joint modelling post hoc analysis of MRM scores, the adjusted estimate for the effect of
microdiscectomy compared with TFESI was –1.72 (95% CI –3.44 to 0.10; p = 0.063). The estimate is
similar to the longitudinal mixed model and the conclusions remained unchanged once adjusted for
informative dropout.
Secondary outcome 6: Core Outcome Measures Index score at 18, 30, 42 and 54 weeks
Table 17 shows change from baseline at each time point for COMI score, where valid measurements
were available within the prespecified time window. As with other outcomes, the largest reduction was
between baseline and week 18, although the scores continued to improve in both groups between
weeks 18 and 54. Figure 9 shows profile plots of the mean COMI score at each scheduled time point.
The longitudinal mixed-model analysis adjusted for baseline COMI initially included a time–treatment
interaction term, but as this was non-significant it was removed from the final model, as prespecified
in the statistical analysis plan. The adjusted estimate for the effect of microdiscectomy compared with
TFESI was –0.77 (95% CI –1.58 to 0.03; p = 0.059).
For the joint modelling post hoc analysis of COMI scores, the adjusted estimate for the effect
of microdiscectomy compared with TFESI was –0.78 (95% CI –1.54 to –0.02; p = 0.046). The estimate
for microdiscectomy compared with TFESI is similar to the longitudinal mixed model; however, the
p-value and CIs suggest a statistically significant treatment effect once adjusted for informative dropout
(but less than the MCID of 2.2).
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FIGURE 9 Mean profile plot of COMI scores with standard error bars.
TABLE 17 Change from baseline summaries for COMI score
Time point (week)
Surgery TFESI Overall
n Mean change (SD) n Mean change (SD) n Mean change (SD)
18 42 –3.93 (2.80) 47 –3.05 (2.69) 89 –3.46 (2.76)
30 32 –4.49 (2.44) 27 –3.33 (2.35) 59 –3.96 (2.45)
42 33 –4.92 (2.18) 32 –3.45 (3.14) 65 –4.20 (2.77)
54 39 –5.02 (2.32) 37 –3.93 (2.81) 76 –4.49 (2.61)
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Secondary outcome 7: work status
Table 18 shows the number of participants who were employed/not employed at baseline. Of those
participants who were employed, the numbers of participants who were off work/at work are also
presented by treatment group.
At baseline, the information collected was whether or not the participant was employed and, if so,
whether or not they were able to work. However, at follow-up the information collected was whether
or not the participant was currently employed and whether or not they had returned to work since the
last visit. As there were extra visits between the key time points when this information could change
but was not collected, based on these questions it was sometimes impossible to say whether or not the
participant had returned to work and whether or not they were currently working.
Owing to the issues with the data collection we are unable to accurately calculate the number of days
lost from work and the work status outcome, and so these data have not been analysed or presented.
Safety analysis
No patients died during the reporting of this trial. Safety outcomes are reported based on actual
treatment received, rather than randomised group. AEs were reportable only if they were considered
to be possibly related to treatment. A total of 26 AEs were reported [18 events (from 15 participants)
associated with microdiscectomy and eight events (from three participants) associated with TFESI].
A summary of reported AEs is given in Table 38. The only events occurring more than once were
dural tear (four events) and pseudomeningocele (two events), and all AEs were related to surgical
incidental durotomy.
There were four SAEs (from four participants, 3.8%) and all were associated with microdiscectomy.
None of the SAEs was unexpected. Listings of SAEs are given in Table 39. One participant developed
a foot drop after an uncomplicated surgical procedure and required surgical exploration to exclude a
postoperative complication. The foot drop had not improved at the end of follow-up.
TABLE 18 Employment summaries at baseline
Status Microdiscectomy (N= 83), n TFESI (N= 80), n Overall (N= 163), n
Unemployed 21 13 34
Employed 62 66 128
Working 41 34 75
Not working 21 32 53
Missing 0 1 1
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Chapter 4 Economic evaluation
Objective
A within-trial economic analysis was performed using individual patient-level data from the NERVES
clinical trial. The analytical approach took the form of a cost–utility analysis, using information on
health-related costs and preference-based health status to calculate an ICER, expressed as cost per
QALY gained.
Methods
The design and reporting of the economic analyses were specified in a separate Health Economics
Analysis Plan (HEAP) (see Report Supplementary Material 2). The primary health economic analysis
followed the approach of NICE’s Guide to the Methods of Technology Appraisal 201342 and adopted the
perspective of the NHS in England. The economic analysis considered the costs and consequences of each
intervention over the 54-week trial period and was reported in accordance with the Consolidated Health
Economic Evaluation Reporting Standards checklist. A secondary analysis that approximates a societal
costing perspective was included, which additionally considered participant out-of-pocket costs and trial
participants’ and their informal carers’ productivity losses arising from time off work. The analysis was
conducted following a series of steps:
l The direct medical costs associated with delivering the treatments through measuring participants’
use of health services were estimated.
l The impact of the interventions on participants’ and informal carers’ productivity losses and
out-of-pocket costs was estimated.
l The estimated mean total cost per participant in each of the two intervention groups was compared.
l The mean number of QALYs for each trial intervention, calculated from EQ-5D-5L questionnaire-
generated utility scores, as a measure of health benefit was estimated.
l ICERs and incremental net health benefits (INHBs) were calculated by comparing the differences
between treatment groups in the mean total costs and the mean QALYs.
l The uncertainty in the results was tested through bootstrapping and generating cost-effectiveness
acceptability curves (CEACs) to estimate the probability of microdiscectomy being cost-effective
compared with TFESI at NICE thresholds for cost-effectiveness.
l Scenario analyses (SAs) were conducted to assess how assumptions in the base-case analysis can
influence results.
Resource use and costs
Measurement of resource use data
Resource use categories that might differ between intervention groups were chosen a priori. These
were further differentiated into sciatica related and non-sciatica related. The measurement of resource
use required complementary approaches using data collected as part of the NERVES trial, as well as
routine NHS data. Within-trial costs were estimated by measuring health-care resource use, including
(1) microdiscectomy and TFESI procedure, and other hospitalisations (e.g. additional treatments),
(2) outpatient appointments and contact with health-care professionals (e.g. GPs, physiotherapists,
other health-care professionals), (3) concomitant medication use, (4) costs incurred in the management
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of AEs and (5) participant out-of-pocket costs. Trial participants’ use of health-care services and other
costs were obtained from the following sources:
i. Routine HES data obtained from NHS Digital on secondary care admitted patient care (inpatient)
and outpatient attendances.
ii. CRFs completed by medical or nursing staff, relating to participant contact with hospital and health-care
professionals, including treatments issued, additional treatments received and medications prescribed.
iii. A RUQ43 completed by the participant at baseline and treatment visits, and at weeks 18, 30, 42 and
54 for information on the use of primary and secondary care services, visits to other health-care
professionals, participant out-of-pocket expenditures on over-the-counter medications and travel
costs, as well as productivity losses resulting from days off work, in the previous 3 months (6 weeks
at treatment visit) or since the questionnaire was last completed.
iv. AE and SAE forms completed by research staff when trial participants were admitted to hospital for
events considered possibly related to the trial intervention.
Valuation of unit costs
All resource use was valued in monetary terms (Great British pounds) using appropriate UK unit costs
for the cost year 2017/18. When necessary, adjustments were made for inflation using the new Hospital
and Community Health Service (HCHS) Index and using the Consumer Prices Index.44 No discount rate
was applied as follow-up was approximately 1 year.
Healthcare Resource Groups (HRGs) were the main currency of secondary care attendances, including
the trial interventions, additional treatments, other hospitalisations, and day case, outpatient and
accident and emergency (A&E) visits (Tables 19–21). NHS National Schedule of Reference Costs 2017–1845
TABLE 19 Unit costs of admitted patient care
Intervention HRG codea Description Attendance
Cost per
episode (£)b
Microdiscectomy HC64C Intermediate Extradural Spinal
Procedures with CC Score 0–1c
Day case 1971
Elective 4231
Non-elective 5162
HC64B Intermediate Extradural Spinal
Procedures with CC Score 2–3
Elective 4782
Non-elective 6261
HC63C Major Extradural Spinal Procedures
with CC Score 0–1
Elective 4858
Non-elective 5696
TFESI AB20Z Epidural Under Image Control for Pain
Management
Day case 711
Hospitalisation without
surgical intervention
HC27N Degenerative Spinal Conditions without
Interventions, with CC Score 0–2
Non-elective 1827
Other AA26H Muscular, Balance, Cranial or Peripheral
Nerve Disorders, Epilepsy or Head
Injury, with CC Score 0–2
Day case 523
Non-elective 1490
WH50B Procedure Not Carried Out, for Other
or Unspecified Reasons
Day case 338
Elective 599
CC, complication and comorbidity.
a Medication costs associated with delivery of interventions, including TFESI steroid and local anaesthetic, assumed to
be included in the HRG cost.
b NHS National Schedule of Reference Costs 2017–18.45
c CC Score is a measure of severity and complexity, with higher scores reflecting increased patient complications
or comorbidities.46
Note
The HRGs listed represent those reported > 2% by frequency of all HRGs.
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TABLE 20 Unit costs of outpatient attendances
Treatment area HRG code Description
Consultant led or
non-consultant led
Cost per
episode (£)a
Anaesthetics WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Consultant led 124
Neurosurgery WF01B Non-Admitted Face-to-Face
Attendance, First
Consultant led 257
WF01B Non-Admitted Face-to-Face
Attendance, First
Non-consultant led 153
WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Consultant led 179
WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Non-consultant led 174
Pain management WF01B Non-Admitted Face-to-Face
Attendance, First
Consultant led 193
WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Consultant led 147
Physiotherapy WF01B Non-Admitted Face-to-Face
Attendance, First
Non-consultant led 61
WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Non-consultant led
and consultant led
52
Spinal surgery service WF01B Non-Admitted Face-to-Face
Attendance, First
Consultant led 163
WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Consultant led 135
WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Non-consultant led 81
Trauma and orthopaedics WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Consultant led 119
WF01A Non-Admitted Face-to-Face
Attendance, Follow-up
Non-consultant led 93
a NHS National Schedule of Reference Costs 2017–18.45
Note
The HRGs listed represent those reported > 2% by frequency by treatment area.
TABLE 21 Unit costs of A&E visits
Admission HRG code Description
Cost per
episode (£)a
Emergency
medicine
VB01Z, VB02Z, VB03Z, VB04Z, VB05Z,
VB06Z, VB07Z, VB08Z, VB09Z, VB10Z,
VB11Z, VB99Z
Weighted mean cost by proportion
of attendances by code to Accident
and Emergency
160.32
a NHS National Schedule of Reference Costs 2017–18.45
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were applied, as these most closely reflect the actual cost of the provision of care by NHS service
providers. Medication costs for steroid and local anaesthetic associated with TFESI were assumed to be
included in the HRG costs, as were all costs relating to microdiscectomy. HRGs were further subcategorised
according to whether the episode of care took place in the day case, elective or non-elective setting.
The unit costs for all other NHS primary health-care resource use items were obtained from the
Personal Social Services Research Unit44 (Table 22). Visit costs to other health-care professionals
(i.e. private physiotherapists, osteopathy and chiropracty, acupuncture) were obtained from publicly
available sources.48–51
Concomitant medications were valued in monetary terms using prescription cost analysis data from
September 201752 and supplemented by the British National Formulary (BNF).53 Over-the-counter
medication costs were obtained from published retail pharmacy sources.54 The unit costs of the
10 most commonly prescribed medications are presented in Table 23.
TABLE 22 Unit costs of health-care professional attendances
Health-care professional attendance Cost per episode (£)a
Costing
perspective Source
GP: surgery 31.43 NHS PSSRU 201844
GP: out-of-hours surgery 109.59 NHS PSSRU 201844
GP: home visit (call-out) 102.10 NHS PSSRU 2013,47 PSSRU 201844
NHS physiotherapist 46.00 NHS PSSRU 201844
Acupuncture 43.10 Wider perspective NHS 201648
Osteopath/chiropractor 48.75 Wider perspective NHS 2018,49 NHS 201750
Private physiotherapist 50.70 Wider perspective Capital Physio 201651
PSSRU, Personal Social Services Research Unit.
a All costs not reported in base-case year prices are inflated to 2017/18 values using new HCHS Index and the
Consumer Prices Index.44
TABLE 23 Unit costs of the top 10 most commonly prescribed medications
Medication Formulation
Cost per
unit (£)a
Gabapentin 100-mg capsule 0.02
300-mg capsule 0.14
400-mg capsule 0.03
600-mg tablet 0.06
800-mg tablet 0.30
50-mg/ml sugar-free solution 0.46
Paracetamol 250-mg/5-ml oral suspension 0.01
500-mg tablet 0.02
Naproxen 250-mg tablet 0.03
500-mg tablet 0.04
Morphine 10-mg tablet (Sevredol®; Napp Pharmaceuticals Ltd, Cambridge, UK) 0.09
10-mg tablet (MST Continus®; Napp Pharmaceuticals Ltd, Cambridge, UK) 0.09
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TABLE 23 Unit costs of the top 10 most commonly prescribed medications (continued )
Medication Formulation
Cost per
unit (£)a
10-mg capsule (Zomorph®; Ethypharm, UK Ltd, High Comber, UK) 0.06
30-mg capsule (Zomorph®; Ethypharm, UK Ltd, High Wycombe, UK) 0.14
100-mg capsule (Zomorph®; Ethypharm, UK Ltd, High Wycombe, UK) 0.36
10-mg/5-ml oral solution (Oramorph®; Boehringer Ingelheim Ltd, Bracknell, UK) 0.02
Tramadol 50-mg capsule 0.03
50-mg modified-release capsule 0.12
100-mg modified-release capsule 0.24
50-mg/2-ml injection 1.12
Co-codamol 8-mg/500-mg tablet 0.03
15-mg/500-mg tablet 0.05
30-mg/500-mg tablet 0.04
30-mg/500-mg tablet (Zapain®; Advanz Pharma, London, UK) 0.03
Ibuprofen 200-mg tablet 0.03
400-mg tablet 0.03
256-mg tablet [Nurofen Express®; Reckitt Benckiser Healthcare (UK) Ltd, Slough, UK] 0.14
200-mg long-lasting capsules (Boots®; The Boots Company plc, Nottingham, UK) 0.21
Gel 5% 0.05
Gel 5% [Nurofen®; Reckitt Benckiser Healthcare (UK) Ltd, Slough, UK] 0.09
Gel 10% 0.05
Amitriptyline 10-mg tablet 0.03
20-mg tablet 0.05
25-mg tablet 0.03
35-mg tablet 0.06
50-mg tablet 0.09
10-mg/5-ml solution 0.74
Pregabalin 75-mg capsule (Lyrica®; Upjohn UK Ltd, Sandwich, UK) 1.15
150-mg capsule (Lyrica®; Upjohn UK Ltd, Sandwich, UK) 1.15
300-mg capsule (Lyrica®; Upjohn UK Ltd, Sandwich, UK) 1.15
50-mg capsule 0.14
75-mg capsule 0.10
100-mg capsule 0.12
150-mg capsule 0.15
200-mg capsule 0.15
300-mg capsule 0.18
Codeine phosphate 15-mg tablet 0.03
30-mg tablet 0.04
60-mg tablet 0.05
a Prescription cost analysis, September 201752 or published retail pharmacy prices.54
Note
A unit refers to a single tablet or capsule, or per ml or per mg for liquids and topical gels.
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Lost productivity was based on participant-reported lost earnings. In SAs, Office for National Statistics
(ONS) Annual Survey of Hours and Earnings median wage values were applied based on full-time
employment55,56 (Table 24). Other out-of-pocket participant costs associated with public transport to
attend medical appointments were based on participant self-report. If travel was undertaken in a private
car, a cost per mile of £0.68, including vehicle running costs, was applied.57,58
Cost analysis
Resource use data were collected from 3 months (84 days) prior to baseline to the end of the trial at
54 weeks. For completeness, all resource use was measured and costed irrespective of reason. However,
to allow for SA, it was categorised as sciatica related or non-sciatica related, as reported in the CRFs or
patient questionnaire. Medications were categorised in the CRFs based on reason for prescription, which
allowed for identification of those prescribed for sciatica-related reasons. HES data were categorised by
reason for admission, based on HRG code, to identify admissions and visits associated with sciatica. The
trial design also allowed for further treatment at the discretion of the clinician in the event of incomplete
symptom resolution (see Chapter 2, Trial treatments for further details) and costs for subsequent
treatments within the trial period were collected via the HES data set and included in the analysis.
TABLE 24 Net daily earnings (alternative productivity losses)
Category
Net daily earnings (£)
Malea Femalea
By hospital local
authority areab
Age (years)
22–29 75.16 70.18
30–39 93.64 85.82
40–49 102.63 84.27
50–59 100.40 79.35
≥ 60 87.87 71.05
Hospital local authority area
Middlesbrough 79.39
Cambridge 92.02
Sheffield 81.85
Preston 79.94
Stoke-on-Trent 76.69
Nottingham 77.52
Salford 81.20
Birmingham 84.95
Leeds 84.13
Liverpool 82.41
Southampton 88.68
a Calculated from ONS 2017. Annual Survey of Hours and Earnings 2017, Table 6.1a. Weekly pay – Gross (£) –
For full-time employee jobs: United Kingdom, 2017.55
b Calculated from ONS 2017, Annual Survey of Hours and Earnings, 2017 provisional and 2016 revised results.
9. Regional Earnings, Figure 13. Median full-time gross weekly earnings by place of work, Great Britain, April 2017.56
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When multiple sources reported the same type of resource use (e.g. hospital inpatient admissions),
a hierarchical approach was applied, with priority given to routine HES data, followed by researcher-
completed CRFs and, last, participant self-reported questionnaires. The different data sources were
compared to ensure that all resource use was captured, but also to avoid any overlapping of data and
consequent double counting.
To cost secondary care episodes, HES data were sourced from NHS Digital in the form of a series of
routinely available codes and dates, including participant diagnoses, admission dates and discharge
dates, and then converted into HRG codes using the NHS Digital HRG4+ 2018/19 Payment Grouper.59
When unavailable, hospital events were assigned an appropriate HRG code based on reason for
admission, condition and any complications, by reference to baseline, treatment, additional treatment,
AE CRFs and patient questionnaires. Appropriate HRGs were manually applied to unassignable HRG
codes (e.g. UZ01C and WA14Z) appearing in the HES data using clinical codes. Costs were assigned
according to HRG code, length of stay (incorporating any excess ward bed-days) and whether the
case was a day case, elective or emergency, according to the National Schedule of Reference Costs
2017–2018.45 Locally negotiated unbundled HRGs were similarly identified through the cost grouper
and costs were assigned directly from the national schedule. Privately treated participants were
assigned the corresponding national schedule NHS HRG code to ensure that costs were appropriately
apportioned. Visits to A&E were costed based on participant self-report, and a mean cost per visit was
applied according to the national schedule. Participants admitted from A&E to hospital were further
identified and costed according to the HES admitted patient care data set. If a hospital admission
spanned the period preceding randomisation or beyond the trial period, an adjustment was made to
apportion costs to only those incurred during the 54-week trial. To allow for follow-up visits that
occurred out of the trial window, all protocol-related visits that were scheduled identically in both
intervention groups were included, but all other visits outside the 54-week trial were excluded.
The RUQ collected participant-reported resource use for the preceding 3 months (or 6 weeks at the
treatment visit). All visits were face to face except weeks 30 and 42 when questionnaires were issued
by post with a pre-paid return envelope. Quantities of resource use for primary care services, including
visits to the GP (i.e. surgery, out of hours or home visit), physiotherapist, acupuncturist, chiropractor and
osteopath and any other health-care professional, were taken from participant responses and multiplied
by unit costs to estimate total costs. As the base-case analysis takes the NHS perspective, all visits to the
GP were included, as were NHS physiotherapist visits, assumed on the basis of a participant-reported
out-of-pocket cost of < £20, which was attributed to travel costs. Physiotherapy visits with costs of
> £20 were assumed to be private physiotherapy visits and were included in the secondary analysis
adopting a wider perspective. As some physiotherapy visits were also identified in the HES outpatient
data set, a cross-check was performed to avoid double counting and to include NHS physiotherapy
visits reported by participants that were not identified in the HES data set. The costs of visits to an
acupuncturist, chiropractor, osteopath and any other health-care professionals, as well as any over-the-
counter medications, were considered to be participant out-of-pocket costs and included only in the
secondary analysis on the basis that the NHS does not routinely fund these treatments. Questionnaires
not completed within the predefined visit windows were protocol deviations but, nonetheless, were
included in the analysis using appropriate time-based adjustments.
Medication costs were calculated based on CRF-recorded medication usage at baseline, treatment
and follow-up visits weeks 18 and 54. All tablets, capsules, oral liquids, sprays and inhalers were costed
on a unit dose basis, and creams and gels were assumed to be supplied on a one pack per month basis.
If a medication administration spanned the period preceding randomisation, or beyond the trial time
period, an adjustment was made to apportion costs to those administered only during the 54-week
trial. For medications with missing start and/or end dates, but recorded as ongoing treatments, the
start date was assumed to be 3 months (84 days) prior to baseline and the end date the trial exit
date. When doses and frequencies were omitted, estimated values based on participants’ medication
histories or BNF-recommended doses were applied. Medications administered on an ‘as needed’ basis
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were costed assuming administration based on 50% of the standard dose recommended in the BNF.
In cases where prescribed doses did not match formulation doses, costs were calculated by combining
different strengths to form the appropriate dose.
Out-of-pocket travel costs and participant or carer productivity losses were also obtained from the
RUQ. Participants were asked to report both the number of days off work and lost earnings. When the
number of days off work was reported but lost earnings values were missing, it was assumed that
there were no lost earnings (i.e. participants received sick pay).
Health outcome measures
Health benefits were measured in QALYs (NICE’s preferred outcome for economic evaluations). QALYs
are a generic measure of health that integrate preference-based measures of health status (utility)
over time into a single index. The EQ-5D-5L descriptive measure of health status was administered to
participants at baseline, and at weeks 18, 30, 42 and 54. At each time point, a five-digit code describing
a participant’s health status was generated from the EQ-5D-5L participant responses. In the base-case
analysis, the EQ-5D-5L to EuroQol-5 Dimensions, three-level version (EQ-5D-3L), crosswalk valuation
set (i.e. the current NICE preferred value set42) was employed to generate utility scores. QALYs
were calculated according to the ‘area under the curve’ approach60 for each participant’s longitudinal
measures of utility, and assuming linear changes in utility values over time. In instances where EQ-5D-5L
completion was subject to a trial visit time deviation, standardisation of values was achieved through
adjustment to the relevant visit time point.
Missing data
Data sets for hospital admissions, outpatient care and concomitant medications were considered to be
complete, but the resource use and EQ-5D questionnaires were subject to missing data. For the resource
use and EQ-5D questionnaires, missing data were observed when responses were not provided or were
incomplete at baseline, treatment visit and at the 18-, 30-, 42- and 54-week follow-ups. Return rates were
particularly low for the postal questionnaires at weeks 30 and 42. If a participant did not return or fully
complete either or both EQ-5D-5L questionnaires for weeks 30 and 42, then these utility scores were
imputed by linear interpolation using observed utility values at weeks 18 and 54. Linear interpolation was
also used to adjust observed utility scores based on the post-randomisation timing of the data collection
relative to the scheduled collection dates. This was done to standardise the utility scores in terms of timing
prior to imputing the remaining missing observations.
The utilities and costs at missing time points were then imputed via multiple imputation by chained
equations (MICE) using the ‘mice’ package in the R statistical computing environment, version 3.6.1
(The R Foundation for Statistical Computing, Vienna, Austria), assuming that missing data were missing
at random.61 This was applied using a data set that included utility scores at each observation and
cost variables at each observation derived from the RUQ (including visits to GPs, other health-care
professionals and A&E), baseline and follow-up cost of concomitant medications, cost of admitted
patient care and outpatient visits according to the HES data set, and participant information (including
age group, sex, duration of leg pain symptoms, treatment allocation and trial centre). The predictor
matrix for the MICE procedure was specified such that all the other variables were used to impute
missing values for each variable that had missing data, with the exception of baseline costs or utilities,
which did not use treatment allocation.
Missing values were generated using the method of predictive mean matching and the MICE iterative
procedure used a maximum of 30 iterations to achieve convergence. For the base-case analysis, and in
all SAs, a total of 10 complete imputed data sets were generated. The multiple imputation was not
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used to obtained standard errors on subsequent regression coefficients as this was achieved via a
bootstrap procedure. Therefore, 10 was considered to be a sufficient number of imputations to achieve
a high level of efficiency.62
Approach to analysis
The analysis is reported in accordance with the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS).63 The analysis was based on the ITT population (i.e. 163 participants were recruited
to the trial, but six participants withdrew early on and were excluded from the cost-effectiveness analysis
because no outcome data nor HES data were available). Data from 157 participants were therefore
included in the economic evaluation (80 participants in the microdiscectomy group and 77 participants in
the TFESI group). Participants’ use of health-care resources for the 3 months prior to randomisation was
analysed (n = 163) to allow for adjustment for any imbalance in costs and outcomes observed at baseline,
as well as to identify any correlation between any baseline variables and outcomes. Unadjusted mean
differences between the treatment groups in utility scores, QALYs and incremental costs were reported
with 95% CIs for the pre-baseline and trial periods.
Total costs at baseline were correlated with follow-up costs and this was also true on examination of
baseline utilities and follow-up QALYs. Therefore, regression analyses were conducted to quantify
the impact of treatment allocation on follow-up costs and QALYs while controlling for baseline costs
and utilities, respectively. Plotting costs and QALYs against other potential independent variables
(i.e. participant age group and sex, trial centre and duration of leg pain symptoms) did not indicate any
associations, but these were included in the regression model development nonetheless. Regression
models were estimated using each of the 10 imputed data sets and coefficients were averaged to
obtain point estimates as per Rubin’s rules.64
Participant QALYs were modelled using multiple linear regression, with treatment allocation and
baseline utilities as covariates. Additional models were estimated, including combinations of the other
potential independent variables listed above; however, these were ruled out based on F- or t-tests for
nested model comparisons and inspection of residual plots. Participant follow-up costs were modelled
using a generalised linear model with a log-link function and gamma probability distribution. Identity
link, or log-link and Gaussian probability distribution were considered as alternatives. These were ruled
out based on comparisons of the Akaike information criterion statistic and inspection of residual plots.
In both models, trial centre was tested as a random-effect coefficient; however, it was not included
because the estimated variance was close to zero. The analysis was performed using the R statistical
computing environment, according to the regression models presented below.
Follow-up costs regression model
Ci
e
Gamma(υi, α), (1)
ln(υi) = γ0 + Tiγ1 + C0iγ2, (2)
where C is follow-up total cost, ν is predicted follow-up total cost, α is the gamma shape parameter,
γ0 is the regression intercept, γ1 is the coefficient of injection, γ2 is the coefficient of baseline total cost,
T is 1 for TFESI and 0 for microdiscectomy and C0 is the baseline total cost.
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Quality-adjusted life-years regression model
Qi
e
Norm(µi, σ
2), (3)
µi = β0 + Tiβ1 + U0iβ2, (4)
where Q are QALYs, µ is the predicted QALY, σ is the residual error SD, β0 is the regression intercept,
β1 is the coefficient of treatment allocation, β2 is the coefficient of baseline utility score, T is 1 for TFESI
and 0 for microdiscectomy and U0 is the baseline utility score.
Incremental cost-effectiveness ratio
The cost-effectiveness of microdiscectomy compared with TFESI was assessed by its ICER calculated
according to the formula:
ICER = Δcosts/ΔQALYs, (5)
where Δcosts is the difference in mean total costs between interventions (i.e. cost microdiscectomy
minus cost TFESI) and ΔQALYs is the difference in mean QALYs gained between interventions
(i.e. QALYs microdiscectomy minus QALYs TFESI).
The INHB allows for further interpretation of cost-effectiveness in reporting the net health benefits
that would arise further to adopting microdiscectomy rather than TFESI, conditional on a cost-
effectiveness threshold of £20,000 per QALY, as specified by NICE.42 This was calculated by:
INHB = ΔQALYs − (Δcosts/λ), (6)
where λ is the chosen cost-effectiveness threshold.
Uncertainties in QALYs, the incremental results and resulting cost-effectiveness metrics were evaluated
using a non-parametric bootstrap of the patient-level data. The bootstrap used 10,000 replicates and
empirical bootstrap CIs were obtained for the statistics of interest. The uncertainty in the ICER was
represented graphically on the cost-effectiveness plane to illustrate the joint uncertainty in incremental
costs and QALYs and also as a CEAC to illustrate the probability of either microdiscectomy or TFESI
being cost-effective for given cost-effectiveness thresholds.65 Estimates of ICERs were compared with a
threshold of £20,000 per QALY.
Base-case analysis
The base-case analysis was defined as pertaining to the 54-week trial period, based on the imputed
data set to account for missing data and subject to the regression analysis. The mean QALYs and costs
and incremental values were reported for each treatment group with 95% CIs in accordance with the
bootstrap analysis.
The main assumptions made in the base-case scenario are detailed in Table 25.
Sensitivity and scenario analyses
A number of sensitivity and SAs were conducted to assess the impact of considering alternative perspectives,
inputs and costs on the ICER (Table 26). Scenario 1 reflects the wider perspective of the secondary analysis
and follows the same approach as the base-case analysis, but in approximating to a societal perspective
included participant costs associated with time off work and other out-of-pocket costs (Table 27).
A complete-case SA included participants presenting complete-cost data for all cost variables at all time
points and outcome data at baseline and at weeks 18 and 54. To assess the impact of alternative value
sets, the more recent but yet to be widely adopted value set based on the EQ-5D-5L66 was used in a SA,
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TABLE 25 Base-case analysis key methods
Item Description and approach
Comparator Microdiscectomy vs. TFESI
Population NERVES trial participants diagnosed with sciatica secondary to PID
Analysis approach ITT, but excluding withdrawn participants
Model type and description Within-trial cost-effectiveness analysis, imputed data set, subject to regression
Cost-effectiveness metrics Non-parametric bootstrap, mean and 95% CI
Perspective NHS
Time horizon 54 weeks
Discount rate Not applicable, trial limited to ≈ 1 year
Utility values EQ-5D-5L mapped using a three-level crosswalk value set
Health outcome QALYs measured from utility values
AEs Costs only, associated with secondary care admissions
Resource use
Secondary care HES
Primary care GP visits, GP out of hours and GP home visits
Physiotherapy NHS costs associated with physiotherapy
A&E A&E visits
Medications Prescribed concomitant medications
TABLE 26 Scenario (sensitivity) analyses
Scenario Scenario description and approach Base-case analysis
1 Approximating to a societal perspective NHS perspective
2 Complete cases only Imputed data set
3 QALYs from the five-level valuation set QALYs from the three-level valuation set
4 QALYs inferred from EQ-VAS QALYs from the three-level valuation set
5 Alternative RUQ assumption based on ‘since last completed’
approach
RUQ completed based on ‘last 3 months’
6 Sciatica-related costs only All costs
7 ‘When-needed’ medications assumed at 25% of
BNF-recommended dose
‘When-needed’ medications assumed at
50% of BNF-recommended dose
8 ‘When-needed’ medications assumed at 75% of
BNF-recommended dose
‘When-needed’ medications assumed at
50% of BNF-recommended dose
9 Approximating to a societal perspective, sciatica costs only NHS perspective
10 Approximating to a societal perspective, missing cost of lost
days at work assumed based on median salary by age and sex
(participants) and postcode salary (carer)
NHS perspective
11 Approximating to a societal perspective, missing RUQ
productivity losses obtained, when possible, using
clinician-recorded employment status and median salary
by age and sex
NHS perspective
12 Approximating to a societal perspective, all productivity losses
based on reported days lost, where costs were median salary
by age and sex (participants) and postcode salary (carer)
NHS perspective
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as was a further evaluation using the EQ-VAS, also collected in the NERVES trial, which records the
respondent’s self-rated health on a vertical VAS. The EQ-VAS requires a participant to report how they
are feeling on the day of questionnaire completion, by reporting a score between 0 and 100 (anchored
at the respondent’s worst and best health they can imagine) and, as such, provides the participant’s own
overall assessment of their health. This contrasts to the EQ-5D-3L or EQ-5D-5L utility scores, which are
based on public preference valuation of EQ-5D health states.
The wording of the RUQ asked participants to report their resource use over the last 3 months or
since the questionnaire was last completed (approximately 3 months). In the base case it was assumed
that participants consistently reported resources use over the last 3 months. An alternative approach
assumed that participants reported resource use since they last completed a questionnaire, which may
exceed 3 months in cases where observations were missed. This reduced the extent of missing data
in assuming that later observations include resource use that cover previous missing observations.
Further analyses included evaluating the cost-effectiveness for costs related to only sciatica, as well as
scenarios to account for uncertainty in dosing regimens for ‘when-needed’ medication.
A number of alternative costing approaches for societal costs associated with productivity losses were
also conducted. To account for missing values in patient questionnaires relating to costs of time off
work, but when the number of days off work were reported, a substitute value of a day off work was
applied using ONS median gross weekly pay by sex and age for full-time employees55 and converted to
daily net take-home pay. For carers, for whom age and sex were unknown, the cost of missing a day’s
work was based on the median full-time gross weekly earnings by place of work, assuming that this was
in the same local authority district as the hospital centre where the participant’s sciatica treatment was
undertaken.56 To supplement the RUQ data, an alternative scenario was conducted whereby missing
patient questionnaires were supplemented, if feasible, with employment status as reported in the CRF.
In this scenario, all patients with reported days off work but no costs were costed using ONS median
wage by age and sex. Finally, a further SA accounted for implausible reported lost productivity cost
values, by ignoring all participant-reported productivity losses costs and recosting based on number of
reported days off work alone, using the median ONS median wage by age and sex as the cost basis for
participants and median wage by postcode for carers.
Results
Data completeness
Resource use and EQ-5D-5L questionnaires were not completed by all participants. Missing data were
observed when whole questionnaires were not returned or when questionnaires were returned with
some questions incomplete and were therefore non-evaluable. Completion rates were highest at
baseline, treatment and week 18 visits, but high levels of missingness were observed for the 30- and
42-week postal questionnaires (Table 28).
TABLE 27 Scenario 1 (secondary analysis) key methods, approximating to a societal perspective
Item of resourcea Description and approach
Other health-care professional Participant-reported out-of-pocket costs for physiotherapy, acupuncture,
chiropractor, osteopath and other healthcare professionals
Medications Participant-reported out-of-pocket costs for over-the-counter medications
Lost productivity Participant-reported cost of lost days at work and participant-reported cost of lost
carer days at work
Medical appointment travel Participant-reported public transport costs and participant-reported car mileage
distance
a As for the base case, except with inclusion of listed societal costs.
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TABLE 28 Missing observations for patient-reported EQ-5D-5L and RUQ, by trial visit
Item
Time point, number (%) of missing observations
Baseline Treatment Week 18 Week 30 Week 42 Week 54
Surgery TFESI Surgery TFESI Surgery TFESI Surgery TFESI Surgery TFESI Surgery TFESI
Utility scores
EQ-5D-5L 4 (5) 2 (2.6) 12 (15) 14 (18.2) 29 (36.3) 34 (44.2) 29 (36.3) 33 (42.9) 16 (20) 20 (26)
Resource usea
GP 16 (20) 14 (18.2) 15 (18.8) 10 (13) 18 (22.5) 20 (26) 33 (41.2) 38 (49.4) 35 (43.8) 41 (53.2) 25 (31.2) 26 (33.8)
Physiotherapy 3 (3.8) 3 (3.9) 12 (15) 7 (9.1) 11 (13.8) 11 (14.3) 29 (36.2) 34 (44.2) 30 (37.5) 33 (42.9) 17 (21.2) 18 (23.4)
A&E 4 (5) 4 (5.2) 14 (17.5) 7 (9.1) 12 (15) 12 (15.6) 29 (36.2) 33 (42.9) 29 (36.2) 33 (42.9) 18 (22.5) 18 (23.4)
OTC medication 3 (3.8) 3 (3.9) 13 (16.2) 7 (9.1) 12 (15) 11 (14.3) 30 (37.5) 33 (42.9) 31 (38.8) 32 (41.6) 17 (21.2) 19 (24.7)
Public transport 4 (5) 3 (3.9) 12 (15) 7 (9.1) 11 (13.8) 12 (15.6) 29 (36.2) 33 (42.9) 29 (36.2) 34 (44.2) 16 (20) 18 (23.4)
Private car 4 (5) 3 (3.9) 12 (15) 8 (10.4) 12 (15) 12 (15.6) 30 (37.5) 35 (45.5) 29 (36.2) 35 (45.5) 18 (22.5) 19 (24.7)
Lost productivity: participant 4 (5) 3 (3.9) 12 (15) 7 (9.1) 11 (13.8) 12 (15.6) 30 (37.5) 34 (44.2) 30 (37.5) 32 (41.6) 16 (20) 18 (23.4)
Lost productivity: carer 3 (3.8) 2 (2.6) 12 (15) 7 (9.1) 11 (13.8) 11 (14.3) 29 (36.2) 34 (44.2) 29 (36.2) 32 (41.6) 16 (20) 18 (23.4)
OTC, over the counter.
a Considered a missing item when it was not possible to calculate a cost because frequency of visits and/or visit cost was missing.
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Resource use and cost analysis
Observed participant use of health-care resources for all randomised patients (n = 163) and corresponding
NHS HES admitted patient care and outpatient data [available only for patients who did not withdraw
from the study (n = 157)] were comparable at baseline in both intervention groups for the 3 months prior
to randomisation (Table 29). The main cost drivers for the pre-baseline period were related to admitted
patient care (£353 for microdiscectomy vs. £422 for TFESI), outpatient visits (£208 for microdiscectomy
vs. £251 for TFESI) and lost productivity (£809 for microdiscectomy vs. £614 for TFESI), accounting for
22%, 13% and 41% of all costs, respectively.
Tables 30 and 31 present the observed disaggregated health-care resource use and costs, respectively,
over the 54-week trial period. HRG code HC64C was the most frequent intervention observed in the
microdiscectomy group, with a reported occurrence of 66.2 per 100 participant-years, whereas HRG
code AB20Z was the predominant TFESI intervention, with a rate of occurrence of 86.3 per 100
participant-years. The observation in the TFESI group of an occurrence rate for HRG code HC64C of
28.8 per 100 participant-years reflects the trial protocol, which allowed for participants to receive
additional treatments as necessary. Mean observed total NHS costs were higher for microdiscectomy
(£6683, 95% CI £5632 to £8074) than for TFESI (£4422, 95% CI £3682 to £5291; difference in mean
£2261, 95% CI £706 to £3589), but no difference was observed in participant out-of-pockets costs for
microdiscectomy (£878, 95% CI £538 to £1204) compared with TFESI (£1307, 95% CI £708 to £2092).
The main cost difference between groups related to admitted patient care, with microdiscectomy
costing £1926 (95% CI £467 to £3128) more than TFESI. The cost of outpatient attendances also
differed between groups, with costs for microdiscectomy being £237 (95% CI £50 to £414) greater
than TFESI. Total combined NHS and societal costs were higher for the microdiscectomy group
(difference in mean £1832, 95% CI £53 to £3555).
Outcomes
Utility and quality-adjusted life-years
Observed participant responses by trial visit to each of the EQ-5D dimensions (i.e. anxiety and
depression, mobility, pain and discomfort, self-care and usual activities) indicated less impairment (more
lower scores) in the microdiscectomy group (Figures 10–14). Figure 15 presents the utility scores for the
observed data using the three-level crosswalk valuation set. For participants with complete responses
to the EQ-5D-5L at baseline and weeks 18 and 54, baseline mean utility values using the three-level
value set were 0.328 (95% CI 0.259 to 0.392; n = 55) for the microdiscectomy group and 0.276 (95% CI
0.188 to 0.366; n = 48) for the TFESI group (Table 32), and were comparable between groups (difference
in mean 0.052, 95% CI –0.060 to 0.157). Similarly, over the duration of the trial, comparable QALYs
were observed in the complete-case groups (i.e. participants who completed the EQ-5D at baseline and
weeks 18 and 54), with 0.654 QALYs in the microdiscectomy group and 0.591 QALYs in the TFESI group
(difference in mean 0.062, 95% CI –0.033 to 0.155). The five-level value sets and VAS results exhibited a
tendency to generate higher utility scores than the three-level value set, but showed minimal differences
in QALY gains over the 54-week trial period, which were also not statistically different.
Cost-effectiveness analysis results
Base-case analysis
The results following multiple imputation and statistical analysis, averaged over 10,000 bootstrap
replicates and for the 54-week trial time horizon, reported mean total costs for the microdiscectomy
group of £6919 (95% CI £5503 to £8046) and for the TFESI group of £4706 (95% CI £3821 to
£5516). The mean total QALYs were 0.616 (95% CI 0.570 to 0.671) and 0.559 (95% CI 0.503 to 0.620)
for the microdiscectomy and TFESI groups, respectively. The mean incremental costs and QALYs were
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TABLE 29 Observed baseline costs in the 3 months prior to randomisation
Item
Treatment allocation, mean cost (£) (95% CI)a
Difference in mean cost (£) (95% CI)Microdiscectomy TFESI
Sciatica-related Total Sciatica-related Total Sciatica-related Total
Total NHS and societal 1707 (1246 to 2299) 1790 (1326 to 2358) 1596 (1192 to 2015) 1684 (1280 to 2155) 111 (–583 to 795) 106 (–609 to 783)
NHS 807 (602 to 1032) 882 (673 to 1135) 866 (610 to 1174) 950 (677 to 1291) –59 (–410 to 315) –68 (–422 to 334)
Admitted patient care 327 (141 to 525) 353 (171 to 552) 384 (159 to 660) 422 (182 to 699) –56 (–357 to 282) –69 (–376 to 276)
Outpatient 185 (150 to 221) 208 (169 to 252) 231 (172 to 311) 251 (187 to 330) –47 (–127 to 42) –43 (–125 to 51)
Concomitant medications 51 (38 to 69) 63 (48 to 83) 34 (24 to 47) 45 (32 to 60) 17 (–3 to 36) 19 (–4 to 41)
GP 152 (125 to 180) 169 (140 to 202) 142 (108 to 183) 153 (118 to 195) 10 (–35 to 57) 16 (–31 to 64)
Physiotherapy 59 (37 to 84) 59 (37 to 84) 52 (24 to 84) 52 (26 to 84) 7 (–30 to 47) 7 (–30 to 46)
A&E 89 (59 to 124) 92 (62 to 125) 80 (57 to 108) 89 (59 to 122) 9 (–33 to 51) 4 (–40 to 50)
Societal 900 (495 to 1423) 907 (497 to 1427) 730 (473 to 1031) 734 (480 to 1051) 170 (–433 to 699) 174 (–433 to 697)
Physiotherapy and other
health-care professionals visits
69 (35 to 112) 69 (35 to 111) 93 (53 to 140) 93 (55 to 134) –24 (–81 to 31) –24 (–82 to 32)
OTC medication 28 (19 to 37) 28 (20 to 38) 21 (13 to 31) 22 (13 to 31) 7 (–6 to 19) 6 (–6 to 19)
Lost productivity: participant
and carer
804 (398 to 1363) 809 (392 to 1388) 611 (353 to 895) 614 (349 to 913) 193 (–407 to 718) 196 (–401 to 711)
Medical appointment transport 45 (24 to 76) 46 (25 to 75) 34 (24 to 47) 35 (24 to 49) 10 (–23 to 35) 11 (–23 to 37)
OTC, over the counter.
a Admitted patient care, outpatient and concomitant medications data considered complete. RUQ missing values excluded to reflect participants with missing data in Table 28. Mean
values based on the number of patients reporting each item.
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TABLE 30 Observed disaggregated health-care resource use
Health-care resource usea
Occurrences per 100
participant-years
Difference (95% CI)Microdiscectomy TFESI
Admitted patient care HRG
HC64C, Intermediate Extradural Spinal Procedures with
CC Score 0–1
66.2 28.8 37.4 (17.8 to 57.1)
HC64B, Intermediate Extradural Spinal Procedures with
CC Score 2–3
█ █ –2.6 (–7.5 to –0.1)
HC63C, Major Extradural Spinal Procedures with CC
Score 0–1
█ █ 9.4 (2.0 to 19.2)
AB20Z, Epidural Under Image Control for
Pain Management
9.6 86.3 –76.7 (–91.4 to –64.4)
HC27N, Degenerative Spinal Conditions without
Interventions, with CC Score 0–2
█ █ –3.8 (–8.7 to –3.8)
AA26H, Muscular, Balance, Cranial or Peripheral Nerve
Disorders, Epilepsy or Head Injury, with CC Score 0–2
█ █ –7.6 (–12.5 to –7.6)
WH50B, Procedure Not Carried Out, for Other or
Unspecified Reasons
█ █ 4.8 (4.8 to 9.7)
Outpatient HRG
Neurosurgery 306.9 200.1 107 (60 to 153)
Physiotherapy 158.9 53.8 105 (78 to 132)
Anaesthetics 110.7 147.6 –37 (–71 to –2)
Pain management 45.7 68.8 –23 (–45 to –1)
Spinal surgery service 60.2 56.3 4 (–21 to 26)
GP and health-care professional visits
GP 296.1 356.4 –60.3 (–242.9 to 121.9)
Physiotherapy 72.2 91.3 –19.1 (–104.9 to 71.2)
Acupuncture 16.9 6.3 10.6 (–17.1 to 31.2)
Chiropractor/osteopath 4.8 2.5 2.3 (–6.2 to 8.5)
Other 32.5 16.3 16.2 (–25.3 to 50.4)
A&E 19.3 26.3 –7.0 (–26.8 to 12.9)
Lost productivity
Days off work: participant 1999 2146 –147 (–1615 to 1353)
Days off work: carer 229 144 84 (–126 to 265)
CC, complication and comorbidity.
a Admitted patient care and outpatient data were considered complete, but follow-up data were variable in duration
and trimmed to 54 weeks when it exceeded 54 weeks. No adjustment was made to patients with < 54 weeks’ data,
this was assumed to be complete. RUQ missing values excluded to reflect participants with missing data in Table 28.
Notes
HRGs recorded > 2% by frequency over 54 weeks from randomisation.
Redacted text: to comply with the HES Analysis Guide67 (as per data-sharing agreement with NHS Digital) HRGs
observed seven times or less in either of the treatment groups are not reported.
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TABLE 31 Observed disaggregated and total 54-week costs from randomisation
Itema
Treatment allocation, mean cost (£) (95% CI)
Difference in mean cost (£) (95% CI)Microdiscectomy TFESI
Sciatica Total Sciatica Total Sciatica Total
Total NHS and societal 6522 (5839 to 7292) 7561 (6465 to 8985) 5171 (4193 to 6213) 5729 (4596 to 7006) 1351 (127 to 2573) 1832 (53 to 3555)
NHS 5780 (5191 to 6420) 6683 (5632 to 8074) 4150 (3440 to 4928) 4422 (3682 to 5291) 1630 (674 to 2580) 2261 (706 to 3589)
Admitted patient care 4523 (3975 to 5144) 5168 (4271 to 6475) 3110 (2452 to 3731) 3242 (2617 to 3924) 1413 (560 to 2275) 1926 (467 to 3128)
Outpatient 1066 (953 to 1181) 1186 (1045 to 1327) 885 (792 to 977) 949 (842 to 1066) 181 (28 to 325) 237 (50 to 414)
Concomitant medications 155 (107 to 219) 262 (168 to 385) 126 (80 to 181) 183 (125 to 252) 29 (–49 to 105) 78 (–62 to 199)
GP 44 (23 to 72) 93 (52 to 137) 49 (18 to 90) 103 (56 to 166) –5 (–45 to 39) –10 (–77 to 62)
Physiotherapy 38 (3 to 84) 38 (3 to 88) 18 (0 to 44) 18 (0 to 44) 19 (–37 to 62) 19 (–35 to 62)
A&E 15 (0 to 40) 50 (10 to 100) 45 (13 to 90) 71 (26 to 128) –30 (–74 to 20) –20 (–94 to 50)
Societal 742 (457 to 1124) 878 (538 to 1204) 1021 (516 to 1659) 1307 (708 to 2092) –279 (–884 to 407) –429 (–1140 to 403)
Physiotherapy and other
health-care professional visits
10 (2 to 20) 10 (2 to 20) 24 (7 to 47) 24 (7 to 47) –14 (–34 to 10) –14 (–34 to 10)
OTC medication 27 (18 to 39) 33 (22 to 45) 20 (13 to 30) 25 (16 to 35) 7 (–7 to 21) 8 (–7 to 23)
Lost productivity: participant
and carer
660 (373 to 1033) 781 (455 to 1160) 939 (476 to 1561) 1128 (557 to 1850) –279 (–887 to 425) –347 (–1037 to 510)
Medical appointment transport 45 (30 to 62) 54 (39 to 72) 38 (24 to 57) 130 (29 to 319) 7 (–16 to 31) –76 (–184 to 123)
OTC, over the counter.
a Admitted patient care, outpatient and concomitant medications data considered complete. RUQ missing values excluded to reflect participants with missing data in Table 28.
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£2212 (95% CI £629 to £3677) and 0.057 (95% CI –0.009 to 0.124), respectively, resulting in an ICER
of £38,737 per QALY gained and, at a threshold of £20,000 per QALY, an INHB loss of 0.054 QALYs
(Table 33). The cost-effectiveness plane (Figure 16) similarly indicated that the mean and the density of
the joint distribution of incremental costs and QALYs was located in the north-east quadrant, indicating
microdiscectomy to be more costly but with greater health benefits than TFESI. The CEAC (Figure 17)
shows that the probability of microdiscectomy being cost-effective at £20,000 per QALY is 0.17 and
the probability of microdiscectomy being cost-effective at a higher threshold of £30,000 per QALY
is 0.37. These results are consistent with those produced in the deterministic analysis, which generated
a mean incremental cost of £2240, a mean incremental QALY of 0.057 and an ICER of £39,334 per
QALY gained (Table 34).
TABLE 32 Health outcomes for participants with observations at baseline, week 18 and week 54, adjusted for visit
time deviations
Analysis
Health
outcome
Microdiscectomy (n= 55),
mean (95% CI)
TFESI (n= 48), mean
(95% CI)
Difference in mean
(95% CI)
EQ-5D-3L
value set
Baseline utility 0.328 (0.259 to 0.392) 0.276 (0.188 to 0.366) 0.052 (–0.060 to 0.157)
54-week utility 0.718 (0.649 to 0.784) 0.659 (0.573 to 0.739) 0.059 (–0.051 to 0.165)
QALYs over
54 weeks
0.654 (0.588 to 0.709) 0.591 (0.518 to 0.658) 0.062 (–0.033 to 0.155)
EQ-5D-5L
value set
Baseline utility 0.443 (0.377 to 0.513) 0.409 (0.322 to 0.486) 0.034 (–0.071 to 0.137)
54-week utility 0.794 (0.728 to 0.851) 0.737 (0.660 to 0.807) 0.057 (–0.041 to 0.157)
QALYs over
54 weeks
0.746 (0.686 to 0.801) 0.683 (0.614 to 0.746) 0.063 (–0.024 to 0.148)
Microdiscectomy (n= 60),
mean (95% CI)
TFESI (n= 55), mean
(95% CI)
EQ-VAS Baseline utility 0.490 (0.428 to 0.550) 0.473 (0.414 to 0.529) 0.017 (–0.068 to 0.099)
54-week utility 0.744 (0.682 to 0.801) 0.677 (0.606 to 0.741) 0.067 (–0.029 to 0.161)
QALYs over
54 weeks
0.706 (0.653 to 0.752) 0.645 (0.593 to 0.692) 0.061 (–0.011 to 0.130)
TABLE 33 Cost-effectiveness at 54 weeks, QALYs, costs (£) and ICER, base-case bootstrapped analysis
Cost-effectiveness
Mean values (95% CI) Cost-effectiveness threshold (95% CI)
Microdiscectomy TFESI Incremental effect £20,000/QALY £30,000/QALY
Cost (£) 6919
(5503 to 8046)
4706
(3821 to 5516)
2212
(629 to 3677)
QALY 0.616
(0.570 to 0.671)
0.559
(0.503 to 0.620)
0.057
(–0.009 to 0.124)
ICER 38,737
INHB (QALYs) –0.054
(–0.166 to 0.060)
–0.017
(–0.110 to 0.077)
Probability
cost-effective
0.17 0.37
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Scenario analyses
For all scenarios that utilised imputed data sets to address the missing data (i.e. all except the
complete-case analysis, SA 2), none resulted in an ICER < £20,000 per QALY gained (see Table 34).
In scenarios in which only cost inputs differ, mean QALYs are also observed to differ slightly, relative
to the base case. This can occur because the cost variables, among others, are used in the multiple
imputation procedure to predict missing values in utility scores and, therefore, different costs can affect
the value of imputed utilities. In the complete-case analysis (i.e. SA 2) an ICER of £16,512 per QALY
6000
5500
5000
4500
4000
3500
3000
2500
2000
1500
1000
500
−500
−1000
−1500
−0.10 −0.05 0.00 0.05 0.10 0.15 0.20 0.25
In
cr
em
en
ta
l c
o
st
s 
£
 (m
ic
ro
d
is
ce
ct
o
m
y 
vs
. T
F
E
SI
)
0
Incremental QALYs (microdiscectomy vs. TFESI)
Cost-effectiveness thresholds
INHB (microdiscectomy)
£20,000 per QALY
£30,000 per QALY
Mean of incremental 
costs and QALYs
INHB > 0 at £20,000
INHB < 0 at £20,000
INHB < 0 at £30,000
FIGURE 16 Cost-effectiveness plane: base-case analysis.
P
ro
b
ab
ili
ty
 o
f b
ei
n
g 
co
st
-e
ff
ec
ti
ve
n
es
s
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 10 20 30 40 50 60 70 80 90 100
Cost-effectiveness threshold (£000 per QALY)
Cost-effectiveness thresholds
Treatment allocation
£20,000 per QALY
£30,000 per QALY
Surgical microdiscectomy
TFESI
FIGURE 17 Cost-effectiveness acceptability curve: base-case analysis. Vertical dotted lines represent the NICE threshold
range of £20,000–30,000 per QALY.42
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
gained was estimated, but there were only 35 participants providing complete data and, therefore,
owing to this small sample of participants, these results should be interpreted with caution.
When the approximating to societal perspective was adopted (i.e. SA 1), mean total costs increased to
£8353 for microdiscectomy and £6856 for TFESI, but the mean incremental cost difference reduced
to £1497. As there was no difference in incremental QALYs between this scenario and the base case,
including productivity losses lowers the ICER to £26,290 per QALY gained. Alternative costing approaches
for productivity losses (i.e. SAs 10–12) had an impact on the results and effectively reduced the
cost-effectiveness of microdiscectomy by increasing the ICER to £27,981, £32,807 and £36,621 per QALY
gained, respectively.
Scenario analyses 3 and 4 considered the impact of applying alternative utility scoring methods (i.e. the
EQ-5D-5L tariffs and EQ-VAS). Using the five-level valuation set had minimal effect, but applying the
EQ-VAS scores increased the ICER to £48,113 per QALY gained. The EQ-VAS, however, is not
generally used to inform decision-making.
Taking an alternative approach to costing resource use and assuming that respondents completed the
questionnaire ‘since last completed’ (i.e. SA 5) reduced the ICER to £35,717 per QALY gained, whereas
considering only sciatica-related costs (i.e. SA 6) had a larger effect, reducing the ICER to £28,251 per
QALY gained. The effect of combining only sciatica-related costs in a wider perspective (i.e. SA 9)
resulted in a lower ICER of £22,923 per QALY gained. Varying the dose of ‘when-needed’ medications
to 25% and 75% of the time (i.e. SAs 7 and 8) resulted in ICERs of £41,422 and £36,163 per QALY
gained, respectively.
TABLE 34 Scenario analysis, including deterministic results
Scenario
Treatment allocation,
total cost (£)
Treatment allocation,
total QALYs Incremental
ICER
(£/QALY)
INHB
Microdiscectomy TFESI Microdiscectomy TFESI
Cost
(£) QALY
£20,000/
QALY
£30,000/
QALY
Base casea 6919 4706 0.616 0.559 2212 0.057 38,737 –0.054 –0.017
Base case,
deterministic
6941 4701 0.617 0.560 2240 0.057 39,344 –0.055 –0.018
SA 1 8353 6856 0.611 0.554 1497 0.057 26,290 –0.018 0.007
SA 2 5816 3948 0.730 0.617 1868 0.113 16,512 0.020 0.051
SA 3 6913 4689 0.709 0.653 2224 0.056 39,392 –0.055 –0.018
SA 4 6925 4702 0.690 0.644 2222 0.046 48,113 –0.065 –0.028
SA 5 6901 4669 0.615 0.553 2232 0.062 35,717 –0.049 –0.012
SA 6 5920 4299 0.616 0.558 1620 0.057 28,251 –0.024 0.003
SA 7 6886 4693 0.610 0.557 2193 0.053 41,422 –0.057 –0.020
SA 8 6935 4690 0.621 0.559 2245 0.062 36,163 –0.050 –0.013
SA 9 7115 5824 0.608 0.551 1291 0.056 22,923 –0.008 0.013
SA 10 8566 6967 0.613 0.555 1600 0.057 27,981 –0.023 0.004
SA 11 8147 6363 0.613 0.559 1784 0.054 32,807 –0.035 –0.005
SA 12 10,194 8239 0.608 0.555 1956 0.053 36,621 –0.044 –0.012
a Base-case analysis, non-parametric bootstrapped approach.
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Chapter 5 Discussion
Aim of the study
Guidelines exist and recommend several options of treatment for sciatica secondary to PID without
recommending one form of treatment over another. ESIs have been reported to have poor efficacy for
sciatica, with a high cost per QALY, and this has led to variations in commissioning of this treatment across
the UK.TFESIs are recommended along with microdiscectomy for sciatica secondary to PID; however,
with the exception of cohort studies, long-term evidence pertaining to safety and effectiveness of TFESI
is lacking. Given that it is widely recognised that PIDs often resolve spontaneously within 12–24 months,
patients may well need only a short-term solution for their radicular pain episode. We therefore presented,
to the best of our knowledge, the first RCT comparing two recommended treatment options for sciatica
secondary to PID (i.e. microdiscectomy and TFESI) and conducted a health economic evaluation of the
two treatments.
Clinical effectiveness
There was no significant difference observed between the two treatments at the primary outcome time
point of 18 weeks post randomisation. A total of 73.8% of surgical participants and 68.3% of TFESI
participants achieved the MCID (i.e. a 10-point reduction in ODQ) at 18 weeks. Overall, ODQ scores from
baseline in 86.9% of surgical participants compared with 90.5% of TFESI-treated patients. Microdiscectomy
resulted in an average improvement in ODQ of < 5 points compared with TFESI, which is less than the
MCID in ODQ. This level of benefit was sustained at longer follow-up time points.
Although point estimates suggested that microdiscectomy produced a greater reduction in scores for
VAS leg and back pain, MRM and COMI, there was no significant difference between the two treatments
and CIs did not include the MCIDs (where known). For VAS leg pain, TFESI resulted in a > 40-point
reduction from baseline score compared with a > 50-point reduction following microdiscectomy. Similar
trends were found for VAS back pain, MRM and COMI scores, with improvements from baseline after
both treatments, but no significant differences between the treatments. There was an observed
difference between the level of satisfaction for the two treatments, but both were deemed to be
satisfactory among patients.
Cost-effectiveness
The economic evaluation indicated that the ICER for microdiscectomy, in comparison with TFESI, exceeds
the threshold range usually implemented in the NHS. Standard NICE decision-making applies a ceiling
ratio of £20,000 per QALY, but allows for a higher threshold of up to £30,000 per QALY when certain
criteria are met, including whether or not treatments are life-extending or innovative and if QoL or
broader societal issues may not be captured adequately in the QALY. However, it is unlikely, given the
nature of sciatica, that microdiscectomy and TFESI would qualify for appraisal with reference to the
higher threshold, and, therefore, a threshold of £20,000 per QALY was assumed. The results indicate
that, although microdiscectomy generates greater health benefits than TFESI, it is more costly and, with
a cost-effectiveness ratio of £38,737 per QALY gained, it would not be considered a cost-effective option
for the treatment of persistent radicular pain secondary to PID herniation. This result is consistent under
alternative assumptions and methods considered in the SAs. The secondary analysis, which considered an
approximating to societal cost perspective, demonstrated an improvement in the cost-effectiveness of
microdiscectomy, although this was sensitive to the costing method applied.
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Strengths and limitations
Design
To the best of our knowledge, this study is the first to directly compare two nationally recommended
treatments for persistent sciatica secondary to PID. Previous studies comparing surgery with conservative
care have included multiple treatment options, including physiotherapy, ESI and pharmacological
treatments, and have not been a direct comparison of two treatments. Hitherto, there is little evidence
supporting ESI for > 3–4 weeks after the onset of sciatica outside single cohort studies. The pragmatic
nature of this study allowed local NHS treatment and probably contributed to successful recruitment
and ‘buy-in’ for the trial by regional units. Eleven centres contributed to recruitment, and this improved
the representation and validity of the results. Previously, the only comparable RCT comparing surgery
with ESI had been a single-centre study14 of > 100 patients that utilised a posterior interlaminar
injection route.
We wanted to exclude patients with a rapid positive natural history, and therefore the minimal length
of symptoms was arbitrarily taken as 6 weeks, in keeping with the NICE back pain and radiculopathy
guidelines recommending investigations after 6 weeks of symptoms. Initially, the authors wanted to
minimise duration of radiculopathy up to 6 months in an attempt to coincide with statutory sick pay.
However, this negatively affected recruitment rates because of long NHS waiting times, hence, this
inclusion criterion was modified to allow recruitment of patients with up to 12 months of radicular
symptoms. Post hoc analysis of interaction between duration of symptoms and treatment allocation
indicated that duration of symptoms does not appear to be a treatment effect modifier.
The ODQ was chosen as the primary outcome measure because of its long history of clinical
validation and in accordance with previous recommendations of core outcome sets.36 Although
this study was devised prior to a recent publication from Chiarotto et al.,38 the core outcome sets
recommended have been collected within the NERVES trial. For physical functioning, the ODQ or
MRM is recommended, and we collected both. A numerical pain intensity score and health-related
QoL score is also recommended, and we recorded VAS and EQ-5D-5L scores. Finally, recording
mortality rates is recommended and, again, this was captured by our safety reporting and no
participants died during the trial period. The COMI has the advantage of being easily tolerated by
participants because of its small number of questions and so this was included in the NERVES trial.
The COMI is gaining popularity across Europe and may allow wider comparison with large registry
data sets of routinely collected outcomes for sciatica. This study found that there was no significant
difference between microdiscectomy and TFESI for the primary outcome. Future studies may utilise a
single physical function outcome domain, perhaps COMI, for participant co-operation.
The study suffered from missing data, and patients whose data were incomplete were excluded from
the primary analysis. Participants with missing data were, however, incorporated into secondary analyses
and sensitivity analyses of the primary outcome indicated robustness to the assumptions made about
the missing data. The number of missing data may reflect the large numbers of questionnaires being
presented to participants, but this was an accepted risk to capture as much clinical data as possible.
Future studies could use fewer outcome measures, such as those recommended by Chiarotto et al.38
(i.e. ODQ, VAS and EQ-5D).
Conduct
Overall, 163 participants consented to taking part in the study; however, 168 patients declined
or were not asked, giving an overall consent rate of 49%. Some units declined to take part in the
study, reflecting pre-existing clinical preference for one treatment over another, with some clinicians
favouring surgery and others favouring TFESI. The difficulty of obtaining consent may reflect the
stark difference between the two treatments. Of those participants who were asked to provide
consent, the reasons given for not providing consent were related to treatment preference. The
reasons provided were not wanting to be randomised (n = 60), not wanting surgery (n = 33 patients)
and not wanting TFESI (n = 22 patients). This is typical of surgical trials, but may be considered slightly
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lower than expected, possibly because of the difference between the two treatments (i.e. one being a
day-case procedure carried out under local anaesthetic and the other a surgical procedure carried out
under general anaesthetic and necessitating an overnight or short hospitalisation). Given the current
study findings, it would be difficult to justify ethically comparing the same two treatments in future
studies because of the lack of clinical difference and the clear difference in safety profiles of the two.
Clinical effectiveness analysis
The trial found no evidence of a significant difference in ODQ scores between the two treatment
groups at 18 weeks post randomisation. Furthermore, no difference in any of the other secondary
outcome domains (i.e. COMI or MRM) was found.
Overall, 28 out of 80 patients (35%) in the TFESI group received microdiscectomy as an additional
treatment and, therefore, TFESI was effective in avoiding microdiscectomy in 65% of participants
randomised to TFESI. Of these patients, half received the additional treatment following the primary
outcome assessment, thereby having only a minimal impact on interpretation/validity of the results.
The authors feel that this level of additional treatment is an improvement compared with previous
studies of microdiscectomy versus conservative care, in which the rate was > 40%.11
One additional possibility regarding the interpretation of these data is that neither treatment was
effective, given the lack of a third, control, group receiving no treatment. The TMG did not think that this
was an ethics design option as all participants recruited had disabling sciatica (i.e. a baseline VAS score
for leg pain of > 7). A recent paper by Bailey et al.68 explored an almost identical cohort of participants,
treating sciatica secondary to PID of between 4 and 12 months’ duration either conservatively or with
surgery. The fact that we included only patients with symptoms of > 4 months’ duration was important,
as previous studies have focused on patients with symptoms of typically < 3 months’ duration.11,12,14,68
The majority of symptoms may well improve naturally in this time frame, but beyond 3 months symptoms
are less likely to resolve quickly and it may take up to 12–24 months for natural improvement to manifest.
The NERVES trial baseline data recorded an average duration of sciatica of > 4 months at recruitment
and, therefore, a similarly matched group to the study by Bailey et al.68 In the study by Bailey et al.,68 the
conservative treatment arm received medication and physiotherapy with the possibility of also receiving
ESI, but it is not clear what proportion of participants received injections. Importantly, Bailey et al.68
found a clear difference between surgery and conservative management, with surgery improving VAS
scores for leg pain more effectively than conservative treatment. This is not the same result reported by
our data. We speculate that a rigorously controlled injection group, as presented in this study, accounts
for the difference in reported efficacy and therefore the benefit of TFESI is real. Furthermore, the
precipitous drop in outcome scores post treatment seen in both groups does suggest a treatment effect.
Finally, because the participants recruited had significant sciatica (i.e. a baseline VAS score for leg pain
of > 7) with an average duration of > 4 months, we do not believe that spontaneous resolution of
symptoms would have occurred as quickly as it did without treatment. For these reasons, we believe
that both TFESI and surgery are effective treatment options for this group of patients.
Economic analysis
The economic analysis has strengths in that it utilised routine patient-level NHS data sets and
nationally reported costs collected within a pragmatic RCT that is designed to reflect current
management and NHS practice for the care of the trial population. Unlike previous economic analyses,
the NERVES trial used patient-level data and, therefore, avoided the use of non-trial data and any
subsequent bias that might be introduced as a consequence. Participant-reported health outcomes
were measured at key time points using the EQ-5D-5L questionnaire, which offered greater sensitivity
than the three-level version to assess the impact of treatment on each health domain. However,
because of presently unresolved issues regarding the five-level value set for deriving health state
utility scores, NICE currently recommends mapping from the five-level to a three-level value set, which
was the approach applied in the base case. Alternative valuation sets, explored in a SA, demonstrated
that the five-level valuation set had minimal effect on the ICER and would not affect decision-making.
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This is contrary to other reported findings comparing the five- and three-level value sets, which
suggest that in most cases ICERs are substantially higher when the five-level value set is applied.69
Deriving EQ-5D scores from the NERVES trial primary outcome measure, the ODQ, was not deemed
feasible as no robust relationship exists between these measures.70
There were also some weaknesses to the economic analysis. Given the pragmatic nature of the trial
and reliance on participant-reported outcomes, it was inevitable that there would be a degree of
missing data. In particular, completion rates were lower for the two data collections that were reliant
on postal questionnaires (i.e. weeks 30 and 42). When possible, assumptions around resource use,
costs and QoL were made to maximise the use of data acquired within the trial. When this was not
possible, multiple imputation was used to impute missing values, conditional on observed data that
were considered informative to the imputation.71 Imputing missing data associated with health state
utilities and resource use may act as an additional source of uncertainty. It is also acknowledged that
the participant-completed RUQ may be subject to recall bias; however, patient questionnaires are an
important supplement to clinical records and provide resource use and costing data that would otherwise
not be readily available. The 3-month recall period used in the NERVES trial is representative of the
median recall time frame employed in UK National Institute for Health Research (NIHR) HTA programme-
funded trials.72 A further limitation was to limit the time horizon of analysis to 54 weeks, consistent with
the clinical trial follow-up period. No extrapolation or modelling was performed to include a longer-term
assessment of costs and consequences. Given that recurrence rates of lower back pain after discectomy
of 65% at 3 years have been reported,73 a longer analytical time horizon might be more informative, but
liable to bias given the absence of longer-term follow-up of NERVES trial participants.
Our estimation of productivity losses was subject to both missing data and incomplete questionnaire
reporting of time off work. To address the gaps in question completion, a number of assumptions were
made and alternative scenarios were constructed, including replacing partially completed questions
with missing costs based on ONS data on reported median salaries, as well as applying median salary
data to account for questionable reported lost productivity costs. However, the wider perspective that
approximated societal costs remains subject to bias, and limited in its robustness and generalisability,
but nonetheless corresponds with findings from Koenig et al.29 (i.e. the ICER is reduced when loss of
productivity costs are taken into account).
Previous economic evaluations were found not to be generalisable to the present analysis because of
differences in setting, perspective and interventions tested. Although, to the best of our knowledge,
this is the first UK study to compare microdiscectomy with TFESI, Price et al.,18 in a comparison of ESI
with placebo, reported an ICER of £44,701 per QALY gained from a provider perspective, increasing
to £354,171 per QALY gained from a purchaser perspective. However, it is not feasible to draw
comparisons between this analysis and the present NERVES trial for a number of reasons. The WEST,18
conducted between 1999 and 2002, compared blind ESI (see Chapter 1, Scientific background), whereas
the NERVES trial has used the transforaminal route, which delivers the injectate much nearer to the
site of pathology (i.e. the prolapsed disc and involved nerve root).
In terms of costing, Price et al.18 utilised a bottom-up approach based on unit costs from a single NHS
trust. This differs from the approach undertaken in the NERVES trial, which follows the NICE reference
case,42 which recommends a HRG costing approach and utilises NHS reference costs.45 These costs
represent national average unit costs from all NHS organisations in England. Moreover, Price et al.18
considered only the direct medical costs that were associated with the epidural technique and its
follow-up, whereas the greatest cost component – resource use relating to clinical staff time – was
calculated from non-RCT-based survey data. Regarding health outcomes, Price et al.18 derived utility
scores from the Short Form questionnaire-36 items, which differs from the NICE-preferred EQ-5D, and
QALYs gained were based on only completed 12-week data, despite follow-up extending to 52-weeks.
Small incremental differences (< 0.006) in QALYs were observed between ESI and placebo over the
12 weeks, which have the effect of making the ICER highly unstable, as reflected in the wide variation
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in ICERs reported. In contrast to Price et al.18 who use a placebo control, the NERVES trial was unable
to estimate a value for cost-effectiveness of TFESI per se, as we did not feel ethically justified in including
a ‘no-treatment’ group in this study. From our inclusion criteria, all participants had previously exhausted
simple conservative care and required further treatment.
Safety
There was a clear difference in the safety profiles of the two treatment arms, with four SAEs in the
surgical group and none in the TFESI group. Two patients who experienced a SAE had to be readmitted
to hospital for surgical intervention for cerebrospinal fluid-related complications: one required repeat
microdiscectomy for a recurrent disc and one required exploration microdiscectomy for an unexplained
foot drop post procedure. AEs were deemed minor in the TFESI group. No participant in the TFESI group
required admission to hospital during the 54-week follow-up period. The authors acknowledge that the
follow-up time is unlikely to capture a late discitis in this group, but theoretically this risk should diminish
over time.
Implications for practice and health care
To the best of our knowledge, the NERVES trial is the first RCT comparing surgical microdiscectomy
with TFESI. We feel that there is good evidence to support the use of TFESI for patients with
radiculopathy not improving with simple medical treatments. Further studies would assist in the
establishment and safety of TFESI as the primary treatment of choice for sciatica secondary to PID.
We feel that the streamlining of patients down a TFESI pathway (with careful safety of patient
selection/triage) could increase the accessibility for patients requiring TFESI and could potentially
reduce waiting times for treatment, given the larger availability of TFESI skill mix NHS personnel than
surgical skill mix NHS personnel. We suggest that outside emergency cases (e.g. foot weakness/cauda
equina syndrome), microdiscectomy should be reserved for patients who have either declined or failed
to benefit from TFESI.
Conclusions
In summary, we found there to be no significant difference in clinical outcome following the two treatments:
microdiscectomy and TFESI. The results indicate that microdiscectomy is not expected to be cost-effective
when compared with TFESI at usual thresholds of cost-effectiveness operating in the UK.
Implications for future research
To the best of our knowledge, the NERVES trial is the first RCT comparing microdiscectomy with
TFESI for sciatica secondary to PID. Moreover, it provides valid long-term outcomes for TFESI up to
54 weeks following the onset of radicular pain. Further studies could extend the period of follow-up
to assess the outcome of patients beyond 54 weeks and to see the number of patients receiving
microdiscectomy in addition to TFESI over a longer time scale. We would recommend further studies
addressing the streamlining of services across the UK with the aim of creating a treatment pathway for
sciatica secondary to PID. Perhaps the second step in the process following on from the NERVES trial
is a health economic assessment of a sciatica treatment paradigm whereby patients are triaged into a
TFESI treatment pathway and then followed up for a slightly longer time (e.g. 2 years). Participants
could then be referred for surgical consideration only if symptoms did not improve substantially.
This could allow an accurate and real assessment of cost-effectiveness for microdiscectomy for
this failed TFESI group and would lend further support to the suspected safety of this paradigm.
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No difference was found between any of the outcome tools employed (i.e. ODQ, COMI and MRM).
The capture of several outcome domains will allow comparison of the current data with routinely
collected large data sets or registries that regularly capture outcome data in the form of COMI or ODQ.
Future sciatica studies could limit the number of physical functioning outcome domains employed to one
of ODQ, COMI or MRM, based on Chiarotto et al.’s38 recommendations, although capturing COMI in
addition would incorporate Deyo et al.’s36 recommendations and also allow comparison with European
registry data. In addition, Short Form questionnaire-12 items may be used instead of EQ-5D-5L.
Given the clear difference in safety profiles between surgery and TFESI (in favour of TFESI) and
with no clinical difference in outcome and no health economic benefit, it is difficult to imagine ethics
committees agreeing to the same trial design again. The authors believe that there is no longer clinical
equipoise between the two treatments. Future studies would likely be variations of newer TFESI
injectate agents or cohort studies utilising health economic analyses.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Acknowledgements
We would like to thank the external members of the TSC for their advice and support on theproject: Mr Phil Sell (TSC chairperson, Queen’s Medical Centre, Nottingham), Mr Ioannis Fouyas
(Western General Hospital, Edinburgh), Professor Chris Rogers (University of Bristol, Bristol),
Professor Turo Nurmikko (University of Liverpool, Liverpool), Mr Jake Timothy (Leeds General
Infirmary, Leeds) and Mrs Sharon Morgan (PPI representative).
Our thanks go also to the IDSMC: Mr John O’Dowd (IDSMC chairperson, Harley Street Clinic, London),
Dr Simon Thomson (Orsett Hospital, Essex) and Professor John Norrie (University of Edinburgh,
Edinburgh; Professor John Norrie is a member of the NIHR HTA and Efficacy and Mechanism Evaluation
Editorial Board).
Our thanks also go to the following TMG members: Gillian Hamblin (sponsor representative),
Dave Watling (sponsor representative), Maria Thornton (sponsor representative), Paul Sacco
(University of Liverpool, Liverpool), Hoo Kee Tsang (University of Aintree, Liverpool) and
Stephen Lawlor (PPI representative).
We would like to thank the following LCTC staff: Carolyn Hopkins (trial co-ordinator), Kirsty Marrow
(trial co-ordinator), Kelly Davies (trial co-ordinator assistant), Beth Conroy (trial statistician),
Clare Jackson (senior data manager) and Sue Howlin (senior data manager).
We would also like to thank Dr Colin Ridyard and Yankier Pijeira Perez from Bangor University for
assisting with the economic evaluation.
We are grateful to all the participants for their commitment to the trial. We would like to thank the
principal investigators, research nurses and other members of the team who recruited patients and
supported them during the trial: The Walton Centre, Liverpool – Simon Clark (principal investigator),
Kate O’Hanlon, Keren Smallwood and Louise Fasting; James Cook University Hospital, Middlesbrough –
Nitin Mukerji (principal investigator), Simon Tizzard and Emanuel Cirstea; Seacroft Hospital, Leeds –
Ganesan Baranidharan (principal investigator), Simon Thomson, Paulito Castino, Tracey Crowther and
Sena Desmennu; Solent MSK, Southampton – Cathy Price (principal investigator), Anna Thornhill
and Colin Griffiths; Addenbrooke’s Hospital, Cambridge – Richard Mannion (principal investigator),
Peter Hutchinson and Karen Caldwell; Salford Royal Hospital, Manchester – John Leach (principal
investigator), Lisa Hankinson and Diane Daniel; Queen’s Medical Centre, Nottingham – Nasir Quraishi
(principal investigator), Lovelyn Umeloh, James Hegarty, Jacob Szolin-Jones and Carolynn Wake;
Royal Hallamshire Hospital, Sheffield – Yahia Al-Tamimi (principal investigator), Rose Clegg and
Grace Cole; Royal Orthopaedic Hospital, Birmingham – Adrian Gardner (principal investigator) and
Claudette Jones; Royal Stoke University Hospital, Stoke-on-Trent – Nikolaos Tzerakis (principal
investigator) and Joanne Hiden; and Royal Preston Hospital, Preston – Aprajay Golash (principal
investigator) and Janice Birt.
Contributions of authors
Martin J Wilby (https://orcid.org/0000-0001-6647-9040) (Chief Investigator and Consultant Spinal
Neurosurgeon) developed the trial protocol in collaboration with co-investigators. He oversaw the
delivery of the trial, assisted in preparing trial update reports, oversaw clinical aspects of the statistical
analysis plan and clinical interpretation of the trial data. He led the preparation of the final report
(drafting, reviewing and editing) and was chairperson of the TMG.
DOI: 10.3310/hta25240 Health Technology Assessment 2021 Vol. 25 No. 24
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Wilby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
71
Ashley Best (https://orcid.org/0000-0002-7268-8735) (Trial Statistician) undertook the final statistical
analysis under the supervision of Girvan Burnside, prepared data for reports, prepared data tables and
figures for the final report, and co-led the preparation of the final report. He was a member of the TMG.
Eifiona Wood (https://orcid.org/0000-0002-2785-7325) (Trial Health Economist) undertook the
economic analysis under the supervision of Dyfrig A Hughes, contributed to the final report (drafting,
reviewing and editing) and was a member of the TMG.
Girvan Burnside (https://orcid.org/0000-0001-7398-1346) (Senior Statistician) contributed to protocol
development and data capture methods, proposed statistical analysis methods and approved the
statistical analysis plan, oversaw trial monitoring activities and co-led the preparation of the final
report. He was also a member of the TMG.
Emma Bedson (https://orcid.org/0000-0001-5209-1854) (Senior Trials Manager) contributed to
protocol development, gave guidance and support on all aspects of governance and trial delivery,
and supported the preparation of progress reports. She contributed to the final report (drafting and
reviewing) and was a member of the TMG.
Hannah Short (https://orcid.org/0000-0003-4215-9258) (Trial Co-ordinator) contributed to all aspects
of governance, trial delivery and preparation of progress reports. She contributed to the final report
(drafting and reviewing) and was a member of the TMG.
Dianne Wheatley (https://orcid.org/0000-0002-9230-8349) (Trial Data Manager) contributed to trial
delivery and was a member of the TMG.
Daniel Hill-McManus (https://orcid.org/0000-0002-1936-3907) (Health Economist) contributed to the
economic evaluation and the final report (drafting).
Manohar Sharma (https://orcid.org/0000-0002-0354-3145) (Co-investigator and Consultant in Pain
Medicine) contributed to the development of the trial protocol. He contributed to trial delivery and the
final report (reviewing and editing). He was also a member of the TMG.
Simon Clark (https://orcid.org/0000-0003-1225-2320) (Principal Investigator and Consultant
Neurosurgeon) contributed to trial delivery and the writing of the final report (reviewing). He was also
a member of the TMG.
Jennifer Bostock (https://orcid.org/0000-0001-9261-9350) (PPI Representative) contributed to the
writing of the final report (reviewing) and was a member of the TMG.
Sally Hay (PPI Representative) contributed to the writing of the final report (reviewing) and was a
member of the TMG.
Ganesan Baranidharan (https://orcid.org/0000-0002-1898-8243) (Consultant in Anaesthesia and
Pain Medicine) contributed to trial design, trial delivery and the writing of the final report (reviewing).
Cathy Price (https://orcid.org/0000-0003-0111-9364) (Consultant in Pain Medicine) contributed to
trial design, trial delivery and the writing of the final report (reviewing).
Richard Mannion (https://orcid.org/0000-0001-6010-6227) (Consultant Neurosurgeon) contributed to
trial design, trial delivery and the writing of the final report (reviewing).
Peter J Hutchinson (https://orcid.org/0000-0002-2796-1835) (Co-applicant and Professor of
Neurosurgery) contributed to trial design, trial delivery and the writing of the final report (reviewing).
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
Dyfrig A Hughes (https://orcid.org/0000-0001-8247-7459) (Co-applicant and Senior Health Economist)
led the economic evaluation, contributed to development of the funding application, protocol development
and data capture methods. He contributed to the final report (drafting, reviewing and editing) and was a
member of the TMG.
Anthony Marson (https://orcid.org/0000-0002-6861-8806) (Co-applicant and Consultant Neurologist)
contributed to the writing of the final report (reviewing) and was a member of the TMG.
Paula R Williamson (https://orcid.org/0000-0001-9802-6636) [Co-applicant, Clinical Trials Research
Centre (now LCTC) Director (from 1 April 2005 to 31 December 2018) and Professor of Medical
Statistics] contributed to trial design, development of the funding application, trial protocol, data
capture methods and statistical analysis, in collaboration with co-investigators. She contributed to
the preparation of the final report (reviewing and editing) and was a member of the TMG.
Publications
Wilby MJ, Hopkins C, Bedson E, Howlin S, Burnside G, Conroy EJ, et al. NErve Root Block VErsus
Surgery (NERVES) for the treatment of radicular pain secondary to a prolapsed intervertebral disc
herniation: study protocol for a multi-centre randomised controlled trial. Trials 2018;19:475.
Wilby MJ, Best A, Wood E, Burnside G, Bedson E, Short H, et al. Surgical microdiscectomy versus
transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc
(NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation
[published online ahead of print March 18 2021]. Lancet Rheumatol 2021.
Data-sharing statement
All requests for data should be sent to the corresponding author. Access to available anonymised data
may be granted following review.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to make
better use of information from people’s patient records, to understand more about disease, develop new
treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect
everyone’s privacy, and it’s important that there are safeguards to make sure that it is stored and used
responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You
can find out more about the background to this citation here: https://understandingpatientdata.org.uk/
data-citation.
DOI: 10.3310/hta25240 Health Technology Assessment 2021 Vol. 25 No. 24
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Wilby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
73

References
1. de Campos TF. Low back pain and sciatica in over 16s: assessment and management NICE
Guideline [NG59]. J Physiother 2017;63:120. https://doi.org/10.1016/j.jphys.2017.02.012
2. Konstantinou K, Dunn KM. Sciatica: review of epidemiological studies and prevalence
estimates. Spine 2008;33:2464–72. https://doi.org/10.1097/BRS.0b013e318183a4a2
3. Osterman H, Seitsalo S, Karppinen J, Malmivaara A. Effectiveness of microdiscectomy
for lumbar disc herniation: a randomized controlled trial with 2 years of follow-up.
Spine 2006;31:2409–14. https://doi.org/10.1097/01.brs.0000239178.08796.52
4. Rados I, Sakic K, Fingler M, Kapural L. Efficacy of interlaminar vs transforaminal epidural
steroid injection for the treatment of chronic unilateral radicular pain: prospective, randomized
study. Pain Med 2011;12:1316–21. https://doi.org/10.1111/j.1526-4637.2011.01213.x
5. Jensen RK, Kongsted A, Kjaer P, Koes B. Diagnosis and treatment of sciatica. BMJ
2019;367:l6273. https://doi.org/10.1136/bmj.l6273
6. Stochkendahl MJ, Kjaer P, Hartvigsen J, Kongsted A, Aaboe J, Andersen M, et al. National
clinical guidelines for non-surgical treatment of patients with recent onset low back pain or
lumbar radiculopathy. Eur Spine J 2018;27:60–75. https://doi.org/10.1007/s00586-017-5099-2
7. Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, et al. Surgery
versus prolonged conservative treatment for sciatica. N Engl J Med 2007;356:2245–56.
https://doi.org/10.1056/NEJMoa064039
8. NHS Digital. Data Access Environment (DAE). URL: https://digital.nhs.uk/services/data-access-
environment-dae (accessed September 2020).
9. Taylor VM, Deyo RA, Cherkin DC, Kreuter W. Low back pain hospitalization. Recent United
States trends and regional variations. Spine (Phila Pa 1976) 1994;19:1207–12. https://doi.org/
10.1097/00007632-199405310-00002
10. Koebbe CJ, Maroon JC, Abla A, El-Kadi H, Bost J. Lumbar microdiscectomy: a historical
perspective and current technical considerations. Neurosurg Focus 2002;13:E3. https://doi.org/
10.3171/foc.2002.13.2.4
11. Weinstein JN, Lurie JD, Tosteson TD, Tosteson AN, Blood EA, Abdu WA, et al. Surgical versus
nonoperative treatment for lumbar disc herniation: four-year results for the Spine Patient
Outcomes Research Trial (SPORT). Spine 2008;33:2789–800. https://doi.org/10.1097/
BRS.0b013e31818ed8f4
12. Atlas SJ, Deyo RA, Keller RB, Chapin AM, Patrick DL, Long JM, Singer DE. The Maine Lumbar
Spine Study, Part II. 1-year outcomes of surgical and nonsurgical management of sciatica.
Spine 1996;21:1777–86. https://doi.org/10.1097/00007632-199608010-00011
13. Peul WC, van den Hout WB, Brand R, Thomeer RT, Koes BW, Leiden-The Hague Spine
Intervention Prognostic Study Group. Prolonged conservative care versus early surgery in
patients with sciatica caused by lumbar disc herniation: two year results of a randomised
controlled trial. BMJ 2008;336:1355–8. https://doi.org/10.1136/bmj.a143
14. Buttermann GR. Treatment of lumbar disc herniation: epidural steroid injection compared
with discectomy. A prospective, randomized study. J Bone Joint Surg Am 2004;86:670–9.
https://doi.org/10.2106/00004623-200404000-00002
DOI: 10.3310/hta25240 Health Technology Assessment 2021 Vol. 25 No. 24
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Wilby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
75
15. Lewis R, Williams N, Matar HE, Din N, Fitzsimmons D, Phillips C, et al. The clinical effectiveness
and cost-effectiveness of management strategies for sciatica: systematic review and economic
model. Health Technol Assess 2011;15(39). https://doi.org/10.3310/hta15390
16. Cohen SP, Bicket MC, Jamison D, Wilkinson I, Rathmell JP. Epidural steroids: a comprehensive,
evidence-based review. Reg Anesth Pain Med 2013;38:175–200. https://doi.org/10.1097/
AAP.0b013e31828ea086
17. Lutz GE, Vad VB, Wisneski RJ. Fluoroscopic transforaminal lumbar epidural steroids: an
outcome study. Arch Phys Med Rehabil 1998;79:1362–6. https://doi.org/10.1016/S0003-9993
(98)90228-3
18. Price C, Arden N, Coglan L, Rogers P. Cost-effectiveness and safety of epidural steroids in the
management of sciatica. Health Technol Assess 2005;9(33). https://doi.org/10.3310/hta9330
19. Pinto RZ, Maher CG, Ferreira ML, Hancock M, Oliveira VC, McLachlan AJ, et al. Epidural
corticosteroid injections in the management of sciatica: a systematic review and meta-analysis.
Ann Intern Med 2012;157:865–77. https://doi.org/10.7326/0003-4819-157-12-201212180-
00564
20. Ghahreman A, Bogduk N. Predictors of a favorable response to transforaminal injection of
steroids in patients with lumbar radicular pain due to disc herniation. Pain Med 2011;12:871–9.
https://doi.org/10.1111/j.1526-4637.2011.01116.x
21. Ghahreman A, Ferch R, Bogduk N. The efficacy of transforaminal injection of steroids for
the treatment of lumbar radicular pain. Pain Med 2010;11:1149–68. https://doi.org/10.1111/
j.1526-4637.2010.00908.x
22. El-Yahchouchi CA, Plastaras CT, Maus TP, Carr CM, McCormick ZL, Geske JR, et al. Adverse
event rates associated with transforaminal and interlaminar epidural steroid injections:
a multi-institutional study. Pain Med 2016;17:239–49. https://doi.org/10.1111/pme.12896
23. Wei G, Liang J, Chen B, Zhou C, Ru N, Chen J, Zhang F. Comparison of transforaminal verse
interlaminar epidural steroid injection in low back pain with lumbosacral radicular pain:
a meta-analysis of the literature. Int Orthop 2016;40:2533–45. https://doi.org/10.1007/
s00264-016-3220-5
24. Jeong HS, Lee JW, Kim SH, Myung JS, Kim JH, Kang HS. Effectiveness of transforaminal
epidural steroid injection by using a preganglionic approach: a prospective randomized
controlled study 1. Radiology 2007;245:584–90. https://doi.org/10.1148/radiol.2452062007
25. Hall JA, Konstantinou K, Lewis M, Oppong R, Ogollah R, Jowett S. Systematic review of
decision analytic modelling in economic evaluations of low back pain and sciatica. Appl Health
Econ Health Policy 2019;17:467–91. https://doi.org/10.1007/s40258-019-00471-w
26. Parker SL, Anderson LH, Nelson T, Patel VV. Cost-effectiveness of three treatment strategies
for lumbar spinal stenosis: conservative care, laminectomy, and the superion interspinous
spacer. Int J Spine Surg 2015;9:28. https://doi.org/10.14444/2028
27. Skidmore G, Ackerman SJ, Bergin C, Ross D, Butler J, Suthar M, Rittenberg J. Cost-effectiveness
of the X-STOP® interspinous spacer for lumbar spinal stenosis. Spine 2011;36:E345–56.
https://doi.org/10.1097/BRS.0b013e3181f2ed2f
28. Udeh BL, Costandi S, Dalton JE, Ghosh R, Yousef H, Mekhail N. The 2-year cost-effectiveness
of 3 options to treat lumbar spinal stenosis patients. Pain Pract 2015;15:107–16.
https://doi.org/10.1111/papr.12160
29. Koenig L, Dall TM, Gu Q, Saavoss J, Schafer MF. How does accounting for worker productivity
affect the measured cost-effectiveness of lumbar discectomy? Clin Orthop Relat Res
2014;472:1069–79. https://doi.org/10.1007/s11999-013-3440-6
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
30. Fitzsimmons D, Phillips CJ, Bennett H, Jones M, Williams N, Lewis R, et al. Cost-effectiveness of
different strategies to manage patients with sciatica. Pain 2014;155:1318–27. https://doi.org/
10.1016/j.pain.2014.04.008
31. van den Hout WB, Peul WC, Koes BW, Brand R, Kievit J, Thomeer RT, Leiden-The Hague Spine
Intervention Prognostic Study Group. Prolonged conservative care versus early surgery in
patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised
controlled trial. BMJ 2008;336:1351–4. https://doi.org/10.1136/bmj.39583.709074.BE
32. Vertuani S, Nilsson J, Borgman B, Buseghin G, Leonard C, Assietti R, Quraishi NA. A cost-
effectiveness analysis of minimally invasive versus open surgery techniques for lumbar spinal
fusion in Italy and the United Kingdom. Value Health 2015;18:810–16. https://doi.org/10.1016/
j.jval.2015.05.002
33. World Medical Association. Declaration of Helsinki: ethical principles for medical research
involving human subjects. JAMA 2013;310:2191–4. https://doi.org/10.1001/jama.2013.281053
34. Ionising Radiation (Medical Exposure) Regulations 2000 (Statutory Instrument 2000 No. 1059).
London: HMSO; 2000.
35. Medicines for Human Use (Clinical Trials) Regulations. Statutory Instrument 2004/1031.
London: HMSO; 2004.
36. Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, Koes B, et al. Outcome measures for
low back pain research. A proposal for standardized use. Spine 1998;23:2003–13. https://doi.org/
10.1097/00007632-199809150-00018
37. Davidson M, Keating JL. A comparison of five low back disability questionnaires: reliability and
responsiveness. Phys Ther 2002;82:8–24. https://doi.org/10.1093/ptj/82.1.8
38. Chiarotto A, Boers M, Deyo RA, Buchbinder R, Corbin TP, Costa LOP, et al. Core outcome
measurement instruments for clinical trials in nonspecific low back pain. Pain 2018;159:481–95.
https://doi.org/10.1097/j.pain.0000000000001117
39. Devogelaer JP, Dreiser RL, Abadie E, Avouac B, Bouvenot G, Carbonell Abello J, et al.
Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low
back pain. Clin Exp Rheumatol 2003;21:691–4.
40. Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswestry low back pain disability
questionnaire. Physiotherapy 1980;66:271–3.
41. Wilby MJ, Hopkins C, Bedson E, Howlin S, Burnside G, Conroy EJ, et al. NErve Root Block
VErsus Surgery (NERVES) for the treatment of radicular pain secondary to a prolapsed
intervertebral disc herniation: study protocol for a multi-centre randomised controlled trial.
Trials 2018;19:475. https://doi.org/10.1186/s13063-018-2677-5
42. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology
Appraisal 2013. Process and Methods [PMG9]. London: NICE; 2013.
43. NERVES Resource Use Questionnaire. In Database of Instruments for Resource Use Measurement.
URL: www.dirum.org/instruments/details/115 (accessed September 2020).
44. Curtis L, Burns A. Unit Costs of Health and Social Care 2018. Canterbury: Personal Social
Services Research Unit, University of Kent; 2018.
45. NHS Improvement. National Schedule of Reference Costs 2017–2018. London: NHS Improvement;
2018.
46. NHS Digital. National Casemix Office 2017. Casemix Companion HRG4+ 2017/18 Local Payment
Grouper. Leeds: NHS Digital; 2017.
DOI: 10.3310/hta25240 Health Technology Assessment 2021 Vol. 25 No. 24
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Wilby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
77
47. Curtis L, Burns A. Unit Costs of Health and Social Care 2013. Personal Social Services Research
Unit, University of Kent, Canterbury; 2013.
48. NHS. Acupuncture. 2016. URL: www.nhs.uk/conditions/acupuncture/ (accessed 18 August 2019).
49. NHS. Osteopathy. 2018. URL: www.nhs.uk/conditions/osteopathy/ (accessed 28 August 2019).
50. NHS. Chiropractic. 2017. URL: www.nhs.uk/conditions/chiropractic/ (accessed 28 August 2019).
51. Capital Physio, London, UK. How Much Does Private Physiotherapy Cost? 2016.
URL: www.capitalphysio.com/general/how-much-does-private-physiotherapy-cost/tle
(accessed 1 August 2019).
52. NHS Business Services Authority. Prescription Cost Analysis (PCA) Data September 2017. 2017.
URL: www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-data
(accessed 27 August 2019).
53. Joint Formulary Committee. British National Formulary. 84 ed. London: BMJ Group and
Pharmaceutical Press; 2017.
54. Boots Ltd. Retail Pharmacy Prices. 2019. URL: www.boots.com/ (accessed 2 April 2019).
55. Office for National Statistics. Annual Survey of Hours and Earnings 2017, Table 6.1a. Weekly Pay –
Gross (£) – For Full-time Employee Jobs: United Kingdom, 2017. 2017. URL: https://www.ons.gov.
uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/datasets/
agegroupashetable6 (accessed 28 August 2019).
56. Office for National Statistics. Annual Survey of Hours and Earnings 2017, 9. Regional Earnings,
Figure 13. Median Full-time Gross Weekly Earnings by Place of Work, Great Britain, April 2017. 2017.
URL: www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/
bulletins/annualsurveyofhoursandearnings/2017provisionaland2016revisedresults#the-make-
up-of-earnings (accessed 28 August 2019).
57. Royal Automobile Club. Typical Vehicle Running Costs – For a Diesel Engine Car. 2016.
URL: https://media.rac.co.uk/blog_posts/typical-vehicle-running-costs-for-a-diesel-engine-car-42609
(accessed 29 August 2019).
58. Royal Automobile Club. Typical Vehicle Running Costs – For a Petrol Engine Car. 2016.
URL: https://media.rac.co.uk/blog_posts/typical-vehicle-running-costs-for-petrol-engine-cars-42585
(accessed 29 August 2019).
59. NHS Digital. National Casemix Office HRG4+ 201819 Payment Grouper. 2019. URL: https://digital.
nhs.uk/services/national-casemix-office/downloads-groupers-and-tools/payment—hrg4-2018-19-
local-payment-grouper (accessed 4 July 2019).
60. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness
analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96.
https://doi.org/10.1002/hec.944
61. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and
guidance for practice. Stat Med 2011;30:377–99. https://doi.org/10.1002/sim.4067
62. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3–15. https://doi.org/
10.1177/096228029900800102
63. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ
2013;14:367–72. https://doi.org/10.1007/s10198-013-0471-6
64. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons;
1987. https://doi.org/10.1002/9780470316696
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
65. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness
acceptability curves. Health Econ 2001;10:779–87.
66. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an
EQ-5D-5L value set for England. Health Econ 2018;27:7–22. https://doi.org/10.1002/hec.3564
67. NHS Digital. NHS Digital Hospital Episode Statistics (HES) Analysis Guide. Leeds: NHS Digital;
June 2019.
68. Bailey CS, Rasoulinejad P, Taylor D, Sequeira K, Miller T, Watson J, et al. Surgery versus
conservative care for persistent sciatica lasting 4 to 12 months. N Engl J Med 2020;382:1093–102.
https://doi.org/10.1056/NEJMoa1912658
69. Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, et al. EQ-5D-5L
versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health
2018;21:49–56. https://doi.org/10.1016/j.jval.2017.09.004
70. Carreon LY, Bratcher KR, Das N, Nienhuis JB, Glassman SD. Estimating EQ-5D values from the
Oswestry Disability Index and numeric rating scales for back and leg pain. Spine 2014;39:678–82.
https://doi.org/10.1097/BRS.0000000000000220
71. Leurent B, Gomes M, Carpenter JR. Missing data in trial-based cost-effectiveness analysis:
an incomplete journey. Health Econ 2018;27:1024–40. https://doi.org/10.1002/hec.3654
72. Ridyard CH, Hughes DA, DIRUM Team. Development of a database of instruments for
resource-use measurement: purpose, feasibility, and design. Value Health 2012;15:650–5.
https://doi.org/10.1016/j.jval.2012.03.004
73. Suri P, Pearson AM, Zhao W, Lurie JD, Scherer EA, Morgan TS, Weinstein JN. Pain recurrence
after discectomy for symptomatic lumbar disc herniation. Spine 2017;42:755–63. https://doi.org/
10.1097/BRS.0000000000001894
DOI: 10.3310/hta25240 Health Technology Assessment 2021 Vol. 25 No. 24
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Wilby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
79

Appendix 1 Additional tables from clinical
effectiveness results
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TABLE 35 Summary of screening and randomisation by centre
Centre
code
Date centre
opened
Patients
screened, n
Patients
eligible, n (%)
Patients
ineligible, n (%)
Consent provided,
n (% of eligible)
Consent not provided,
n (% of eligible)
Consent provided but
patient not randomised,
n (% of consented)
Randomised, n
(% of consented)
0006 1 April 2016 28 27 (96.43) 1 (3.57) 14 (51.85) 13 (48.15) 0 14 (100.0)
0007 14 July 2016 23 23 (100.0) 0 11 (47.83) 12 (52.17) 0 11 (100.0)
0093 15 August 2016 116 16 (13.79) 100 (86.21) 6 (37.50) 10 (62.50) 0 6 (100.0)
0137 8 August 2016 33 0 33 (100.0) 0 0 0 0
0160 1 December 2015 287 8 (2.787) 279 (97.21) 1 (12.50) 7 (87.50) 0 1 (100.0)
0182 29 July 2016 5 5 (100.0) 0 1 (20.00) 4 (80.00) 0 1 (100.0)
0213 27 September 2017 8 8 (100.0) 0 8 (100.0) 0 (0.000) 0 8 (100.0)
0400 13 April 2015 52 20 (38.46) 32 (61.54) 9 (45.00) 11 (55.00) 0 9 (100.0)
0428 7 October 2015 138 32 (23.19) 106 (76.81) 6 (18.75) 26 (81.25) 0 6 (100.0)
0492 2 March 2016 138 55 (39.86) 83 (60.14) 14 (25.45) 41 (74.55) 0 14 (100.0)
0578 4 March 2015 186 103 (55.38) 82a (44.09) 80 (77.67) 23 (22.33) 0 80 (100.0)
3253 1 April 2016 41 34 (82.93) 7 (17.07) 13 (38.24) 21 (61.76) 0 13 (100.0)
Total 1055 331 (31.37) 723a (68.53) 163 (49.24) 168 (50.76) 0 163 (100.0)
a Eligible yes/no data missing for one patient at centre 0578.
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TABLE 36 Further baseline clinical characteristics
Characteristic Summary Microdiscectomy TFESI Overall
Number randomised 83 80 163
Posture n (missing) 83 (0) 80 (0) 163
Abnormal, n (%) 38 (45.8) 41 (51.3) 79 (48.5)
Normal, n (%) 43 (51.8) 37 (46.3) 80 (49.1)
Not done, n (%) 2 (2.4) 2 (2.5) 4 (2.5)
Range of movement n (missing) 83 (0) 80 (0) 163
Abnormal, n (%) 52 (62.7) 50 (62.5) 102 (62.6)
Normal, n (%) 27 (32.5) 27 (33.8) 54 (33.1)
Not done, n (%) 4 (4.8) 3 (3.8) 7 (4.3)
Muscle strength n (missing) 83 (0) 80 (0) 163
Abnormal, n (%) 12 (14.5) 18 (22.5) 30 (18.4)
Normal, n (%) 67 (80.7) 59 (73.8) 126 (77.3)
Not done, n (%) 4 (4.8) 3 (3.8) 7 (4.3)
Left ankle jerks present n (missing) 81 (2) 77 (3) 158 (5)
No, n (%) 13 (15.7) 11 (13.8) 24 (14.7)
Yes, n (%) 68 (81.9) 66 (82.5) 134 (82.2)
Right ankle jerks present n (missing) 81 (2) 79 (1) 160 (3)
No, n (%) 13 (15.7) 13 (16.3) 26 (16.0)
Yes, n (%) 68 (81.9) 66 (82.5) 134 (82.2)
Left knee jerks present n (missing) 81 (2) 77 (3) 158 (5)
No, n (%) 2 (2.4) 4 (5.0) 6 (3.7)
Yes, n (%) 79 (95.2) 73 (91.3) 152 (93.3)
Right knee jerks present n (missing) 81 (2) 79 (1) 160 (3)
No, n (%) 3 (3.6) 5 (6.3) 8 (4.9)
Yes, n (%) 78 (94.0) 74 (92.5) 152 (93.3)
SLR reduction present n (missing) 81 (2) 80 (0) 161 (2)
No, n (%) 6 (7.2) 4 (5.0) 10 (6.1)
Yes, n (%) 75 (90.4) 76 (95.0) 151 (92.6)
Location of SLR reduction (if present) n (missing) 75 (0) 76 (0) 151 (0)
Bilateral, n (%) 7 (9.3) 9 (11.8) 16 (10.6)
Unilateral (left), n (%) 37 (49.3) 39 (51.3) 76 (50.3)
Unilateral (right), n (%) 31 (41.3) 28 (36.8) 59 (39.1)
Any other abnormalities n (missing) 82 (1) 80 (0) 162 (1)
No, n (%) 63 (75.9) 59 (73.8) 122 (74.8)
Yes, n (%) 19 (22.9) 21 (26.3) 40 (24.5)
SLR, straight leg raise.
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TABLE 37 Summary of protocol deviations
Protocol deviations
Microdiscectomy,
n (%) TFESI, n (%) Total, n (%)
Total 83 80 163
Any protocol deviation 69 (83.1) 74 (92.5) 143 (87.7)
At least one major 26 (31.3) 20 (25.0) 46 (28.2)
Duration of symptoms between 6 and 54 weeks 0 (1.4) 1 (1.4) 1 (0.6)
Severe leg pain non-responsive to conservative, non-invasive
management
1 (1.2) 0 (0.0) 1 (0.6)
Previous spinal surgery at the same intervertebral disc (level) 1 (1.2) 0 (0.0) 1 (0.6)
Treatment compliance 12 (14.5) 10 (12.5) 22 (13.5)
Treatment timeline compliance 6 (7.2) 1 (1.3) 7 (4.3)
Missing primary outcome questionnaire 14 (16.9) 14 (17.5) 28 (17.2)
Protocol-specified assessment tools not used 3 (1.3) 1 (1.3) 4 (2.5)
At least one minora 67 (80.7) 71 (88.8) 138 (84.7)
a All minor protocol deviations related to missing secondary outcome variables.
TABLE 38 List of reported AEs
AE
Microdiscectomy
(N= 105) TFESI (N= 82) Overall (N= 155)
System Organ Class Preferred term
Events,
n
Patients,
n (%)
Events,
n
Patients,
n (%)
Events,
n
Patients,
n (%)
Total 18 15 (14.29) 8 3 (3.66) 26 18 (11.61)
Nervous system
disorders
Hypoaesthesia 1 1 (0.95) 5 2 (2.44) 6 3 (1.94)
Cerebrospinal fluid
leakage
1 1 (0.95) 0 0 (0.00) 1 1 (0.65)
Peroneal nerve
palsy
1 1 (0.95) 0 0 (0.00) 1 1 (0.65)
Radicular pain 1 1 (0.95) 0 0 (0.00) 1 1 (0.65)
Injury, poisoning
and procedural
complications
Dural tear 4 4 (3.81) 0 0 (0.00) 4 4 (2.58)
Pseudomeningocele 2 2 (1.90) 0 0 (0.00) 2 2 (1.29)
Surgical procedure
repeated
1 1 (0.95) 0 0 (0.00) 1 1 (0.65)
Wound
complication
1 1 (0.95) 0 0 (0.00) 1 1 (0.65)
Infections and
infestations
Postoperative
wound infection
2 2 (1.90) 0 0 (0.00) 2 2 (1.29)
Wound infection 1 1 (0.95) 0 0 (0.00) 1 1 (0.65)
Musculoskeletal and
connective tissue
disorders
Pain in extremity 1 1 (0.95) 1 1 (1.22) 2 2 (1.29)
Sciatica 1 1 (0.95) 0 0 (0.00) 1 1 (0.65)
Renal and urinary
disorders
Pollakiuria 0 0 (0.00) 1 1 (1.22) 1 1 (0.65)
Urinary
incontinence
0 0 (0.00) 1 1 (1.22) 1 1 (0.65)
General disorders and
administration site
conditions
Swelling 1 1 (0.95) 0 0 (0.00) 1 1 (0.65)
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TABLE 39 Listing of SAEs associated with microdiscectomy
System Organ Class/
preferred term Onset date Serious criteria Severity Expected
Related
Action Outcome
Principal
investigator/
chief investigator
Injury, poisoning and
procedural complications/
surgical procedure repeated
25 November 2015 Required hospitalisation Severe Expected Almost certainly/
almost certainly
Hospital admission, other
action: redo disc surgery
Resolved
Nervous system disorders/
peroneal nerve palsy
11 February 2017 Prolonged existing
hospitalisation, persistent
or significant disability/
incapacity, weakness of
foot, further surgical
intervention
Severe Expected Almost certainly/
almost certainly
Treated with concomitant
medication, re-explored
surgically 12 February 2017
Ongoing at
final follow-up
Infections and infestations/
postoperative wound infection
19 September 2017 Required hospitalisation Severe Expected Almost certainly/
probably
Treated with concomitant
medication
Resolved
Injury, poisoning and
procedural complications/
pseudomeningocele
5 December 2016 Required hospitalisation Moderate Expected Almost certainly/
almost certainly
Treated with concomitant
medication, MRI, outpatient
appointments
Resolved
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